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Introduction: Populations of black ethnicity have a disproportionately high prevalence of 
type 2 diabetes (T2D) compared to their white counterparts. Adiposity and dysfunctional 
lipid metabolism have been shown to trigger and exacerbate tissue-specific insulin resistance. 
Black communities present with pronounced insulin resistance in the presence of lower 
visceral and ectopic fat. These findings have been demonstrated in participants without T2D 
and imply there may be an ethnic distinction in the pathophysiology of T2D. 
Aim: To use highly sensitive techniques to assess and compare whole-body and tissue-
specific insulin sensitivity in black west African (BAM) and white European men (WEM) of 
normal glucose tolerance (NGT), impaired glucose tolerance (IGT) or type 2 diabetes (T2D), 
and to assess the association with regional measures of fat and lipolysis. 
Methods: Forty-nine BAM (21 NGT, 10 IGT,18 T2D) and 47 WEM (23 NGT, 9 IGT, 15 
T2D) underwent a two-step hyperinsulinaemic-euglycaemic clamp with stable glucose and 
glycerol isotopic tracers to assess insulin sensitivity, and a magnetic resonance imaging scan 
to assess visceral adipose tissue (VAT) and intrahepatic lipids (IHL). 
Results: There were no significant ethnic differences in whole-body or tissue-specific insulin 
sensitivity between BAM and WEM in any glucose tolerance group (p>0.05). VAT and IHL 
were significantly lower in BAM than WEM in each glucose tolerance group (p<0.05). There 
were no ethnic differences in the associations of peripheral or hepatic insulin sensitivity to 
glucose homeostasis with VAT or IHL (p>0.05). The association between insulin sensitivity 
to glucose homeostasis with insulin’s antilipolytic actions were weaker in BAM. The 
antilipolytic action of insulin associated with VAT and IHL in WEM but not BAM. 
Conclusions: Black men may have resistance to storing of visceral and ectopic fat and lower 
levels are found in all glucose tolerance groups. This is observed in the presence of similar 
whole-body and tissue-specific insulin sensitivity, therefore lower visceral and ectopic fat 
may be a protective mechanism in black men which prevents pronounced insulin resistance. 
Visceral fat, hepatic fat and a resistance to insulin’s antilipolytic action all appear to play a 
role in insulin resistance to glucose homeostasis in both ethnic groups. The latter association 
is significantly weaker in black men, and the mechanisms behind this relationship may be 
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Chapter 1: An introduction to type 2 
diabetes pathophysiology and ethnicity 
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1.1 Defining type 2 diabetes  
Type 2 diabetes (T2D) is a chronic, multifactorial, endocrine condition, characterised 
by dysfunctional macronutrient metabolism (1-4). This dysfunction stems from impaired 
insulin secretion and sensitivity, leading to persistent hyperglycaemia. The extent of the 
hyperglycaemia is used to define glucose intolerance and is the cornerstone for the diagnosis 
of T2D. Glycaemia occurs along a continuum (3); however, various governing bodies have 
determined cut points for the diagnosis of T2D and intermediate hyperglycaemia 
(‘prediabetes’) (5, 6). The consequence of hyperglycaemia is damage to the vasculature 
which can be subdivided into macrovascular and microvascular (7, 8). The macrovascular 
complications result from damage to the large vessels through the process of atherosclerosis, 
leading to peripheral artery disease, coronary artery disease and stroke. Damage to the 
smaller vessels drives the microvascular complications which include diabetic retinopathy, 
nephropathy and neuropathy. T2D is a progressive disorder and the risk of these 
complications increases with the duration and severity of hyperglycaemia. Overall, the 
complications arising from diabetes increase the risk of mortality and reduce the quality of 
life (7, 8).  
 
1.2 The Epidemiology of type 2 diabetes 
There are multiple forms of diabetes however, T2D accounts for more than 90% of 
all cases and is therefore, the most prevalent (1, 4). The International Diabetes Federation 
(IDF) estimated that there were 425 million cases of diabetes across the globe in 2017 (8.8% 
of all adults), a figure due to rise by almost 50% by 2045 as shown in figure 1 (9). The IDF 
summary statistics also show that diabetes affects high, middle and low income countries, 
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with a high expected prevalence rate in continents undergoing westernisation and rapid 
economic growth. Within the UK, data from the Quality and Outcomes Framework, which 
is contributed to by almost all general practitioners, determined that over 3.3 million people 
had been diagnosed with diabetes in 2014 which comprised 5% of the total population (10, 
11). Whilst the prevalence of diabetes in the UK was lower in comparison to the mean global 
prevalence, diabetes and its complications have been estimated to account for 10% of the 
NHS budget, which highlights its importance as a healthcare priority (12).  
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Figure 1: The number of people between ages 20 and 79 diagnosed with diabetes in 2017 and the 
prediction for 2045. This  figure has been reproduced with permission from the International 
Diabetes Federation atlas eighth edition 2017 (9). 
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1.3 Risk factors for type 2 diabetes 
There are numerous factors which show evidence for increasing the risk of the T2D. 
They can be either genetic factors, environmental factors or both (1, 13, 14). Risk factors 
include, but are not limited to: a physically inactive and sedentary lifestyle (15, 16); 
increasing age (4, 17, 18), a positive family history of T2D (19), other medical conditions 
such as intermediate hyperglycaemia (‘prediabetes’) or gestational diabetes (3, 13), being 
overweight or obese (16, 20, 21) and being from an ethnic “minority” background (notably 
south Asian, Hispanic and black) (1, 22). The latter two risk factors listed have been assessed 
as part of this thesis and will be the focus going forward. 
 
1.3.1 Adiposity as a risk for type 2 diabetes 
Being overweight or obese, as assessed by BMI, is one of the most commonly 
recognised risk factors for T2D (16, 20, 21, 23). The increased risk with increasing BMI 
appears to occur independently of other metabolic dysfunctions such as fatty liver or insulin 
resistance, which highlights the importance of general adiposity (24). However, obesity and 
general adiposity have not consistently been shown to increase the risk of T2D; the 
distribution of adiposity has been identified as a more significant risk factor (25, 26). Central 
adiposity, assessed using the waist circumference, has been shown to be a stronger predictor 
of T2D than BMI alone (27). Individuals with a high waist circumference but a normal BMI 
are at greater risk of T2D than those with normal waist circumference and high BMI, this 
highlights the importance of fat distribution (28).  
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1.3.2 Ethnicity as a risk factor for type 2 diabetes 
In continents across the globe including North America (29, 30) and Europe (31, 32), 
the prevalence of T2D is consistently reported to be higher in ethnic minority groups 
compared to white populations. Data from Pima Indians, a group of native Americans , has 
shown that the incidence of T2D is 19 times higher than the white Americans after adjusting 
for age and sex (33). In addition, the risk of diabetes being the underlying the cause of 
mortality is up to 3.5 times higher in comparison to white Americans (34). Longitudinal 
studies in Pima Indians assessing obesity and T2D physiology have propelled our knowledge 
of the field and highlighted the impact of insulin resistance (33, 35). Another population 
which has been shown to suffer from disproportionately high rates of T2D compared to white 
populations are south Asians. Individuals of south Asian decent include those who live or 
have roots in India, Sri Lanka, Bangladesh, Pakistan and Nepal. There is a degree of 
heterogeneity between the T2D prevalence in each south Asian country. India alone, was 
estimated to have the highest number of individuals suffering from T2D in 2010 at 50.8 
million people (36), an estimated prevalence of 16.8% of the population (37). The high 
prevalence of T2D in south Asia is also observed in migrant populations living outside of 
south Asia. It has been consistently reported that the risk of diabetes is over 3 times higher 
in individuals of south Asian decent compared to white European populations (31, 38). 
Although both South Asians and Pima Indian populations have been demonstrated to exhibit 
high rates of T2D, a study assessing insulin sensitivity and secretion in over 800 Pima Indians 
and over 2000 Asian Indians found profound differences. This may suggest that the 
pathophysiology of T2D is heterogenous among these high risk populations (39).  
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Finally, populations of black ethnicity have also been consistently identified as a high 
risk population (31, 40).  
 
1.3.2.1 Heterogeneity within Black populations 
Although populations of black ethnicity are described in the literature as Black, Non-
Hispanic black, African, African American and Afro-Caribbean; black populations are a 
highly heterogeneous. Ethnicity is a term used to describe a group of people based on factors 
such as geographical origins, biological factors and culture (40). Individuals of black 
ethnicity can descend from Africa however, Africans are a diverse population with different 
behaviours (including attitudes towards physical activity and diet), risk factors, genetics and 
disease experiences (41-43), some of which have been discussed below. 
In terms of dietary factors, within Africa there is a large degree of heterogeneity in 
the patterns of food consumption according to region, culture, the economy and 
environmental factors. Carbohydrates are the common staple however this may in in the form 
of starchy roots such as yams, fruits such as plantain and grains such a millet or rice. As an 
example, in south Africa mashed potatoes are a typical component of the diet however this 
is less commonly consumed in west and east Africa regions (44). As another example, 
sorghum is a food source grown in very arid locations and is a typical component in central, 
but not southern, African diets. Interestingly, a study comparing gastric emptying following 
the ingestion of different carbohydrates in young healthy participants found that gastric 
emptying from sorghum was significantly slower in comparison to rice potato and pasta. 
Slower gastric emptying influences post -prandial glycemia in T2D reduces the glucose 
excursion (44-46). The difference in the common food sources by regions and the data 
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suggesting that the physiological response to carbohydrates differ depending on the type of 
carbohydrate, exemplifies the impact that heterogeneity can have. A dietary intake study 
conducted in the UK further adds to the evidence for differences in dietary intake within the 
black community. Goff et al. conduced an observational assessment of dietary intake in 
healthy adults who identified as west African or African-Caribbean ethnicity using 24-hour 
recall. It was found that total energy intake and total sugars were significantly higher in 
African-Caribbean’s compared to west Africans (47). 
In terms of genetics, Africa has been highlighted as one of the most genetically 
diverse continents with a high degree of admixture from non-Africans, particularly in the 
southern regions. which partially explains the heterogeneity on the continent (43). 
In terms of the heterogeneity in disease experience, a recent study comparing over 
40,000 non-Hispanic black adults who took part in the U.S. National Health survey, divided 
participants into African Americans (born in the USA), African immigrants (born in Africa) 
and African Caribbean (born in the Caribbean). It was found that the prevalence of 
hypertension, type 2 diabetes and obesity was significantly higher in African Americans in 
comparison to the other two groups (48), the difference in obesity rates between African 
Americans and Africans (from rural Ghana) and Caribbean’s (from urban Jamaica) has also 
been reported by a study in 1500 adults (49). As another example, data from population based 
surveys and the WHO which have assessed the degree of obesity across different regions of 
Africa have almost consistently reported heterogeneity in the prevalence of obesity and T2D 
(50, 51). The southern African region (primarily driven by south Africa), and the northern 
region (primarily driven by Egypt), suffer from a significantly higher burden of obesity in 
comparison to the remaining African regions (50). Although these examples display a degree 
 
1.3 Risk factors for type 2 diabetes 
9 
of heterogeneity in the disease experienced by the black community, detailed studies 
comparing the pathophysiology of T2D in various black groups are scarce. The studies which 
have been done suggest glucose, insulin, c-peptide profiles, insulin sensitivity and glucose 
effectiveness measured during oral and intravenous glucose tolerance tests were no different 
between 30 Ghanaian immigrants and 68 African Americans with normal glucose tolerance 
matched for age and BMI (52, 53). A more recent study compared African immigrants 
residing in Washington and divided participants into those born in western (n=61), central 
(n=41) and eastern (n=29) Africa (54). The participants were similar in BMI (overweight), 
diabetes status and blood lipids however the west Africans were significantly older. Each 
participant underwent an intravenous glucose tolerance test and the results showed no 
significant difference in insulin sensitivity or secretion (54). This could imply that the 
differences in the diabetes experience in the different black communities may relate to factors 
outside of insulin sensitivity or secretion.  
 
1.3.2.2 Black ethnicity as a risk factor for type 2 diabetes 
It has been suggested that the disproportionate prevalence of T2D in black 
communities compared to their white counterparts may partially be attributed to ethnic 
differences in social and lifestyle factors (such as physical activity and diet) (40). 
A systematic review combining studies which compare adults from different ethnic 
groups found that African Americans consistently participated in less leisure time physical 
activity compared to white Americans (55). In addition, baseline survey data from the Multi-
Ethnic Study of Atherosclerosis (MESA) study; which includes 1503 African Americans and 
2425 white Americans, found that African Americans reported less vigorous physical activity 
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in comparison to white Americans and were more sedentary during leisure hours (15). The 
importance of this ethnic difference in physical activity is highlighted by the evidence which 
indicates that the incidence of T2D is higher when physical activity is lower, and the risk of 
T2D is lower with more moderate to vigorous physical activity (15, 56, 57). Interestingly, 
this trend appears to be driven more so by the white American population (15) , there may 
be an ethnic difference in the relationship between vigorous or leisurely physical activity and 
the incidence of T2D between white and black communities.  
Studies which have compared dietary intake in black and white communities have 
inconsistent results. A study based in the UK using a 4 day food diary in 37 African 
Caribbean’s and 416 white Europeans found that the proportion of total energy intake derived 
from carbohydrates and starch was significantly higher in African Caribbean’s  compared to 
white Europeans (58). This may suggest the African Caribbean diets are of a higher 
glycaemic load and more likely to be diabetogenic. However, a large US study using data 
from the 1999–2000 National Health and Nutrition Examination Survey including 7 million 
African Americans and 41 million Non-Hispanic white Americans found no ethnic difference 
in carbohydrates but went on to find that adjusting for various macronutrients did not account 
for the ethnic difference in markers of T2D pathogenesis (namely insulin sensitivity) (59). In 
agreement, another study in 95 African American and non-Hispanic white children found 
that adjusting insulin sensitivity for macronutrient intake, measured using 24-hour recall, did 
not affect the ethnic difference in insulin sensitivity (60). These data could imply that the 
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1.3.2.3 Black ethnicity as a risk factor for T2D: the perspective in the UK 
Within the UK, data from the Health Survey for England in 2004 showed that, 
compared to white Europeans, the prevalence of T2D was 2-3 times higher in black African 
or Caribbean men (figure 2A) and women (figure 2B) (61). This disproportionate prevalence 
has also been reflected in a large-scale epidemiological study by Tillin and colleagues (62). 
They predicted that by age 80 years, approximately 40 to 50% of black African Caribbeans 
will have T2D; this is double the predicted prevalence in the white population (62).  
Not only is the prevalence higher in black communities, but the relationship with 
other risk factors appears to be ethnically distinct. Obesity is a risk factor for T2D, which has 
been discussed in section 1.3.1. However, it is persistently reported that T2D presents itself 
at a lower BMI in black communities (63-65). Although both obesity and being of black 
ethnicity constitute as risk factors for T2D, it has become apparent that the association 
between obesity and T2D may differ between different ethnic groups (66). Data from the UK 
biobank which includes over 7,000 black participants and 147,000 white participants, has 
shown that the associations between measures of adiposity (BMI, waist circumference, body 
fat percentage and hip-to-waist ratio) were significantly steeper in black adults compared to 
white adults. This relationship remained significantly stronger in black compared to white 
adults even after adjusting for age, socioeconomic status, physical activity, heart disease, and 
alcohol consumption. For each unit of BMI (kg/m2) or waist circumference (cm), the 
prevalence of diabetes was higher in black compared to white adults (66). In addition to 
obesity, age is also a risk factor for T2D, which was mentioned in section 1.3. Black 
populations have been shown to present with T2D 10 years earlier compared to white 
populations which may imply that the relationship with age is ethnically distinct (63, 67). 
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Clinical data shows higher rates of T2D complications in black communities, 
mirroring the increased prevalence and provides evidence for the subsequent healthcare 
burden (30). Studies from the USA suggest black populations have a higher risk of mortality 
from stroke, lower limb amputations, end-stage renal disease, diabetic retinopathy and are 
overall more likely to be hospitalised for diabetes-related complications (30). Studies from 
the USA also show the response to traditional prevention strategies which target weight loss, 
conducted outside of the controlled research environment, being significantly less effective 
in black compared to white communities (68, 69). Whilst studies in the UK assessing the 
prevention response by ethnicity are scarce, a recent assessment of the UK Diabetes 
Prevention Programme has reported significantly lower weight loss and less of a reduction 
in glycated haemoglobin (HbA1c) in individuals of black ethnicity compared to white (70). 
Therefore, understanding the impact of ethnicity on T2D pathophysiology is a healthcare 










Figure 2: The prevalence of doctor-diagnosed type 2 diabetes in the UK for (A) men and (B) 
women. Data extracted from the Health Survey for England 2004 report on the health of minority 
ethnic groups (61). 
 
1.4 The pathophysiology of type 2 diabetes  
The pathophysiological changes which lead to the development of hyperglycaemia 
and T2D are complex and involve multiple factors (71, 72). Historically, T2D is described to 
result from the progressive failure of the pancreatic beta-cell to secrete sufficient insulin, on 
a backdrop of insulin resistance (1, 72). A resistance to insulin’s action, particularly in the 
muscle and liver, has been shown to occur early in the development of T2D. It is thought to 
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result from either, or both, genetic susceptibility and a positive energy balance linked to 
environmental, socioeconomical and behavioural factors. The pancreatic beta-cell is 
sensitive to changes in blood glucose and over-secretes insulin to compensate for the insulin 
resistance which prevents frank hyperglycaemia from occurring. The beta-cell compensatory 
response encompasses adaptive changes. The beta-cell increases proliferation to increase 
beta-cell mass; although evidence in humans is minimal due to the lack to techniques and 
cadaver studies show a large range in beta-cell mass of patients with T2D, and upregulates 
intracellular mechanisms (unfolded protein response and mitochondrial metabolism) to 
increase beta-cell performance. The prolonged insulin secretory response to the 
hyperglycaemia is suggested to cause stress to the endoplasmic reticulum, oxidative stress, 
mitochondrial dysfunction and inflammation. This leads to either beta-cell death (apoptosis) 
or beta cell differentiation into a new phenotype with altered insulin signalling pathways and 
insulin production pathways, thought to protect the cell from death (73, 74). During the stage 
of beta-cell hypersecretion, patients present with hyperinsulinemia which is also thought to 
lead to a vicious cycle of worsening insulin resistance and the need for more insulin 
production. Overt T2D develops in individuals who fail to elicit the compensatory insulin 
secretion and whose beta-cell function declines allowing hyperglycaemia to occur (71, 72, 
75, 76). Longitudinal data from the Whitehall study based on over 6000 participants who 
were followed up for 9.7 years on average and assessed using fasting insulin secretion indices 
suggest that beta cell function declines exponentially (77).  
In 2009, the term ‘ominous octet’ was conceived and summarised the evidence for 
eight distinct factors which could drive T2D. However, since 2016 the ‘ominous octet’ has 
been updated to the ‘egregious eleven’ as shown in figure 3 (78). Whilst the traditional 
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description of the progression to T2D remains at the centre of the literature exploring the 
pathophysiology, the ‘egregious eleven’ details the complexity of the pathophysiological 
changes and identifies the pancreatic beta-cell failure as the final common denominator for 
hyperglycaemia. The beta-cell failure describes the decline in function and/or a loss of the 
cell mass (apoptosis), leading to a decline in endogenous insulin secretion; also described as 
dysfunctional beta cell mass. Similar to insulin resistance, the tendency towards beta-cell 
failure to adapt and elicit a compensatory response may depend on if a genetic susceptibility 
is present (78). In addition to the final common denominator, beta-cell failure, the other 
distinct pathological processes which promote the development of T2D are summarised as 
follows: 
• A reduction in the incretin effect, which normally functions to augment insulin secretion, 
is thought to contribute towards hyperglycemia. In a healthy individuals, an oral glucose 
load will stimulate the gut to release incretin hormones (glucose-dependent insulinotropic 
polypeptide and glucagon-like peptide-1) which potentiate glucose induced insulin 
secretion (79). 
• A defect in the pancreatic alpha-cells, which secrete glucagon when glucose 
concentrations are below the required demand, has also been suggested to promote 
hyperglycemia. Glucagon releases glucose from glycogen stores in the liver resulting in 
an increase in circulating glucose and may contribute towards the elevated fasting plasma 
glucose seen in T2D (71, 80, 81).  
• An increase in tissue-specific insulin resistance is often described as a driving factor for 
the increased demand on the beta-cells to secrete more insulin, which leads to the beta-
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cell failure and contributes towards hyperglycemia. Insulin resistance can be divided 
based on the different sites of insulin action - 
o Peripheral insulin resistance; a decrease in insulin mediated peripheral glucose 
uptake. The peripheral tissues are primarily composed of skeletal muscle. 
o Hepatic insulin resistance; an increase in endogenous glucose production in the 
presence of insulin. The liver is the primary source of endogenous glucose 
production. 
o Adipose tissue insulin resistance to lipolysis; increased lipolysis in the presence 
of insulin (71). 
• Changes to the neuronal activity which regulates energy homeostasis and metabolism 
such as increasing appetite which can contribute towards hyperglycemia. This may 
represent a form of insulin resistance because insulin has been shown to reduce appetite 
(71, 78, 82). 
• Alterations in gut microbiota have been associated with changes in insulin sensitivity and 
products produced by the microbiome fermenting macronutrients have receptors on beta 
cells which have been shown to augment insulin secretion in vitro (82). 
• A low grade chronic systemic inflammatory response by the immune system has been 
associated with T2D and insulin resistance. Inflammatory cytokines have been shown to 
induce beta-cell damage, apoptosis and reduced function which may contribute towards 
hyperglycemia (83). 
• Increased gastric emptying and glucose absorption in the small intestine may contribute 
towards hyperglycemia. This may occur in response to reduced amylin production as a 
result of beta-cell dysfunction (78).  
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(84). Insulin sensitivity occurs along a spectrum and whilst a few studies have attempted to 
determine the cut-off at which insulin sensitivity is pathologically low (insulin resistant) (84, 
85), this has yet to be replicated extensively in the literature or clinical practice. Insulin 
resistance is defined as a metabolic state by which higher than normal insulin concentrations 
are required to elicit a quantitively normal response; it represents a state of impaired insulin 
response (86, 87). Insulin is well known for its glucose-lowering actions (88), and the term 
insulin sensitivity is generally used to describe insulin-mediated glucose disposal and 
suppression of endogenous glucose production. However, insulin is a peptide hormone 
secreted from the beta cells of the pancreas into the circulation where it acts on cell surface 
receptors on multiple cell types and tissues. This pleiotropic nature of insulin suggests that 
insulin resistance can be tissue-specific (89, 90). Tissue-specific insulin receptor knockout 
models in rodents have confirmed this tissue-specific nature of insulin sensitivity in vivo (91-
94). Understanding insulin actions at different sites provide a better understanding of T2D 
pathophysiology and potential targets for treatment and prevention. The organs and tissues 
which insulin target that have been identified as dysfunctional in T2D include the peripheral 
tissues and the liver. 
 
1.5.1 Peripheral insulin sensitivity to glucose homeostasis  
When considering the actions of insulin, the peripheral tissues are effectively 
comprised of skeletal muscle and adipose tissue, both of which have significant involvement 
in glucose metabolism (95). Glucose is taken up and metabolised in peripheral tissues, 
referred to as peripheral glucose disposal. Insulin has been well characterised as a regulator 
of glucose disposal by increasing the transport of glucose into the peripheral tissues and 
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influencing the intracellular fate of the glucose (oxidative or non-oxidative metabolism). 
Thus, peripheral glucose disposal increases during the insulin-stimulated state, e.g. after 
digestion of a meal. An early tracer study provided evidence that adipose tissue glucose 
uptake accounted for less than 1% of peripheral disposal from intravenous glucose (96, 97). 
Since then, other studies using positron emission tomography with tracers and the 
hyperinsulinaemic clamp have shown adipose tissue to account for less than 5% of total 
glucose disposal (75, 95, 98, 99), although this percentage can be higher in cases of severe 
obesity (BMI over 43 kg/m2) due to the higher volume of adipose tissue (100-102). In 
comparison, studies (mainly in healthy participants) which have quantified the contribution 
of skeletal muscle glucose uptake to peripheral or whole-body glucose disposal using femoral 
artery or vein catheterisation or positron emission tomography with tracers, consistently 
show much higher percentages which range from 70 to 90% (76, 86, 90, 95, 97, 103-106). 
These data indicate that peripheral glucose disposal primarily reflects disposal into the 
skeletal muscle. 
 
1.5.1.1 Peripheral insulin sensitivity, a focus on the cellular process  
Insulin promotes peripheral glucose disposal by affecting multiple cellular processes 
which are summarised schematically in figure 4. To begin peripheral glucose disposal, 
insulin increases the rate of glucose transport across the cell membranes into peripheral tissue 
cells; it does so by binding to and activating the insulin cell surface tyrosine kinase receptor. 
When active, the insulin receptor substrates become phosphorylated and a downstream 
intracellular signalling cascade of substrate phosphorylation dephosphorylation reactions 
occur. This cascade results in the translocation of intracellular glucose transporters (the 
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GLUT 4 isoform) to the cell membrane (95). Glucose can then enter the cell through the 
GLUT 4 transporters. Glucose entry into peripheral tissue cells occurs primarily through 
GLUT 4 transporters and this process is highly regulated by insulin (107). Once glucose 
enters the cell, it is rapidly phosphorylated by a hexokinase enzyme (activated by insulin) 
which traps the glucose in the cell for utilisation. The phosphorylated glucose, glucose 6– 
phosphate, is either stored as glycogen or oxidised for energy by being converted to pyruvate 
then acetyl-coA which can enter the TCA/Krebs cycle in the mitochondria to generate energy 
(95). 
The storage of glucose as glycogen is further regulated by insulin. Insulin activates 
the glycogen synthase enzyme (which drives glycogenesis) and is highly sensitive at 
inhibiting the action of glycogen phosphorylase, which breaks down glycogen. The 
combined effect is a net increase in glycogen, which is later utilised when blood glucose 
levels decline (107). Glucose is stored in the adipose tissue as glycogen but to a lesser extent 
than in muscle (100, 108), for which the function is less clear. Glucose which is not stored 
directly as glycogen is oxidised to release energy and other metabolic by-products. This 
breakdown begins with glycolysis which involves a series of enzymatic reactions also 
regulated by insulin (109). In particular, insulin activates the enzyme 6-phosphofructokinase 
which is part of the glycolytic chain of enzyme reactions (107, 110, 111). The end-stage 
product of glycolysis is pyruvate, which when oxygen is present (oxidative metabolism), is 
transferred to the mitochondria and converted to Acetyl-coA and joins the Krebs/TCA cycle 
which releases energy, CO2 and H2O. Glucose also undergoes glycolysis in the adipose 
tissue, and this forms intermediate by-products which increase de novo lipogenesis (the 
formation of fatty acids and or glycerol which are subsequently esterified into triglycerides) 
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in the adipose tissue (100, 109, 112, 113). However, the magnitude of fatty acids formed 
from de novo lipogenesis is not as high as the fatty acid uptake which is discussed in section 
1.5.3 (100). 
It is thought that when oxygen is limited, e.g. during anaerobic physical activity, the 
pyruvate which represents the end-stage of glycolysis, is converted to other glucogenic 
intermediates such as lactate or alanine. This process releases less energy than oxidative 
metabolism. The lactate is released from the muscle and taken up by the liver for conversion 
to glycogen, lactate is a precursor molecule for this process (109). The molecular process for 
the conversion of glucose to lactate to glycogen in the liver is termed the Cori cycle (107). 
Overall, the direct conversion of glucose to glycogen and the indirect process of lactate to 
glycogen (glycogenesis) are described together as non-oxidative glucose metabolism (95). 
Data from a single tracer study in 11 normal glucose tolerant (NGT) participants free from a 
family history of T2D quantified glucose disposal following a meal (6 kcal/kg) composed of 
50% carbohydrate, 30% fat and 20% protein. Woerle et al. found that 33% of glucose 
entering the cell undergoes direct storage as glycogen; the remaining 67% undergoes 
glycolysis. This can either be oxidative (44%) or non-oxidative (23%) forming glucogenic 
intermediates such as lactate. 12% of these nonoxidative outputs are stored in the liver as 
glycogen and 11% are used by the liver in glucogenesis which reforms glucose (114).What 
is not addressed by Woerle et al. is that the fate of glucose differs when glycogen stores are 
at capacity or depleted and that metabolic demand for the individual varies. Therefore, it is 
likely that there is a range in the percentage of glucose which is stored or undergoes 
glycolysis. Factors which may influence the glycogen storage status include prolonged 
fasting, moderate-to-high intensity exercise or increased intake of fructose (115). In addition 
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to metabolic state, the method used to measure glucose storage may also play a role in 
differences in the reported fate of glucose. Studies based on euglycaemic insulin clamp, 
which use intravenous rather than oral glucose, have provided evidence that 60-90% of 
glucose is stored as glycogen and the remaining is oxidised for energy via glycolysis (95, 
116, 117).  
 
Figure 4: A schematic diagram for the process of glucose disposal in skeletal muscle with the 
processes and proteins/enzymes in green stimulated by insulin and the enzyme in red inhibited by 
insulin. 
1.5.1.2 Peripheral insulin sensitivity changes with impaired glucose tolerance 
In impaired glucose tolerance, peripheral insulin sensitivity for glucose metabolism 
becomes moderately to severely defective. Data from longitudinal studies in Pima Indians 
have been used to assess the progression of T2D (95). 24 NGT participants with an average 
age of 27, an average BMI of 37.6 kg m2/kg at their initial assessment, progressed to impaired 
glucose tolerance (IGT) within the 2 year follow up. Participants underwent a 
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Hyperinsulinaemic-euglycemic clamps and oral glucose tolerance tests. The data show an 
almost consistent fall in peripheral insulin sensitivity (insulin mediated glucose disposal) and 
a rise in hyperinsulinemia when comparing the initial and follow up assessments (118). In 
addition to longitudinal studies, comparing NGT participants with a first-degree relative 
suffering from T2D is thought to provide an insight into the disease progression. This is 
particularly apparent in Mexican-Americans who have up to an 80% increased risk of T2D 
when there is a positive family history of T2D (95). Multiple studies in Mexican-American 
adults (119, 120) and white Europeans (119, 121, 122) have provided evidence for greater 
insulin resistance in normal glucose tolerant individuals with positive family history of T2D 
compared to those with a negative family history of T2D. The pronounced insulin resistance 
found in individuals with a family history and the longitudinal data in particular, suggest that 
that peripheral insulin resistance may be implicated in the development of T2D .Peripheral 
glucose disposal in response to insulin has been shown to decline by over 45% in lean and 
obese subjects with T2D (75, 86, 90, 97) and is approximately 30% lower in impaired glucose 
tolerance (IGT) compared to normal glucose tolerance (NGT) (123). Studies have shown that 
the peripheral insulin resistance is mainly a reflection of impaired glycogen synthesis (non-
oxidative glucose metabolism) rather than oxidative glucose metabolism (95, 106, 124-126) 
although earlier work shows impairments in both oxidative and nonoxidative glucose 
metabolism in T2D compared to NGT (127). 
 
1.5.2 Hepatic insulin sensitivity to glucose homeostasis 
The liver orchestrates a multitude of metabolic reactions which contribute to glucose 
homeostasis. The processes which are well characterised include hepatic gluconeogenesis, 
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glycolysis, glycogen synthesis (glycogenesis) and glycogenolysis, which collectively 
contribute to net hepatic glucose production. Insulin, in combination with other hormones 
and substrates, influences these processes and is well characterised to mediate suppression 
of hepatic glucose production (128). Skeletal muscle is primarily responsive to insulin during 
the stimulated state where it takes up exogenous glucose and any residual hepatic glucose 
production from the liver. The liver is also sensitive to insulin at lower concentrations which 
include those of the basal/fasted state. During such, the primary source of glucose (fuel) to 
glucose-requiring organs, e.g. neural tissues, is endogenous glucose production. This is true 
across glucose tolerance groups. The organs which contribute to endogenous glucose 
production are primarily the liver (95%) and the extrahepatic glucogenic organs (mainly from 
the kidneys; 5%)- therefore, hepatic glucose production is the main component of 
endogenous glucose production, which highlights the importance of the liver in endogenous 
glucose regulation (128-130).  
 
1.5.2.1 Hepatic insulin sensitivity, a focus on the cellular process 
Unlike the muscle, glucose entering the liver occurs primarily independently of 
insulin through GLUT 2 glucose transporters; therefore, insulin does not increase hepatic 
glucose uptake (131). Glucose which enters the liver cell (hepatocyte) is phosphorylated by 
glucokinases, rather than hexokinases found in the muscle, which prevents glucose from 
being exported by the hepatocyte (132). The activation of glucokinases is facilitated by 
insulin; therefore, insulin plays a role in retaining glucose which enters the hepatocyte. The 
glucose is subsequently used as a substrate for glycogen synthesis and for hepatic de novo 
lipogenesis (the production of fatty acids which can be esterified into triglycerides and 
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packaged into very-low-density lipoproteins (VLDLs) for transport in the blood) when 
glycogen stores have reached capacity (113, 133, 134). Similar to muscle, glycogen synthesis 
and glycolysis also occur in hepatocytes and are regulated by insulin as described in section 
15.1.1. 
In addition to taking up glucose, the liver is the primary source of glucose production 
during the fasted state. As discussed previously, insulin is well characterised as a suppressor 
of hepatic glucose production, particularly during feeding when glucose and insulin 
concentrations are high. Insulin suppresses hepatic glucose production by inhibiting 
gluconeogenesis and increasing glycogen synthesis during the insulin-stimulated state. There 
is evidence to support that insulin receptor signalling increases glycogen synthesis by 
activating the glycogen synthase. There is also evidence for insulin-stimulated transcription 
of the FOXO1 gene which reduces gluconeogenesis; however, this effect is much slower. 
Insulin’s combined impact of reducing gluconeogenesis and increasing glycogen synthesis 
is reduced hepatic glucose production. Insulin also has indirect actions on the hepatocyte 
which further reduce hepatic glucose production through reducing gluconeogenesis. Insulin 
inhibits lipolysis in the adipose tissue which reduces the availability of glycerol and fatty 
acids to the liver. Both glycerol and fatty acids can be taken up by hepatocytes and used as a 
substrate for gluconeogenesis. Insulin reduces this indirectly by inhibiting adipose tissue 
lipolysis, which releases glycerol and fatty acids, therefore reduces the substrates for 
gluconeogenesis (107, 128, 135, 136). 
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1.5.2.2 Hepatic insulin sensitivity changes with impaired glucose tolerance 
Studies comparing NGT with IGT show no difference in hepatic metabolism 
(endogenous glucose production) suggesting dysfunctional hepatic metabolism may not 
contribute to IGT (123). However, individuals diagnosed with frank hyperglycaemia (T2D) 
have consistently shown reduced insulin-stimulated suppression of hepatic glucose 
production during physiological and supraphysiological conditions. The basal release of 
hepatic glucose is also significantly higher in T2D which contributes to fasting 
hyperglycaemia (128). The increased hepatic glucose production occurs in the presence of 
hyperinsulinaemia and is termed hepatic insulin resistance. Reduced suppression of hepatic 
glucose production characterises hepatic insulin resistance which is often found in T2D and 
contributes to hyperglycaemia in both the postabsorptive (fasting) and postprandial (feeding) 
state. Studies comparing NGT and T2D metabolism have shown impairments in the hepatic 
insulin receptor signalling in hepatocytes and impairments in the indirect insulin action 
(increased lipolysis end products), both of which result in increased gluconeogenesis. 
Glycogenolysis has not been shown to change in T2D (128, 132); however, the dual effect 
of increased gluconeogenesis and no change in glycogenolysis is an increase in hepatic 
glucose production which contributes to hyperglycaemia. 
 
1.5.3 Adipose tissue insulin sensitivity to lipolysis 
Adipose tissue was historically thought to be a metabolically inactive tissue which 
stored lipids as triglycerides. However, it is now understood to have several metabolic 
functions which affect glucose and lipid homeostasis (107, 137). As discussed in section 
1.5.1, adipose tissue forms part of the peripheral tissues which are subject to insulin-
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stimulated glucose disposal. The adipose tissue contribution to peripheral glucose uptake has 
been shown to be marginal in comparison to the muscle (100). An assessment of adipose 
tissue glucose uptake in obese and lean participants has shown that in the presence of lower 
whole-body insulin sensitivity in obese participants, adipose tissue glucose uptake was lower 
in obese compared to lean participants when expressed per unit of fat mass. However, when 
multiplied by fat mass to reflect total adipose tissue glucose uptake, there was no difference 
in adipose tissue uptake between lean and obese participants due to the higher fat mass in 
obesity. For both lean and obese participants, adipose tissue glucose uptake accounted for 
less than 5% of total glucose uptake and it was suggested that resistance to adipose tissue 
glucose uptake may not be the culprit for whole-body insulin resistance (98). 
This section focuses on insulin’s effects on lipid metabolism in the adipose tissue (the 
adipocytes). Insulin is known for its actions in reducing circulating fatty acids. It does so in 
part, by inhibiting lipolysis in the adipose tissue. Lipolysis is defined as the hydrolysis (break 
down) of triglycerides into glycerol and fatty acids (138). Insulin is a potent antilipolytic 
hormone, this action is sensitive at lower concentrations of insulin than insulin-mediated 
glucose disposal in the muscle. Insulin inhibits adipose tissue lipolysis by binding to and 
phosphorylating the insulin tyrosine kinase receptor which triggers a downstream signalling 
cascade. This cascade ends with reduced phosphorylation and thus inactivation of hormone-
sensitive lipase, an enzyme which cleaves triglycerides as part of the lipolysis process (72, 
100, 107, 139-142).  
In addition to insulin-regulated lipolysis in adipose tissue, lipolysis can also occur 
extracellularly in the circulation (138); although the magnitude of this is minimal in 
comparison to intracellular lipolysis (143-145). Triglycerides are hydrophobic molecules, 
 
1.5 Insulin sensitivity 
28 
and the circulation is an aqueous environment. Therefore, the primary source of circulating 
triglycerides is within triglyceride-rich lipoprotein complexes (e.g. chylomicrons or VLDLs) 
(146). Lipoprotein lipases are a group of enzymes which hydrolyse triglycerides within the 
circulating lipoproteins and therefore facilitate triglyceride clearance (135). This action 
releases fatty acids and glycerol which are taken up by adipose tissue or muscle by passive 
diffusion or through fatty acid transporters. They are either used to produce energy via fatty 
acid oxidation or are re-esterifed into triglycerides for storage; depending on the cellular 
requirement (145). This process particularly occurs during the fed, insulin-stimulated state. 
Studies have shown that insulin increases the expression and activity of lipoprotein lipase 
(107, 146-148) and increases the translocation of fatty acid transporters (e.g. CD36 or 
FATP1) which facilitate fatty acid entry into adipose tissue primarily for storage (100, 107, 
137, 147, 149, 150) or muscle (145). 
Overall data suggest insulin promotes fat accumulation through increasing storage 
and mobilisation of triglycerides (as discussed here) and by stimulating de novo lipogenesis 
which occurs when glycogen stores reach capacity during glucose uptake (as discussed in 
section 1.5.1.1) (100, 113).  
 
1.5.3.1 Adipose tissue insulin sensitivity changes with impaired glucose tolerance 
Resistance to the antilipolytic action of insulin in adipose tissue has been implicated 
in the development of T2D (151-154). This resistance results in excessive fatty acids release 
in the presence of insulin. A cross-sectional study has shown that adipose tissue insulin 
resistance to lipolysis is present in obese NGT, IGT and T2D, with insulin resistance getting 
progressively worse. This provides evidence for the role of adipose tissue insulin resistance 
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in T2D development. On average, adipose tissue resistance to insulin stimulated fatty acid 
suppression was 2.5 and 4 times higher in IGT and T2D, respectively, compared to lean NGT 
(154); although differences in fat mass and age were not accounted for in that study. Similar 
findings have also been found in adolescents when comparing NGT and IGT in a cross-
sectional study (153). 
 
1.5.4 Other insulin actions and tissues 
Sections 1.5.1 and 1.5.2 discuss insulin’s effect on glucose metabolism in peripheral 
and hepatic tissues; however, insulin is also able to affect lipid metabolism in peripheral and 
hepatic tissues. In skeletal muscle, insulin decreases the oxidation of fatty acids which is 
thought to compete with glucose oxidation as described in the Randle cycle (107, 155). 
Insulin also has actions which influence protein metabolism in the muscle and liver (107). 
These aspects of lipid and protein metabolism are beyond the scope for this thesis but should 
also be noted. 
The descriptions in sections 1.5.1 and 1.5.2 have focused on insulin-mediated glucose 
disposal and metabolism however, glucose disposal also occurs independently of insulin. 
This is mainly present in neural and some splanchnic (intestine) tissues. The glucose disposal 
in these tissues is not thought to change in the development of T2D and is also beyond the 
scope for this thesis (105).  
 
1.6 Measuring insulin sensitivity 
Despite the many actions of insulin, it is the insulin-mediated glucose disposal and 
suppression of endogenous glucose production that is generally referred to as ‘insulin 
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sensitivity’ in the context of T2D (89). Andres, DeFronzo and colleagues developed and 
published the hyperinsulinaemic-euglycaemic clamp (HEC) as a method for assessing insulin 
sensitivity in vivo (156-158). The principles behind this technique are based on the creation 
of a hyperinsulinaemic environment by infusing insulin peripherally and allowing the 
concentration to achieve a plateau. In order to maintain euglycaemia during the 
hyperinsulinaemia, an exogenous glucose infusion is simultaneously applied. The glucose 
infusion rate required to achieve euglycaemia in the presence of hyperinsulinaemia, is a 
measure of an individual’s sensitivity to insulin. This method assumes that the peripheral 
insulin infusion suppresses any contribution which endogenous glucose production may 
have, so that the glucose infusion is the only glucose source. The glucose infusion rate is, 
thusly, a measure of total glucose disposal or whole-body insulin sensitivity and is expressed 
as the M value (87). To compare this M value between different individuals, it must be 
normalised by expressing the infusion rate per unit of metabolic size. There are multiple 
options such as kg body weight, fat-free mass (FFM) or body surface area (BSA). 
Interestingly, data from the Pima Indian population has identified that normalising by kg 
body weight underestimates insulin sensitivity during the obese state because obese 
individuals have a greater proportion of lower metabolising adipose tissue. FFM is the ideal 
option due to the insulin sensitive nature of FFM. Less data are available on the correction 
for BSA as a surrogate assessment of metabolic size (33, 84, 104). Insulin sensitivity can also 
be expressed as a function of insulin by normalising total glucose disposal per unit of insulin 
(156). 
The pleiotropic nature of insulin suggests assessing the insulin response in each 
tissue, beyond assessing solely total glucose uptake, is of interest in T2D pathophysiology 
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(89). By tracing glucose and glycerol fluxes using isotopic tracers before and during a 
hyperinsulinaemic-euglycaemic clamp, tissue-specific (peripheral, hepatic and adipose) 
assessments of insulin action can be derived (105, 143, 144, 159-161). There are multiple 
methods for expressing insulin sensitivity derived from the hyperinsulinaemic-euglycaemic 
clamp and isotopic tracers. However, there is no consensus for the optimal calculation to 
express insulin sensitivity from clamp measures. Various investigators have employed 
percentage change, insulin adjustments and other calculations across the literature (87, 89, 
162). The most appropriate calculation is dependent on the research question and the 
characteristics of the individuals analysed. Peripheral insulin sensitivity is generally assessed 
during insulin stimulation with the variations being whether the glucose disposal is presented 
alone, whether glucose disposal is adjusted for ambient insulin concentrations (i.e. using the 
peripheral insulin sensitivity index (153)), or whether the percentage increase in glucose 
disposal is presented (163). In comparison, both hepatic and adipose tissue insulin sensitivity 
are frequently assessed during the basal/postabsorptive state using isotopic tracers without 
insulin stimulation (164-167) or as the suppression of glucose or glycerol appearance during 
insulin stimulation (129, 163). 
Bergman and colleagues have also developed and published a dynamic method to 
estimate insulin sensitivity; the frequently sampled intravenous glucose tolerance test 
(IVGTT) with minimal model analysis. This mathematical model couples two equations to 
assess insulin-mediated glucose disposal (87, 168, 169). When modified to include insulin, 
this method closely correlates to the glucose clamp. Without the insulin modification, the 
model is unable to produce meaningful results for insulin sensitivity in cases where insulin 
secretion is low, such as during T2D (87, 170, 171). 
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Whilst the hyperinsulinaemic-euglycaemic clamp has been termed the “gold 
standard” procedure to assess insulin sensitivity (157), it is not without its practical 
limitations (87, 172). Its labour-intensive, time-consuming and expensive nature and the 
expertise required to conduct a glucose clamp make it challenging to apply in large cohort 
studies (87). In addition, the duration and intensity of the hyperinsulinaemia creates a non-
physiological environment implying that using the clamp to measure insulin sensitivity may 
not reflect the human physiological response that would occur following a meal. Several 
simple surrogate estimates of insulin sensitivity have been derived from fasting (static state) 
or the oral glucose tolerance test (dynamic state), which include the homeostatic model 
assessment (HOMA) (173), quantitative insulin sensitivity check index (QUICKI) (171), oral 
glucose insulin sensitivity index (OGIS) (174) and the Matsuda index (175). All these models 
make assumptions about glucose homeostasis which may differ between different subjects. 
The models have been validated by comparing their results against clamp-derived measures.  
 
Table 1: A summary of the different experimental methods used to measure insulin 
sensitivity 
Method Description Strengths Limitations 
HEC A direct measure of glucose 
disposal for a given insulin 
concentration using exogenous 
insulin and glucose 
intravenous infusions. 
Assessments are made during 
the basal and insulin 
stimulated steady state 
whereby the variation in blood 
glucose, insulin and the 
glucose infusion are minimal. 
-When combined with isotopic 
tracers (which allow for a 
multi-compartment model), it 
can be used to assess 
endogenous glucose 
production, peripheral glucose 
disposal and whole-body 
lipolysis. 
-It creates a controlled 
hyperinsulinaemic plateau and 
is highly reproducible. 
-Turns off physiological 
feedback loops and creates a 
supraphysiological 
environment. 
-Risk of hypokalaemia. 
-Time consuming due to the 
steady state requirement. 
-Labour intensive. 






The minimal model 
(MINMOD) is applied to 
glucose and insulin data from 
an IVGTT. There are two 
-Can also be used to assess the 
acute insulin response and 
glucose effectiveness. 
-An indirect assessment 
based on dynamic changes 
in glucose and insulin. 
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MINMOD main equations that define the 
MINMOD; one describes 
glucose dynamics in a single 
compartment and the other 
describes insulin dynamics in 
another remote compartment. 
 
A modified frequently 
Sampled IVGTT, include an 
insulin or tolbutamide dose, is 
applied in participants known 
to be insulin resistant. 
-Does not require a steady 
state and is less labour 
intensive than the HEC. 
 
-Assumes glucose and 
insulin dynamics function in 
separate single 
compartments which is an 
oversimplification of 
glucose homeostasis. 
-Requires frequent sampling 
-The test is known to be less 
reliable in individuals with 
impaired glucose tolerance 
and T2D.  
OGIS It is an equation which has 
been developed based on 
mathematical modelling which 
was optimised to match HEC 
data. The equation uses 
glucose and insulin data 
derived from a 75g OGTT. 
 
-Based on physiological 
response to oral glucose. 
-Can be applied to a large 
group of participants. 
-Requires only 3 sampling 
time points. 
-Can distinguish between 
glucose tolerance groups. 
-Can be used for 3 or 2 hour 
OGTTs. 
-Assumes the relationship 
between glucose clearance 
and insulin is linear. 
-Describes glucose and 
insulin dynamics based on a 
single compartment. 
-Assumes a fixed value for 
endogenous glucose 
production. 
Matsuda An equation which has been 
developed as a composite 
measure of peripheral and 
hepatic insulin sensitivity 
based on glucose and insulin 
data derived from 75g OGTT. 
This is based on the 
understanding that 
endogenous glucose 
production is not suppressed 
by 100%. 
 
- Based on physiological 
response to oral glucose. 
-Can be applied to a large 
group of participants. 
-Requires only 5 sampling 
time points. 
-Incorporates an assessment of 
hepatic insulin sensitivity. 
 
-Endogenous glucose 
production is assumed to 
reflect product of fasting 
glucose and insulin 
-Assumes that whole-body 
insulin sensitivity during 
the OGTT is inversely 
proportional to the 
product of the mean plasma 
insulin and 
mean plasma glucose 
concentrations. 
HOMA A surrogate index for insulin 
sensitivity based a computer-
solved model of insulin and 




-Particularly sensitive in T2D 
where insulin levels are low 
and insufficient to maintain 
euglycemia. 
-Easily applied to large studies 
-Correlates well with hepatic 
insulin sensitivity. 
-Does not reflect post-
prandial insulin sensitivity  
QUICKI An index to assess insulin 
sensitivity based on 
postabsorptive glucose and 
insulin. 
-Easily applied to large studies 
 
-Does not reflect post-
prandial insulin sensitivity 
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1.7 The potential influencers of insulin resistance  
There is a long-recognised link between adiposity and insulin resistance. Studies 
which suggest a causal relationship between excess adiposity and insulin resistance have 
been conducted in humans whereby overfeeding lean individuals with no prior connection to 
obesity or T2D reduces their insulin sensitivity. Assessing the effect of overfeeding on insulin 
sensitivity in controlled research settings has generally focused on acute short-term effects, 
as opposed to chronic overfeeding, due to ethical and resource limitations. An example of 
one of the longer term overfeeding studies measuring insulin sensitivity and body 
composition was authored by Johannsen et al (176). Johannsen and colleagues assessed 29 
healthy men at an average age of 26; free from chronic metabolic disease, free from a history 
of eating disorders and reported to have a stable weight for at least 6 months prior. The 
participants were overfed by 40% of their energy requirement for 8 weeks and re-assessed. 
The participants exhibited an average weight gain of 7.6kg as well as a statistically significant 
increase in fat mass, percentage body fat, abdominal subcutaneous fat, visceral adipose tissue 
and intrahepatic fat. Insulin sensitivity was also assessed using a two-step hyperinsulinaemic-
euglycemic clamp and showed an increase in hepatic and peripheral insulin resistance (176). 
The finding of increased fat and decreased insulin resistance has been echoed in other 
overfeeding studies in healthy participants (177, 178). Interestingly, other overfeeding 
studies using a very high dose of dietary fructose (179), and high-carbohydrate (HC) or high-
fat (HF) overfeeding for 5 days (180, 181) showed no effect on insulin sensitivity. In these 
studies, there was no weight gain which may imply that it is the weight gain associated with 
overfeeding that is linked to the fall in insulin sensitivity.  
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Notably, not all individuals who are obese develop insulin resistance, they are often 
described to be metabolically healthy and at an energy balance (26, 182). A considerable 
amount of research has been conducted to identify and explain what may be influencing 
insulin resistance associated with obesity and T2D. 
 
1.7.1 Visceral adipose tissue 
Visceral adipose tissue (VAT) is defined as the adipose tissue which surrounds the 
intra-abdominal organs (183). Studies have shown that it is the rise in VAT independently, 
as opposed to general obesity, which predicts an increased risk of T2D and prediabetes (25, 
26). Neeland and colleagues assessed 732 obese participants without T2D who were enrolled 
in the Dallas Heart Study; a multi-ethnic population based adult cohort, and followed up for 
a median period of 7 years (184). The participants underwent magnetic resonance imaging 
(MRI), dual-energy x-ray absorptiometry (DEXA) and other biochemical measures. 11.5% 
of participants developed T2D and whilst there was no difference in BMI, body fat % or 
abdominal subcutaneous adipose tissue (SAT) between those who did and did not develop 
T2D; VAT and liver fat % were significantly higher in those who progressed to T2D. 
Dividing the data into tertials also showed a significant trend for increasing T2D incidence 
with higher VAT, this trend was not found for SAT or total body fat. Finally, multivariable 
logistic regression modelling revealed VAT as one of the independent factors associated with 
the incidence of T2D and pre-diabetes (184). Studies assessing the pathophysiology of T2D 
have found a significant association between VAT and insulin resistance (182, 185, 186) 
which may explain the increased risk with increasing VAT. The accumulation of VAT is 
thought to be a marker of SAT dysfunction (185) as VAT is thought to form in response to 
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dysfunctional lipid handling in SAT. SAT has the unique ability to safely store lipids as 
triglycerides by increasing adipocyte number (adipogenesis/ hyperplasia) (187). However, 
during excess caloric intake and reduced energy expenditure, SAT accumulation is thought 
to reach its capacity and is unable to continue this function (188). Therefore, adipocyte 
hypertrophy occurs, and the adipocytes become pro-inflammatory, insulin resistant and 
unable to store fatty acids as depicted in figure 5. This processes is often described as 
unhealthy adipose tissue expansion. The large dysfunctional adipocytes become resistant to 
insulin and allow fatty acids to spill over into other depots which include the visceral cavity 
(VAT) (137, 189) as shown in figure 5. Overall, the inability of SAT to store fatty acids may 
increase fatty acids release which accumulates as VAT (141, 188, 190-193). The 
dysfunctional fat metabolism and change in fatty acid trafficking have been described in 
multiple distinct theories including the “spillover”, “adipose tissue expandability”, “lipid 
overflow” and “sick adipose tissue”, each describes processes which are likely to occur 
simultaneously and may foster VAT accumulation (194). Lipodystrophy is a human model 
which supports the potential for dysfunctional lipid handling in SAT, leading to VAT 
accumulation and metabolic dysfunction. Patients with lipodystrophy show low SAT, but 
high VAT and typically display high insulin resistance. In comparison, studies in humans 
with low VAT and high SAT show participants to be relatively insulin sensitive. Other 
experimental studies in animal models support the theory that VAT is more detrimental to 
insulin sensitivity than SAT (195). 
Whilst individuals with high VAT have been described to be insulin resistant and 
present with dysfunctional glucose metabolism, the role of SAT and insulin resistance is less 
clear with the evidence from the overfeeding studies and the Dallas Heart study leading 
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towards VAT as the culprit and not SAT. In addition, Klein and colleagues have studied 
women with normal glucose tolerance and abdominal obesity; they assessed the effect of 
reducing abdominal subcutaneous adipose tissue (through liposuction) on insulin sensitivity 
assessed by a clamp and found no improvement in insulin sensitivity suggesting the lack of 
a relationship (196). However, there is some evidence to suggest that an increase in SAT is 
associated with a decreased risk of insulin resistance (186, 197). McLaughlin et al. assessed 
overweight and obese adults free from T2D who were stable in weight 3 months prior to their 
study visits. Participants underwent an insulin suppression test to assess insulin sensitivity 
and computerized tomography scans to assess VAT and SAT volume. They categorised 
participants as inulin sensitive or resistant based on previously published data. Using logistic 
regressions, it was found that each increment increase in VAT was associated with an 80% 
increased risk of being insulin resistant whereas each incremental increase in SAT was 
associated with a 42% decreased risk of insulin resistance. Therefore, the insulin sensitive 
phenotype may be associated with having less VAT and more SAT (198). This data implies 
that even though VAT only contributes towards 5-10% of total fat (199), an increase in VAT 
is negatively associated with insulin sensitivity. This link is further supported by a lack of 
insulin resistance in individuals with lower body obesity and the removal of abdominal 
subcutaneous adipose tissue having no effect on insulin resistance (200). Finally, the removal 
of VAT from obese rodent models has shown significant improvements in peripheral insulin 
sensitivity, using the hyperinsulinaemic-euglycemic clamp, which provides evidence for a 
causal association to insulin resistance (201, 202). Studies specifically assessing peripheral 
and hepatic insulin sensitivity have found a significant association with VAT in T2D (203-
205).   
 




Figure 5: Details for the changes which occur during unhealthy adipose tissue expansion in 
response to excess caloric intake and reduced physical activity. Dysfunctional lipid storing and 
adipose tissue remodelling may contribute to the accumulation of visceral and ectopic fat. Created 
with BioRender.com. 
 
1.7.1.1 Visceral adipose tissue and insulin resistance 
Investigations into the potential mechanisms which may explain the link between 
VAT and insulin resistance implicate the secretion of adipose-specific cytokines (adipokines) 
and inflammatory cytokines from visceral adipocytes. The inflammatory cytokines include 
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interleukin 6 (IL-6) and tumour necrosis factor-α (TNF-α), which may potentially drain into 
the portal vein and then into the systemic circulation where they contribute to hepatic and 
peripheral insulin resistance; thus VAT can be described as a diabetogenic fat depot (182). 
These cytokines, particularly TNF-α, have been shown to decrease insulin signalling in the 
liver and muscle, which therefore increases hepatic glucose production and reduce peripheral 
glucose disposal, respectively (206-208). Leptin, an adipokine which impairs insulin 
sensitivity, has been shown to fall in studies where VAT is reduced and improvements in 
peripheral insulin sensitivity are shown (209, 210). This provides evidence to suggest that 
adipokines may mediate the association between VAT and insulin sensitivity. However, in 
vivo human studies to support the role of adipokines and inflammatory markers in insulin 
resistance are scarce. In addition to its inflammatory properties, VAT has also been described 
to be highly lipolytic, hence releases fatty acids which also end up in the peripheral 
circulation and may cause insulin resistance (194, 211). This process has been summarised 
in the “portal theory” which proposes that the highly lipolytic VAT drains free fatty acids 
and inflammatory cytokines into the portal vein, where they are delivered to the liver and 
systemic circulation which contributes to hepatic and peripheral insulin resistance, 
respectively (199, 212-214). The portal theory has been supported by research from multiple 
groups using molecular data (213) animal models (212) and human clinical studies (215). 
Another potential mechanism linking VAT with insulin resistance, which may work with or 
independently from the “portal theory”, suggests that the accumulation of VAT is a signal 
for the accumulation of ectopic lipids which contribute to insulin resistance through 
lipotoxicity (182).  
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1.7.2 Ectopic fat 
Ectopic fat is defined as the storage of triglycerides in non-adipose tissue (137). The 
tissue and organ-specific nature of this storage have been shown to associate with tissue and 
organ-specific dysfunctions. Concerning the development of T2D, longitudinal data support 
the notion that increased visceral and ectopic fat increases the risk of T2D (216). The 
accumulation of ectopic fat increases organ-specific insulin resistance through lipotoxicity 
(195). The organs of interest which have been found to accumulate ectopic fat and insulin 
resistance in T2D include the liver and muscle where it is termed intrahepatic lipid (IHL) and 
intramyocellular lipid (IMCL), respectively (134, 195, 217-219). 
Similar to VAT, the mechanisms which are thought to lead to the development of 
ectopic fat centre around dysfunctional SAT lipid handling in response to a positive energy 
balance (excess caloric intake, reduced energy expenditure) (134, 137, 188, 220). As 
discussed in section 1.7.1, during the healthy state, subcutaneous adipocytes undergo 
hyperplasia to store triglycerides. During the positive energy balance, unhealthy SAT 
expansion is indicated by enlarged and overwhelmed adipocytes. They become pro-
inflammatory, insulin resistant and unable to store fatty acids as triglycerides safely. This 
leads to a spillover of fatty acids into the visceral cavity as well as non-adipose organs such 
as the liver and muscle where they are stored as ectopic fat (figure 5). This deposition may 
occur simultaneously or at different points in the progression to T2D (134, 137, 188, 220). 
Overall, dysfunctional SAT leads to a redirection of triglycerides into VAT and non-adipose 
organs. Within the non-adipose organs during health, fatty acids are metabolised via beta-
oxidation in the mitochondria for fuel. The inability of the mitochondrial function to increase 
and match the increased supply or impairments in the mitochondrial beta-oxidation, leads to 
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the formation of lipids intermediates (e.g. diacylglycerol). In these organs, the lipids promote 
organ-specific insulin resistance by impaired insulin action, thus T2D (137, 195, 221). 
Liver fat is of particular interest in the T2D development because it is described to 
accumulate early in the pathogenesis of T2D; a high proportion of individuals with T2D have 
fatty liver (222). Increased IHL has also been associated with peripheral and adipose tissue 
insulin resistance in a large European cohort which provides further evidence for the role of 
IHL in the development of T2D (137, 223). Interestingly, IHL has been suggested to be 
equally or more detrimental to insulin resistance than VAT (224, 225). Other mechanisms 
outside of the “spillover”, “adipose tissue expandability”, “lipid overflow” and “sick adipose 
tissue” hypotheses have been explored to explain the formation of IHL. This includes the 
“portal” theory which is discussed in section 1.7.1 to explain the potential causal association 
between VAT and insulin resistance. The “portal” theory is also described to increase IHL 
deposition as fatty acids which drain from the lipolytic VAT through the portal vein 
contribute to the accumulation of IHL. Finally, the increased delivery of dietary fatty acids 
and glucose to the liver and fatty acids from adipose tissue lipolysis increases hepatic de novo 
lipogenesis, thus forming fatty acids which are esterified to triglycerides in the liver which 
may also be a mechanism for hepatic insulin resistance (220). 
 
1.7.2.1 Hepatic fat and hepatic insulin resistance 
Hepatic insulin resistance, defined as impaired insulin-mediated suppression of 
hepatic glucose production, increases with increasing IHL content (226, 227). A causal link 
for IHL and hepatic insulin resistance is implied from human interventions which reduce IHL 
and also show a decrease in hepatic insulin resistance (1, 228-230). The causal link between 
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IHL and insulin resistance is further supported by the ‘twin cycle hypothesis’ which has been 
developed to describe the development of T2D. It postulates, using longitudinal study data, 
that excess caloric intake with the backdrop of peripheral insulin resistance and 
hyperinsulinaemia increases ectopic deposition fat in the liver, which causes hepatic 
resistance (222).  
Molecular studies which have assessed the effect of IHL on hepatic insulin sensitivity 
reveal that the accumulation of IHL increases levels of cytosolic hepatic diacylglycerol and 
other fatty acid metabolites which cause cellular dysfunction. Hepatic diacylglycerol is the 
final substrate in the synthesis of IHL. The hepatic diacylglycerol activates a protein kinase 
enzyme which ultimately causes hepatic insulin resistance. It does this by inhibiting the 
phosphorylation of the insulin receptor, thus preventing the downstream signalling cascade 
which leads to insulin-mediated suppression of hepatic glucose production. Therefore, 
hepatic diacylglycerols decrease glycogen synthesis and increase hepatic gluconeogenesis 
(1, 128, 134, 226, 231). 
Whilst there is some evidence for a causal relationship between IHL and insulin 
resistance, it has been suggested that IHL is more of a marker rather than the cause of hepatic 
insulin resistance (232). Amaro and colleagues assessed overweight and obese participants 
with normal intrahepatic triglyceride, non-alcoholic fatty liver disease (NAFLD) and 
individuals with familial hypobetalipoproteinemia (FHBL); a genetic condition which leads 
to the accumulation of 3 times the intrahepatic triglyceride content found in healthy age and 
BMI matched individuals. The participants underwent a hyperinsulinaemic-euglycemic 
clamp to assess peripheral and hepatic insulin sensitivity, magnetic resonance imaging and 
magnetic resonance spectroscopy to assess VAT and intrahepatic triglyceride content (232). 
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There was no difference between the hepatic fat content in participants with NAFLD 
compared to those with FHBL however hepatic and peripheral insulin sensitivity was 
significantly greater in participants with FHBL. The participants with FHBL presented with 
similar peripheral and hepatic insulin sensitivity to healthy participants with normal hepatic 
fat content (232). These data suggest there is a disconnect between hepatic steatosis and 
insulin sensitivity and intrahepatic triglycerides may not cause resistance. It could also be 
interpreted that hepatic insulin resistance causes IHL deposition. Hepatic insulin resistance 
may increase hyperinsulinaemia which increases fatty acid uptake and triglyceride synthesis 
in SAT or ectopic depots (154, 233). In the liver, hyperinsulinaemia increases de novo 
lipogenesis, thus hepatic insulin resistance may increase IHL (134, 219) rather than IHL 
causing hepatic insulin resistance. Finally, studies have shown hepatic insulin sensitivity can 
improve independently of reducing IHL (234) and reducing IHL does not always increase 
hepatic insulin sensitivity (235, 236), suggesting that IHL is not the only contributor to 
hepatic insulin resistance or that in cases of sever steatosis, IHL content needs to reduce to 
normal levels in order to see an effect on hepatic insulin sensitivity. 
 
1.7.3 Adipose tissue insulin resistance 
In addition to visceral and ectopic fat, a resistance to the antilipolytic action of insulin 
in the adipose tissue has also been linked to peripheral and hepatic insulin resistance. As 
discussed in section 1.5.3, insulin has a potent action on adipocytes whereby it suppresses 
lipolysis. Resistance to this action results in inappropriately high rates of adipose tissue 
lipolysis and has been consistently been implicated with peripheral and hepatic insulin 
resistance,  and therefore the progression to T2D (107, 141, 142, 153, 154, 233). 
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It is thought that one of the mechanisms linking excess lipolysis to insulin-resistant 
glucose metabolism is by increasing the availability of fatty acids (220, 237). This 
mechanism is supported by a large number of human studies which have either applied or 
removed fatty acids in vivo and shown reduced and increased insulin sensitivity to glucose 
metabolism, respectively (72, 135, 152, 197, 238). Whilst this mechanism appears promising, 
it has been suggested that the link between adipose tissue insulin resistance to lipolysis and 
peripheral insulin sensitivity is not a response of increased fatty acid availability, but rather 
the result of all tissues becoming resistant at the same time (239). In addition, increased 
availability of fatty acids can be derived from dietary intake or increased hepatic de novo 
lipogenesis (219), thus the mechanism which specifically links lipolysis to insulin resistance 
of glucose metabolism has yet to be concluded. Another proposed mechanism which links 
excess lipolysis with insulin resistance of glucose metabolism (peripheral and hepatic) is that 
increased lipolysis contributes to the formation of ectopic fat and VAT (135, 137, 240), which 
is associated with tissue-specific insulin resistance as discussed in section 1.7.1 and 1.7.2. 
The accumulation of ectopic fat and VAT have been described as part of the “spillover”, 
“lipid overflow”, “adipose expandability” and “portal” theories which identifies 
dysfunctional lipid handling in SAT as the central pathology. Overall the inability of SAT to 
store fatty acids combined with the resistance to insulin’s suppression of lipolysis increases 
the release of fatty acids from the SAT which promote ectopic fat and VAT accumulation 
which may, in part explain the association between excess lipolysis with peripheral and 
hepatic insulin resistance to glucose metabolism (141, 188, 190-193). 
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1.7.3.1 Impact of fatty acid availability on hepatic insulin resistance  
Hepatic insulin resistance, in particular, has been shown to be highly regulated by 
circulating fatty acids. A positive energy balance and an increase in lipolysis in response to 
adipose tissue insulin resistance increase circulating glycerol and fatty acids. This impairs 
insulin-mediated suppression of hepatic glucose production and therefore, increases hepatic 
glucose production. As discussed in section 1.5.2.1, fatty acids and glycerol can be taken up 
by hepatocytes as precursor/substrate molecules for gluconeogenesis. Fatty acids and 
glycerol therefore act as an extrahepatic signal which increases hepatic glucose production, 
and this is supported by in vivo evidence (107, 128, 135, 136, 241). Some investigators have 
suggested that this indirect mechanism of insulin resistance is more dominant than the direct 
action of insulin on the hepatocyte, and further research is required. However, it is accepted 
that FFA driven hepatic glucose production works independently to the direct effects of 
insulin on the hepatocyte (72, 128, 218, 220, 242).  
 
1.7.4 Other influencers 
Other factors which have been shown to influence insulin sensitivity include 
inflammation as described in the “spillover theory” (132, 243) and mitochondrial stress (1) 
/inflexibility during increased fatty acid and glucose availability (134). These influencers of 
insulin sensitivity are beyond the scope for this thesis but are to be acknowledged. 
 
1.8 Indicators for an ethnic-specific pathophysiology of type 2 diabetes 
As discussed in section 1.3.2, ethnicity is a risk factor for the development of T2D, 
particularly in individuals who identify as being of black ethnicity. Although there is a large 
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degree of heterogeneity within the black community, the majority of the literature in this 
section is based on African-Americans, sub-Saharan Africans and first generation black 
African-Caribbean’s residing within the European diaspora. There are several distinctive 
characteristics shown in these black communities which indicate that an ethnic-specific 
process may occur in the development of T2D. 
Prevalence and epidemiology data show from black communities in the UK (who 
identify as black African or Caribbean) and in the USA (who identify as either African-
Americans, non-Hispanic black) are diagnosed with T2D at a lower age, have a lower BMI 
and lower central adiposity (waist circumference) at diagnosis (63-65, 67). Studies which 
have undertaken a more detailed assessment of body composition, show greater muscle mass 
in these black communities (244), lower visceral (245-255) and hepatic fat (246, 247, 252, 
256-258) all of which are anti-diabetogenic characteristics. The progression of T2D increases 
with age, which is likely to reflect increases in adiposity (259, 260) which increases insulin 
resistance and T2D risk. The lower age, BMI and anti-diabetogenic body composition in 
black individuals diagnosed with T2D may suggest that the adiposity related risk occurs to a 
lesser extent in black communities. 
In addition to the prevalence and body composition data, there is also evidence for 
ethnic differences in physiology which is associated with T2D. Hyperinsulinaemia is 
characteristic in the development of T2D; it is often described to result from the 
compensation mechanism for insulin resistance during the early stages of glucose intolerance 
(75). Populations of black ethnicity, who identify as black African, Caribbean, African-
American and non-Hispanic black, are reported to present with exaggerated 
hyperinsulinaemia during the postabsorptive and insulin-stimulated state (251, 261-264). The 
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hyperinsulinaemia was initially thought to result from exaggerated beta-cell function and 
insulin secretion as a response to insulin resistance. This interpretation was based on a 
systematic review of studies assessing insulin sensitivity and the acute insulin response with 
a frequently sampled intravenous glucose tolerance tests in Africans, Caucasians, or East 
Asians participants across a range of glucose tolerances and included over 800 participants 
described as Africans (265). A more recent interpretation has identified reduced insulin 
clearance in black communities to potentially drive the hyperinsulinaemia and therefore, 
reduced clearance may be the initial defect in the black community (266). The reduced insulin 
clearance may also be a protective mechanism employed to preserve the pancreas from the 
beta-cell exhaustion which follows from over secretion of insulin. These observations also 
indicate that black populations may present with distinctive physiology which leads to T2D. 
Having an unfavourable lipid profile is characteristic of metabolic syndrome and 
often associated with T2D (267). An unfavourable lipid profile is characterised by high levels 
of plasma triglycerides (within VLDLs and low-density lipoproteins (LDL)) which have been 
associated with a higher risk of atherosclerosis and cardiovascular disease (268) and less 
high-density lipoproteins (HDL) which have been associated with a lower risk for 
cardiovascular disease (269, 270). A favourable lipid profile is characterised as lower 
circulating plasma triglycerides (contained in VLDL and LDL) but higher HDL. The 
cardioprotection from HDL may result from the HDL cholesterol-lowering capacity via the 
reverse cholesterol transport hypothesis, although these data on this are not conclusive (270, 
271). Whilst the pathophysiology to explain the dyslipidaemia observed in T2D has not been 
fully described, insulin has been shown to inhibit VLDL production by reducing circulating 
fatty acids which are required as a substrate for VLDL production (241). Insulin also 
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promotes the clearance of circulating VLDLs by increasing the activity of lipoprotein lipase 
in adipose tissue, as discussed in section 1.5.2 and 1.5.3 (272, 273). Therefore, a resistance 
to insulin, which occurs during the progression to T2D, is associated with increasing VLDL 
and an unfavourable lipid profile and this has been shown precede the development of overt 
T2D (273). In terms of ethnicity, black communities are consistently reported to display a 
cardioprotective lipid profile compared to their white counterparts in all glucose tolerance 
groups and when matched for BMI (274-277). They repeatedly present with lower 
triglycerides and some USA based studies show that the African-Americans and non-
Hispanic black participants present with higher HDL compared to European-Americans, 
although this is not found in black south Africans suggesting the HDL characteristics may be 
geographically-specific (278). Explanations for the potential causes of the cardio protective 
lipid profile in black communities have implicated ethnic differences in lipoprotein lipase 
activity, which clears triglycerides, and hepatic lipase activity, which clears HDL. Data from 
black participants shows higher lipoprotein lipase activity and lower hepatic lipase activity 
and gene expression which may explain the ethnic differences in lipid profile (276, 279-281). 
What is particularly interesting with respect to black communities is that the cardioprotective 
profile occurs in the presence of insulin resistance (279). Given that insulin resistance is 
associated with dyslipidaemia, this creates a paradox and implies the pathophysiology of 
insulin resistance and therefore T2D, may be ethnically distinct. 
As discussed in section 1.6, there are a number of methods to assess insulin 
sensitivity, including various surrogate indices which estimate insulin sensitivity during the 
postabsorptive state or an oral glucose tolerance test. Population based studies comparing 
insulin sensitivity using the homeostasis model assessment (HOMA) in black and white 
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populations ,covering a range of BMIs, glucose tolerances and health statuses (including 
those with hepatic steatosis), consistently show black communities to have greater insulin 
resistance, particularly in women (256, 282-284). The IVGTT has also been utilised 
extensively in black and white participants and pronounced insulin resistance in black 
participants have predominantly been reported. These studies have assessed participants with 
a range of glucose tolerances, although far more studies have been conducted in participants 
with normal glucose tolerance. In addition, the pronounced insulin resistance in black 
communities has also been reported and adolescents and the ethnic difference in insulin 
sensitivity persist when matching for body composition measures (265, 285, 286). The first 
study to assess insulin sensitivity in black and white participants using the IVGTT with 
minimal model analysis was published in 1993. 22 black and 20 white normal glucose 
tolerant obese women were matched for age, BMI and menopausal status. The insulin 
sensitivity index results suggested that there was no ethnic difference in insulin sensitivity 
(287). Shortly after, Osei and colleagues also assessed normal glucose tolerant black and 
white Americans across a range of BMIs however, the sample size was larger (black =32, 
white = 30) and included men. Their published findings showed between 35 to 52% lower 
insulin sensitivity in black compared to white participants following an IVGTT (261, 288). 
Some of the most compelling data have been derived from ‘The Insulin Resistance 
Atherosclerosis Study’(IRAS) which used the IVGTT with minimal modelling to assess 
insulin sensitivity in over 400 African-Americans and over 600 non-Hispanic white 
participants. The authors report 29 to 41% lower insulin sensitivity in African-Americans 
compared to non-Hispanic white participants without T2D (289) and no ethnic difference in 
those with T2D (290). When participants within the IRAS were pooled, there was no ethnic 
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difference in age or glucose tolerance status however BMI was significantly higher in 
Africans-Americans compared to the non-Hispanic white participants. Insulin sensitivity 
remained lower in Africans-Americans compared to non-Hispanic white participants (291). 
Since then, there has been an abundance of reports for higher insulin resistance in black 
participants without T2D compared to their white counterparts (248, 255, 292-298). 
However, those with T2D appear to have less pronounced differences in insulin sensitivity 
(252, 265) suggesting that impairments occur early on in the progression to T2D. The 
suggestion of an early defect of insulin sensitivity in black compared to white participants is 
further supported by reports of increased insulin resistance in healthy black compared to 
white adolescents (297, 299-302). Whilst the narrative is driven towards black communities 
being more insulin resistant from multiple research studies, the literature is not conclusive, 
with some studies finding no difference from the IVGTT (252, 287, 303, 304). Studies which 
have utilised glucose clamps, termed the “gold standard” method for assessing insulin 
sensitivity, also produce inconsistent results which are discussed in more detail in section 
1.9. It is currently thought that one of the potential influences of insulin resistance during the 
development of T2D is the accumulation of visceral fat, ectopic fat and excess lipolysis as 
discussed in section 1.7 (182, 185, 186, 195, 216). In black populations, the pronounced 
insulin resistance is observed in the presence of lower visceral and ectopic fat. This does not 
align with the views on T2D pathophysiology and further suggests that an ethnic distinction 
in T2D pathophysiology may be present.  
Overall these distinctive characteristics suggest there may be an ethnic-specific 
pathophysiology of T2D, particularly relating to insulin sensitivity. Many research groups 
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have conducted comparisons in black and white adolescents to understand the ethnic-specific 
pathophysiology; however, this thesis will focus on data from adults. 
 
1.9 Insulin sensitivity and black ethnicity 
Assessments of insulin sensitivity based on surrogate estimates have been shown to 
associate with clamp derived measures of insulin sensitivity in black adults (305, 306). 
However, Pisprasert and colleagues have more recently provided data which shows that in a 
group of African Americans and European Americans with the same insulin sensitivity (total 
glucose disposal) measured from the clamp, surrogate estimates show African Americans to 
be more insulin resistant (307). This finding is likely to be the result of pronounced 
hyperinsulinaemia, which is consistently reported in black communities, as discussed in 
section 1.8 (251, 261-264). Hyperinsulinaemia may lead to an overestimation of insulin 
resistance from methods based on mathematical modelling of glucose and insulin dynamics 
such as surrogate indices (307). Pisprasert and colleagues do show correlations between the 
clamp and surrogate indices in black participants. However, in black men, the relationship 
was not consistently significant. The latter finding agrees with a study in UK based afro-
Caribbeans who also found no significant association between HOMA-IR (a measure of 
fasting insulin sensitivity based on fasting glucose and insulin concentrations) and insulin 
sensitivity measured from the clamp (308). Overall these studies suggest that using surrogate 
estimates of insulin sensitivity or resistance in black populations can lead to misleading 
conclusions and should be evaluated with caution (307, 309). Pisprasert and colleagues also 
suggest that the hyperinsulinaemia in black communities may affect insulin sensitivity 
measured from an IVGTT with minimal model analysis (307). The minimal model analysis 
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is also based on mathematical modelling of ambient glucose and insulin concentrations. No 
studies have compared the IVGTT with minimal modelling to the clamp in black participants, 
therefore it is not conclusive as to whether the hyperinsulinaemia overestimates insulin 
resistance in black participants. “Gold standard” highly sensitivity tools to assess insulin 
sensitivity in black and white adults are essential to understand ethnic differences without 
the potential confounding of the hyperinsulinaemia (310). This thesis explores the potential 
ethnic-specific pathophysiology and is focused on in vivo assessments of whole-body and 
tissue-specific insulin sensitivity in black compared to white adults. 
 
1.9.1 Whole-body insulin sensitivity and black ethnicity 
Whole-body insulin sensitivity is generally used to describe the combined effects of 
peripheral glucose uptake and suppression of hepatic glucose production in response to 
insulin and is often represented as the M value or total glucose disposal. Studies in black and 
white adults which have assessed whole-body insulin sensitivity during the 
hyperinsulinaemic-euglycaemic clamp have shown inconsistent results. This may be due to 
factors such as sex, glucose tolerance, BMI and family history which may influence ethnic 
specific findings. 
The majority of studies assessing whole body insulin sensitivity using the 
hyperinsulinaemic-euglycaemic clamp in populations of black and white ethnicity have 
focused on women, all of which do not have T2D. The studies are based on obese and 
overweight South African and African-American women with an average BMI ranging from 
32 - 26 kg/m2. The sample sizes ranged from 9 to 10 black women and 10 to 26 white women. 
The black and white participants were matched for BMI and age however whole-body insulin 
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sensitivity was lower in black compared to white women. The mean difference in whole-
body insulin sensitivity was between 40% and 60% lower in obese black women compared 
to obese white women, due specifically to lower non-oxidative glucose disposal (glycogen 
storage) (245, 251, 311). In comparison, studies focused solely on men are absent and have 
not been a focus for any research groups. That being said, studies which have recruited both 
men and women but analysed the data by sex provide some evidence for potential ethnic 
differences in whole body insulin sensitivity in men. A single study found 25% greater 
whole-body insulin sensitivity in non-diabetic black men compared to non-diabetic white 
men all of whom where similar in BMI with an average BMI of 29.0 kg/m2 (312). All other 
studies which have recruited both sexes show no ethnic difference in whole-body insulin 
sensitivity (307, 312-318). These studies contain sample sizes of over 30 and include 
participants with a range of BMIs and glucose tolerances. However, the black and white 
participants were not consistently matched for BMI such that black participants were heavier 
which may confound results and make interpretations more complex considering the 
influence of adiposity, particularly central adiposity, on insulin sensitivity. 
A more recent focus, driven by the Pathobiology of Prediabetes in A Biracial Cohort 
(POP-ABC) study, has been on the impact of family history and ethnicity. This was a mixed 
sex study recruiting participants across a range of BMIs. They have published data from 
clamps showing that in the absence of family history, male and female black participants 
have lower insulin sensitivity (the mean is 37% lower) compared to white participants (319). 
The obesity status of participants was not reported however the same group have published 
another report showing that when a positive family history was present, there was either a 
trend towards or significantly lower insulin sensitivity in black participants compared to their 
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white counterparts (319-321). In these reports, similar to some of the studies discussed 
previously, participants were not matched for BMI such that the black participants were more 
obese which may confound the insulin sensitivity findings. 
Overall data from hyperinsulinaemic-euglycaemic clamp studies are inconsistent 
with most evidence pointing towards either lower insulin sensitivity in black compared to 
white participants or no ethnic difference in whole-body insulin sensitivity. Some of these 
interpretations are based on study populations which are not matched for BMI, which may 
confound results and the impact of this is not clear. In addition, most of the evidence points 
towards black women being more insulin resistant; however, studies in black and white men 
are scarce. Finally, an understanding of whole-body insulin sensitivity in each glucose 
tolerance group in isolation is limited- most studies assess NGT and IGT collectively or T2D 
alone.  
 
1.9.2 Peripheral insulin sensitivity and black ethnicity 
Peripheral insulin sensitivity is primarily an assessment of insulin-mediated skeletal 
muscle glucose disposal. The first study to use a glucose isotopic tracer to assess peripheral 
glucose disposal in lean black and white women showed 26% lower insulin sensitivity in 
black compared to white women. This difference was observed during the low and high dose 
insulin infusion in a population of participants well matched from BMI and age. In this study, 
participants were healthy, lean and young with an average BMI of 22.7 kg/m2 and an average 
age of 24 years (322). By using indirect calorimetry, DeLany et al. were able to ascertain that 
the ethnic difference in peripheral insulin sensitivity was the result of lower non-oxidative 
glucose disposal as opposed to ethnic differences in glucose oxidation (322). This agrees 
 
1.9 Insulin sensitivity and black ethnicity 
55 
with Ryan et al., who also found lower non-oxidative glucose disposal in black women but 
no difference in glucose oxidation (251). Goedecke and colleagues are the only other authors 
to assess peripheral insulin sensitivity in black and white women. They assessed peripheral 
insulin sensitivity in obese non-diabetic South-African and white participants matched for 
age and BMI, although fat percentage was higher in the black women. The study included 
participants with impaired glucose tolerance which was not equally distributed by ethnic 
group however, the authors completed a subgroup analysis to confirm that this did not alter 
their findings of no ethnic difference in peripheral insulin sensitivity (323). In addition to 
comparing peripheral insulin sensitivity in white and black women, Goedecke and colleagues 
also assessed the relationship with VAT. As discussed in section 1.7.1, VAT has consistently 
been associated with insulin sensitivity and increasing VAT accumulation may decrease 
insulin sensitivity. Goedecke and colleagues found no significant relationship between 
peripheral insulin sensitivity and VAT in black women, but a significant negative in white 
women. This suggests that having high VAT is not indicative of insulin resistance or having 
low VAT is not indicative of insulin sensitivity in black women. Whether these findings can 
be extrapolated to men of different glucose tolerances and BMI statuses is unknown. 
 
1.9.3 Hepatic insulin sensitivity and black ethnicity 
Hepatic insulin sensitivity is primarily used to describe insulin-mediated suppression 
of endogenous glucose production. The investigations into hepatic insulin sensitivity using 
glucose isotope tracers in black and white populations show inconsistent results which may 
be due participant characteristics such as sex and obesity, or due to the method used to assess 
hepatic insulin sensitivity, i.e. basal or insulin stimulated assessments. 
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Chung et al. studied 24 obese black and 22 obese white women with normal glucose 
tolerance and pre-diabetes who were matched for age and BMI which was an average of 37 
years and 32.5 kg/m2, respectively. They found no ethnic difference in basal hepatic insulin 
sensitivity between black or white individuals calculated based on the inverse of the  product 
of basal endogenous glucose production and insulin (246). However, Goedecke et al. studied 
15 obese black and 15 obese white south African women with normal glucose tolerance and 
pre-diabetes who were matched for age and BMI which was an average of 36 years and 36.6 
kg/m2, respectively. They found that insulin stimulated hepatic insulin sensitivity was over 
three times greater in black compared to white women (323). In opposition, Ellis and 
colleagues studied 23 African-American and 30 European American women across a range 
of BMIs (from 18.7 to 38.6 kg/m2). The women were normal glucose tolerant with an average 
age of 25 years; they were recruited to be matched for age and BMI. Their data showed that 
mean basal hepatic insulin resistance was 18% higher in black compared to white women 
(296). In lean black and white women with normal glucose tolerance at an average age of 24 
years, DeLany and colleagues present data showing no ethnic difference in basal or insulin 
stimulated hepatic insulin sensitivity (322). Finally, a single study authored by Stefan and 
colleagues recruited and pooled both sexes. The participants were normal glucose tolerant 
and there were no ethnic differences in age (an average of 31 years) or BMI (an average of 
30 kg/m2). In their analyses they showed no ethnic difference in insulin stimulated hepatic 
insulin sensitivity (315). Overall, the literature shows no consensus as to whether hepatic 
insulin sensitivity is similar, lower or higher in black compared to white populations. 
As discussed in sections 1.7, VAT and IHL have been shown to associate with hepatic 
insulin sensitivity, with some evidence for a causal link. Studies in obese women have 
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assessed these relationships in black and white women. They show a significant association 
between basal hepatic insulin sensitivity and IHL in both ethnic groups (246). However, 
insulin stimulated hepatic insulin sensitivity only associated with IHL and VAT in black but 
not white women (323).  
To summarise, studies in obese women provide evidence for a significant relationship 
between VAT and IHL in black women however, whether this can be extrapolated to men 
has yet to be determined.  
 
1.9.4 Adipose tissue insulin sensitivity and black ethnicity 
Adipose tissue insulin sensitivity to lipolysis can be assessed by quantifying the 
insulin-mediated suppression of lipolysis during an insulin clamp. A single study has used a 
glycerol isotopic tracer to assess adipose tissue insulin sensitivity in obese black and white 
women during insulin stimulation (304). Albu et al. studied 16 obese African-American and 
13 obese non-Hispanic white participants free from T2D who were matched for age (35 years 
on average) and BMI (on average 35.9kg/m2). They show significantly greater adipose tissue 
insulin sensitivity in obese black compared to white women. The insulin infusion provoked 
a 60% suppression of lipolysis in black women compared to a 40% suppression in white 
women (304). In comparison, a more recent study in obese women with an average BMI of 
32.5 kg/m2 authored by Chung et al. showed no ethnic difference in adipose tissue insulin 
sensitivity which was assessed during the basal state; participants were matched for BMI 
(246). The conflicting results may reflect differences in the method used to determine adipose 
tissue insulin sensitivity or VAT content which is of importance because VAT is highly 
lipolytic and an indicator of metabolic dysfunction (324). 
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No other studies have assessed adipose tissue insulin sensitivity in black and white 
populations. However, basal lipolysis in healthy women free from T2D matched for BMI and 
age has been shown to be similar in the presence of similar basal insulin levels which may 
imply that there are no ethnic differences in adipose tissue insulin sensitivity (303). In 
contrast, other studies in obese women who were also matched for BMI have shown lower 
basal lipolysis in African-American black compared to white women in the presence of 
similar insulin levels, which suggests higher adipose insulin sensitivity (252, 325). Overall, 
data are inconsistent, and there is scarcity of such studies in men. 
Adipose tissue insulin sensitivity has been implicated in peripheral and hepatic 
insulin resistance as well as ectopic fat accumulation, as discussed in sections 1.7.3. No study 
has assessed this in black populations who unexpectedly, display insulin resistance in the 
presence of lower ectopic fat. A single study has shown a significant relationship between 
IHL and adipose tissue insulin resistance in black and white participants(326). This may 
suggest that adipose tissue insulin resistance is linked to hepatic insulin resistance through 
ectopic fat accumulation. However, the authors assessed adipose tissue insulin resistance 
using a surrogate index of adipose tissue insulin resistance and the participants included a 
mix of participants with and without T2D and non-alcoholic fatty liver disease thus, whether 
this finding can associated to T2D physiology cannot be concluded (326). 
 
1.9.5 Insulin sensitivity and black ethnicity summary 
To conclude, although the narratives in the literature have implicated black 
populations to have greater insulin resistance compared to white populations, the studies 
which assess and compare whole-body and tissue-specific insulin sensitivity from the clamp 
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and/or isotopic tracers produce conflicting findings and have primarily been conducted in 




1.10 Aims  
This thesis aims to determine if there are ethnic differences in whole-body and tissue-
specific insulin sensitivity between black west African (BAM) and white European men 
(WEM) at three stages of glucose tolerance: normal glucose tolerance (NGT), impaired 
glucose tolerance (IGT) or early type 2 diabetes (T2D). It also aims to assess if there are 
ethnic differences in the relationship between insulin sensitivity and potential influencers of 
insulin sensitivity.  
Black west African men have been chosen to reduce the heterogeneity within the 
black participants derived from factors such as genetics, behaviour and cultural factors, 
discussed in section 1.3.2. 
 
1.10.1 Objectives 
1. To quantify whole-body insulin sensitivity in BAM and WEM. 
2. To quantify peripheral insulin sensitivity in BAM and WEM. 
3. To quantify hepatic insulin sensitivity in BAM and WEM. 
4. To quantify adipose tissue insulin sensitivity to lipolysis in BAM and WEM 
5. To compare the associations between peripheral and hepatic insulin sensitivity with 
visceral fat, hepatic fat and adipose tissue lipolysis. 
Each of the above will be performed in three glucose tolerance groups: NGT, IGT and early 
T2D, matched within glucose tolerance groups for BMI.  
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2.1 Soul-DeEP study 
The data analysed in this thesis have been collected as part of a cross-sectional 
observational study, the South London Diabetes and Ethnicity phenotyping (Soul-DeEP) 
study (327). This project was able to assess and compare metabolic functions and body 
composition parameters related to type 2 diabetes (T2D) in black west African (BAM) and 
white European men (WEM) with normal glucose tolerance (NGT), impaired glucose 
tolerance (IGT) and T2D. The primary aim of the Soul-DeEP study was to investigate the 
hypothesis that early pronounced peripheral insulin resistance in black men, leads to an early 
and exaggerated compensatory insulin secretion, that ultimately fails and drives the 
development of early-onset T2D in the BAM population. The study was powered to detect 
an ethnic difference in insulin secretory function; secondary outcomes focused on 
quantifying tissue-specific insulin sensitivity and fat depots to generate an all-encompassing 
view of potential ethnic differences in the pathophysiology of T2D between BAM and WEM. 
A schematic for the overall Soul-DeEP study design is shown in figure 6. The participants 
attended 4 separate visits following their screening appointment however, only data collected 
from visits C and D have been discussed as part of this thesis. 
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2.2 Participants  
The Soul-DeEP study was divided into two phases (Soul-DeEP I & II) based on the 
recruitment of men with T2D in the first phase, then combining the recruitment of IGT and 
NGT in the second phase. Data collection for the former took place between April 2013 to 
January 2015 and data collection for the latter took place between April 2016 and May 2018. 
Participants were either self-referred from advertisements in newspapers, social media, the 
King’s College London university staff and students community, research study websites, 
local colleges, religious groups, community groups, local business, word of mouth or were 
identified as high risk based on their glycated haemoglobin (HbA1c) or diagnosed with T2D 
for <5 years by their primary care practice in south London. All participants provided 
informed consent prior to any study procedures and the study was approved by the London 
Bridge National Research Ethics Committee (approval no. phase I; 12/LO/1859, phase II 
15/LO/1121). 
As discussed in chapter 1 (section 1.10), this study is focused on men. Men of black 
west African (BAM) and white European, (WEM) ethnicity between the ages 18 to 65 were 
invited to participate. Participant inclusion criteria included; a BMI range from 25 – 35 kg/m2 
for Soul-DeEP I and 25 – 40 kg/m2 for Soul-DeEP II, NGT as defined by a 2-hour plasma 
glucose of <7.8 mmol/l during a 75g oral glucose tolerance test, or IGT as defined by a 2-
hour plasma glucose of 7.8-11.0 mmol/l during a 75g oral glucose tolerance test, or a 
diagnosis of T2D <5 years and being treated with either metformin or lifestyle changes. 
Fasting plasma glucose was not used to define participant glucose tolerance status. 
Participants were excluded if they were being treated with thiazolidinedione, SGLT-2 




the study outcomes or if they had constraints to the magnetic resonance imaging protocol 
(MRI) such as a metal plate/implant/prosthesis or were unable to comply with the study 
protocol. 
Eligibility was assessed during a comprehensive screening visit which took place at 
King’s College Hospital. Ethnicity was self-declared by selecting either white British, white 
European, black west African or black other. The countries of origin used to characterise 
west Africa were based on the United Nations Statistics Division (UNSD) (328) and includes: 
• Benin 
• Burkina Faso 
• Cabo Verde 










• Saint Helena 
• Senegal 
• Sierra Leone 
• Togo 
The countries of origin used to characterise European were also based on the UNSD however, 






• Republic of Moldova 
• Romania 
• Russian Federation 
• Slovakia 
• Ukraine 
• Åland Islands 
• Channel Islands 
• Denmark 
• Estonia 














• United Kingdom of 











Self-declared ethnicity was confirmed by parental and grandparental birthplace. 
Anthropometric measurements and fasting blood samples were also taken to assess 
eligibility. Weight and height were measured in light clothing and whilst wearing no shoes 
to determine BMI. Waist circumference was measured at the mid-point between the lower 
margin of the last palpable rib and the top of the iliac crest in line with the WHO 
recommendations (329). Screening blood samples were taken at fasting to assess HbA1c, 
confirm normal kidney and liver function, the absence of sickle cell (although the trait was 
permitted) and a normal full blood count. In addition to the screening safety blood tests, 
participants with T2D during Soul-DeEP I were screened for antibodies and were excluded 
if they tested positive for the auto-antibodies; anti-insulin, anti-glutamic acid decarboxylase 
or anti-A2. Family history of type 2 diabetes (within first degree relatives and extended 
family), past medical history (including known allergies), smoking and alcohol intake habits 
(including frequency and preferences) and triplicate seated blood pressure measurements 
(obtained from the non-dominant arm) were also documented at the screening visit. 
 
2.3 Procedures 
In preparation for the metabolic assessments, participants were instructed to fast from 




and strenuous physical activity for 48 hours, avoid smoking the morning of the visit and to 
ensure their evening meal contained a portion of carbohydrate. Patients with T2D were 
instructed to ensure approximately 50% of their energy intake came from carbohydrate 
spread evenly throughout the day and their evening meal contained no more than 30% of 
daily carbohydrate consumed in the evening meal. However, the research team did not 
scrutinise this and thus, it was not requested in the second phase of the study involving 
participants with NGT and IGT.  
 
2.3.1 Screening 
NGT and IGT status was confirmed by a 75g oral glucose tolerance test using the 
WHO cut-off points. The OGTT procedure began with the insertion of a cannula into the 
antecubital fossa vein in the arm for blood sampling at fasting (timepoints -10 and 0 minutes) 
then 10, 30, 60 and 120 minutes after a single 75g anhydrous oral glucose load. 2-hour plasma 
glucose <7.8mmol/l defined NGT, plasma glucose  7.8 and <11.1mmol/l defined IGT based 
on the WHO criteria (6). Participants were selected to be similar in age and BMI within each 
glucose tolerance group.  
 
2.3.2 Hyperinsulinaemic-euglycaemic clamp 
Whole-body and tissue-specific insulin sensitivity were assessed using a two-step 
hyperinsulinaemic-euglycaemic clamp with stable glucose and glycerol isotopic tracer 
infusions. As discussed in chapter 1 (section 1.6), it has been termed the optimal in vivo 
assessment of insulin sensitivity to glucose homeostasis and provides a quantitative 




of insulin sensitivity manipulates the glucose and insulin continuous feedback loops by 
creating a hyperinsulinaemic environment at a steady state. The glucose infusion required to 
maintain euglycaemia during hyperinsulinaemia is an assessment of total glucose disposal 
and therefore insulin sensitivity (89, 156). When combined with stable isotope tracers, which 
allow for direct measurements of substrate appearance and disappearance from the 
circulation, tissue-specific measurements of insulin sensitivity can be derived from the basal 
and insulin-stimulated state of the clamp (159). Stable isotopic tracers are chemically 
identical to their tracee but, differ in their molecular weight due to the number of neutrons 
they contain, making them distinct and quantifiable using mass spectrometry. In this study, 
deuterated glucose ([6,6-2H2]-glucose) and glycerol ([
2H5]-glycerol) were used at a low 
concentration to prevent a significant imbalance in tracee kinetics which is discussed in more 
detail in section 2.6.2. 
Upon arrival at the Clinical Research Facility of King’s College Hospital, participants 
were weighed in light clothing with an empty bladder on digital scales or a body composition 
analyser (Tanita MC780MA) where available, to determine body weight, fat-free mass 
(FFM) and body surface area (BSA, using the Mosteller formula; square root of the height 
(cm) multiplied by the weight (kg) divided by 3600) for infusion calculations and insulin 
sensitivity indices. To begin the overall procedure, a cannula was placed into a vein on the 
dorsum of the hand in a retrograde fashion. The hand was kept in a 55 hand-warming unit 
to mimic arterialised sampling (330). Duplicate baseline samples were taken to determine 
naturally occurring background [6,6-2H2]-glucose and [
2H5]-glycerol isotope enrichment 
before the basal phase commenced. An infusion cannula was inserted into the antecubital 




Bagsvaerd, Denmark) bound to albumin in 4% autologous blood/saline, 20% (wt/vol) 
dextrose, [6,6-2H2]-glucose and [
2H5]-glycerol tracers (CK Gases, Cambridgeshire, UK). The 
basal phase of the hyperinsulinaemic-euglycaemic clamp was assessed from time -120 to 0 
minutes and was initiated with a primed (2.0 mg/kg), continuous infusion (0.02 mg/kg−1 
min−1) of [6,6-2H2]-glucose and a primed (0.12 mg/kg), continuous infusion (0.0067 mg/kg
−1 
min−1) of [2H5]-glycerol (234). A steady-state isotopic enrichment and saturation is achieved 
after 90 minutes, whereby the rate of tracer flux is in equilibrium with that of the tracee (160, 
331). Blood samples were drawn at -30,-20,-10 and 0 minutes to determine basal 
assessments. The first step (low dose insulin) of the two-step hyperinsulinaemic-euglycaemic 
clamp began with a primed and continuous insulin infusion (10mU/m2BSA/min) which was 
maintained for 120 minutes. The final 30 minutes of the low dose insulin infusion was 
defined as the steady-state period, whereby glucose appearance equals glucose disposal. 
Blood samples drawn during this time were used to assess hepatic and adipose tissue insulin 
sensitivity. For the second step (high dose insulin) of the two-step hyperinsulinaemic-
euglycaemic clamp, the [2H5]-glycerol isotope infusion was terminated and the continuous 
insulin infusion was primed and raised to 40mU/m2BSA/min for 120 minutes. The final 30 
minutes of the high dose insulin infusion was defined as the steady-state period, whereby 
glucose appearance equals glucose disposal. Blood samples drawn during this time were used 
to assess whole-body and peripheral insulin sensitivity (156, 332). Euglycaemia was defined 
as 5 mmol/l and was maintained during both steps using a 20% dextrose infusion. The 
dextrose was enriched with [6,6-2H2]-glucose (8 mg/g glucose at low-dose insulin and 10 
mg/g at high-dose insulin) to maintain a constant tracer-to-tracee ratio (333). The dextrose 




on plasma glucose readings taken every 5 minutes using an automated glucose analyser 
(Yellow Spring Instruments, 2300 STAT Glucose Analyzer, Yellow Springs, OH, USA). 
Samples were taken at 30, 60, 90, 100, 110, 120, 150, 180, 210, 220, 230 and 240 minutes 
for assessment of plasma glucose, insulin and isotopic enrichment. The hyperinsulinaemic-
euglycaemic clamp sampling and infusion protocol are detailed in figure 7, and an example 
of the graphs produced during the procedure to influence the dextrose infusion rate decision 











Figure 8: A graphical representation of the plasma glucose (blue line) and dextrose infusion rate (orange line) during a single hyperinsulinaemic-







































2.3.3 Magnetic resonance imaging  
Magnetic resonance imaging (MRI) of the abdominal cavity was employed as a 
highly sensitive method to quantify visceral adipose tissue (VAT), subcutaneous adipose 
tissue (SAT) and intrahepatic lipids (IHL). Participants were invited to attend a single 
visit at the clinical imaging department of Guy’s Hospital London Bridge. A radiologist 
conducted the MRI scan and all prior safety checks. Participants were asked to lay in a 
supine position with body coils fixed in place. A 1.5 T Siemens Aera scanner was used 
to scan the abdominal cavity. Multiple contiguous axial T1-weighted gradient-echo 
images with a slice thickness of 3mm were obtained. From these images, the Dixon 
sequence was used to derive corresponding fat and water images for analysis by a blinded 
analyst using the open-source image analysis software HOROS V 1.1.7 
(www.horosproject.org; accessed 21/10/2017). 
Using the fat image from the L4/5 lumbar anatomical position, which aligns with 
the umbilicus, VAT and SAT area was highlighted to quantify VAT and SAT cm2. To 
quantify IHL %, fat and water images at two abdominal positions, approximately 30mm 
apart encompassing the superior and inferior surface of the liver were analysed. Four 
identical circular regions of interest were positioned within the liver tissue in both pairs 
of images. The circles included the posterior, anterior, medial and lateral sections of the 
liver and aimed to cover as large an area as possible whilst avoiding blood vessels, ducts 
and fascia, thus the regions of interest were different for each participant. Within each 
area, the hepatic fat fraction (%) was calculated using the formula: (F/(F+W))*100, where 
F is the pixel signal intensity of the fat image and W is the pixel signal intensity of the 
water image. The mean hepatic fat fraction for all eight regions of interest was used as a 
measure of IHL% (334). 
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2.5 Sample laboratory analyses and materials 
2.5.1 Automated assays 
Plasma glucose concentration during the screening visit and the 
hyperinsulinaemic-euglycaemic clamp was measured at the bedside on an automated 
glucose analyser following centrifugation at room temperature for 15 seconds (Yellow 
Spring Instruments, 2300 STAT Glucose Analyzer, Yellow Springs, OH, USA). This 
method utilises a biosensor containing an immobilised enzyme membrane which oxidises 
the glucose from the sample into gluconolactone and hydrogen peroxide. The hydrogen 
peroxide is then oxidised, and the resulting electron flow is linearly proportional to the 
hydrogen peroxide and therefore the glucose concentration. The inter and intra 
coefficients of variation were <2%. For all other metabolites, samples were collected in 
BD vacutainers, centrifuged at 4°C at 3000rpm for 10 minutes to extract the plasma, 
which was stored at -80 for analysis in batches.  
For insulin concentration analysis, samples were collected in plain vacutainers 
and allowed to clot for 20 minutes before centrifugation to extract the serum. This serum 
was measured by immunoassay using chemiluminescent technology (ADVIA Centaur 
System, Siemens Healthcare, Camberley, UK). This required the sample to be incubated 
with two insulin specific monoclonal mouse antibodies; one was labelled with an 
acridinium ester, and the other was covalently coupled to a paramagnetic particle. This 
created a two-site sandwich immunoassay with insulin being the protein of interest. 
Following an incubation period, a magnetic field was applied which held the insulin 
sandwich structure together in a solid phase on the sample reaction cuvette. Any 
components not bound to the magnetic field remained in the liquid phase and were 
removed. The cuvette was then washed with deionised water before a hydrogen peroxide 
reagent was added to begin the light emission reaction with the acridinium ester. The light 
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emission intensity was measured on a luminometer as relative light units which has a 
directly proportional relationship to the insulin concentration given in international units 
per litre (mIU/L). The intra-assay coefficient of variation was between 3.2 – 4.6% and 
the inter-assay coefficient of variation was between 2.6 – 5.9%. 
Measurement of the screening blood samples (for triglycerides, total cholesterol, 
HDL-cholesterol and LDL-cholesterol) was conducted in the central laboratory at King’s 
College Hospital from SST vacutainers. For HbA1c, samples were collected in EDTA 
vacutainers and measured by boronate affinity and high-performance liquid 
chromatography (Premier Hb9210 analyser, Trinity Biotech, Jamestown, NY, USA). 
Glycated haemoglobins have a glucose moiety bound by a ketoamine bond which creates 
a diol group. Bonorate affinity chromatography involves the binding of a bonorate to this 
diol group and the glycated haemoglobin is quantified. The intra-assay coefficient of 
variation was between 0.72 – 1.26% and the inter-assay coefficient of variation was 
between 1.28 – 1.62%. 
 
2.5.2 Isotope enrichment sample procedure 
Whole blood samples were collected in fluoride and lithium heparin vacutainers 
for glucose and glycerol, respectively. 
For assessment of glucose isotope enrichment, plasma samples were subjected to 
a two-step derivatisation process to create a penta-O-trimethylsilyl-D-glucose-O-
methoxime derivative of natural and [6,6-2H2]-glucose. The resulting derivatives undergo 
electron impact ionisation, creating molecular fragments which can be identified and 
quantified using a combined gas chromatograph-mass spectrometer (GCMS) (Agilent 
GCMS 5975C MSD, Agilent Technologies, Wokingham, UK). The benefit of using a 
derivative is the ability to distinguish glucose from other monosaccharides in the plasma 
 
2.5 Sample laboratory analyses and materials 
76 
matrix (335). The protocol for this method has been published (336) however in brief, the 
process was initiated with the centrifugation of 50µl of plasma and 500µl of ethyl alcohol 
which deproteinises the sample. The supernatant was then transferred to a dram vial 
where it was left to dry under oxygen-free nitrogen at 50°C for 20minutes in a sample 
concentrator (Techni, Philip Harris). For step 1 of the derivatisation process, 100µl of 
methylhydroxamine hydrochloride made up in pyridine 2% (w/v) was added to the dried 
residue and heated at 90°C for 2 hours. After being left to cool, step 2 of the derivatisation 
process was conducted by adding 50µl of N, O-bis(Trimethylsilyl)-trifluoroacetamide 
with 1% trimethylchlorosilane (BSTFA) to the residue which was then heated at 120°C 
for 15minutes. The derivatising agent was removed by leaving the solution to cool and 
dry under oxygen-free nitrogen at room temperature; the final product was reconstituted 
in 500µl of decane solvent for analysis in the GCMS. The derivatised solution was 
inserted into the gas chromatograph where it underwent electron ionisation using an 
ionisation energy of 70eV to induce ionised derivate fragments which are volatile and 
therefore detectable (335, 337, 338). These ions were accelerated then separated within 
the GCMS by electromagnetic deflection based on their charge to mass ratio (m/z) (160), 
the fragments were detected and quantified based on the fragment abundance. The 
electron impact ionisation mass spectra were obtained from m/z 650 to 50. Selected ion 
monitoring was used to measure the peak area under the curve for ions with a m/z of 319 
and 321, representing natural glucose derivative and [6,6-2H2]-glucose derivative, 
respectively. The peak areas were calculated and expressed as the tracer (m/z 321 [6,6-
2H2]-glucose)-to -tracee (m/z 319 glucose) ratio to quantify isotopic enrichment at each 
time point (335, 336). 
For assessment of glycerol isotope enrichment, glycerol was first extracted from 




GCMS. The protocol to assess glycerol enrichment has been published (161); however, 
the process was slightly modified. In brief, 500µl of plasma was deproteinised by 
centrifugation before being combined with 1000µl 3.5% (w/v) 5-sulphosalicylic acid 
solution to remove the fatty acids. Chromatography columns were set up to remove amino 
acids, lactate, pyruvate and other plasma components with either a positive or negative 
charge. Neutral plasma components, including glycerol, passed through the columns and 
the resulting eluate was collected and placed in a freeze drier overnight. For 
derivatisation, the dried residue was combined with 100µl of pyridine and 100µl N-
methyl-N-[tert-butlydimethylsilyl]-trifluroacetamide and heated at 70°C for 4 hours. The 
sample was then left to stand at room temperature for 24 hours before the derivatising 
agent was removed under oxygen-free nitrogen. The final product was reconstituted in 
50µl of decane solvent for analysis in the GCMS. Similar to the glucose enrichment 
analysis, the derivatised solution underwent gas chromatography and mass spectrometry. 
However, the selected ion monitoring mode used to detect and measure the peak area 
under the curve for fragment ions was m/z of 377 and 382, representing the natural 
glycerol derivative and [2H5]-glycerol derivative, respectively. The peak areas were 
calculated and expressed as the tracer (m/z 382 [2H5]-glycerol)-to -tracee (m/z 377 
glycerol) ratio to quantify isotopic enrichment at each time point (161).  
 
2.6 Calculations 
2.6.1 Whole-body insulin sensitivity 
Whole-body insulin sensitivity was expressed using the M value, which was 
calculated using the mean glucose (dextrose) infusion rate during the final 30 minutes of 
the high dose insulin infusion. At this point, a steady-state equilibrium was presumed to 




average glucose infusion rate is corrected for deviations in the plasma glucose pool. These 
adjustments were made every 10 minutes during the steady-state and were not a result of 
changes in glucose disposal, but rather too much or too little glucose infusion termed the 
‘space correction’ (156). The space correction incorporates the change in glucose between 
two time points, the time between those timepoints and the total glucose volume 
distribution (assumed to be 19% of body weight) (156). The equation for the M value at 
each 10-minute interval is corrected for by this ‘space correction’ and the equation is as 
follows (the space correction is subtracted from the glucose infusion rate ): 
 




The results were averaged to provide the final M value (total glucose disposal). 
For comparisons between groups, total glucose disposal must be normalised for 
measurements of metabolic body size to account for the metabolic mass, which uses 
insulin during a clamp procedure (33, 84, 104). In this study glucose disposal was 
expressed as a function of body weight (mg/kg min-1), body surface area (BSA; mg/m2 
BSA min-1) and free fat mass (FFM; mg/kg FFM min-1), where the data were available. 
Studies have shown that normalising for kg body weight, underestimate insulin sensitivity 
in obese participants due to obese participants having a larger proportion of tissue which 
is less responsive to insulin and thus FFM is the ideal normalisation to reflect metabolic 
mass which is sensitive to insulin (84, 104, 339). Whole-body insulin sensitivity was also 
measured as M/I ; (mg/m2 BSA min-1)/(pmol/l) and (mg/kg FFM min-1)/(pmol/l), which 
is the total glucose disposal rate divided by insulin concentration during the final 30 
minutes of the high dose insulin infusion. This expresses glucose disposal in relation to 





2.6.2 Tissue-specific insulin sensitivity 
The isotopic tracer dilution technique can be used to quantify the appearance and 
disposal of glucose across body compartments, enabling a more accurate assessment of 
glucose production and disposal (105, 159). It can also be used to quantify the appearance 
of glycerol across body compartments, enabling a measure of total lipolysis (143, 144, 
160, 161).  
In its simplest form, during the basal state, the isotopic tracer dilution technique 
assumes a single compartment model for glucose and glycerol metabolism. Glucose and 
glycerol entry and removal from the compartment are at a steady-state equilibrium such 
that, the rate of appearance (Ra) equals the rate of disappearance (Rd). The technique 
requires a continuous infusion of a labelled isotopic tracer, which instantaneously and 
uniformly distributes throughout the pool until it reaches an equilibrium with the tracee. 
The Ra of any new glucose or glycerol (tracee) entering the system will be unlabelled, 
thus diluting the tracer concentration. This dilution provides a quantification for glucose 




tracer − to − tracee − ratio
 
 
In humans, glucose is extracted by multiple compartments before entering the 
glucose pool from which it is sampled from. However during the basal state, the rate of 
glucose appearance equals the glucose disappearance creating a steady state. Insulin 
disrupts this steady-state therefore, the simplified single-compartment model cannot be 





2.6.2.1 Peripheral and hepatic insulin sensitivity 
To quantify the insulin-mediated increase in peripheral glucose disposal 
(peripheral insulin sensitivity) and the suppression of endogenous glucose production 
(primarily from the liver which reflects hepatic insulin sensitivity) during the clamp, 
modified versions of the single-compartment model equation have been employed (340). 
The modified equations provide quantification for the glucose Rd and Ra during the 
clamp steady states (the final 30 minutes of each insulin dose). The modifications to the 
equations account for the changes to steady-state metabolism which occur as a response 
to the insulin infusion.  
Similar to the single-compartment model, the modified equations also require a 
quantification of the glucose isotope tracer. However, in addition to the continuous 
isotopic tracer infusion, the modified equations for non-steady state equations also 
account for the variable glucose infusion and the [6,6-2H2]-glucose tracer which has been 
mixed with the variable glucose infusion(333). 
As discussed, the single-compartment model equation used at baseline requires 
the basal/steady-state tracer to tracee ratio (TTR). The tracer infusion is thought to reach 
an equilibrium during the final 30 minutes of the basal phase (after 90 minutes of 
infusion), such that the tracer and tracee flux is equal. A single value is used as the TTR 
during the basal/steady-state as the model assumes that the TTR is equal during the final 
30 minutes of the basal state infusion. The TTR is also required to assess glucose 
dynamics during the clamp and is incorporated into the modified equations. However, in 
comparison to the basal state where the TTR is assumed to be steady throughout the basal 
state, the hyperinsulinaemic-euglycaemic clamp changes the TTR. During the clamp, 
compared to the basal TTR, the TTR rises as insulin stimulates glucose disposal and 




(where the tracer and tracee flux are equal) is achieved and maintained throughout the 
procedure using the continuous isotope infusion and by enriching the variable glucose 
infusion with [6,6-2H2]-glucose. The average TTR and the change in TTR over time is 
incorporated into the modified equations to reflect this action. Optimal segments analysis 
(341) was used to smooth the TTR slope during the clamp to improve the fit with the 
mathematical equations.  
The steady-state single-compartment model also assumes that the glucose 
concentration during the basal state does not change and is equal during the 30 minutes 
of the basal infusion. In comparison, the non-steady state modified equations are adapted 
to incorporate the changes in the glucose pool that occur during the clamp over time. 
Similar to the TTRs, optimal segments analysis (341) was used to smooth the glucose 
slope during the clamp to improve the fit with the mathematical equations. The model 
assumes that the total glucose volume distribution is 22% of the participant body weight; 
therefore, the change in glucose is adjusted to reflect the glucose volume distribution. 
Finally, unlike the steady-state single-compartment model, the modified 
equations better acknowledge the complexity of glucose dynamics which are likely to be 
misrepresented in a single compartment model. The non-steady state equations account 
for the multiple compartment nature of glucose flux. The non-steady state equations 
introduce a coefficient which reflects the proportion of the glucose pool which is rapidly 
equilibrating compared to a slower equilibrating pool. This is more reflective of glucose 
dynamics. The model assumes that the readily mixable compartment (effective fraction) 
constitutes 65% of the total glucose pool (333, 340). The participants’ body weight was 
multiplied by the effective fraction to provide the readily equilibrating glucose pool 
fraction. Whilst this coefficient is an improvement on the single-compartment model, it 




maintaining a constant TTR, particularly in cases where glucose turnover is high after 
(e.g. after an insulin infusion), is important to prevent the oversimplification from 
producing invalid results (342). 
Overall the non-steady state equations calculated at 10-minute intervals during the 
final 30 minutes of the basal, low and high dose insulin state are as follows: 
 
Total Glucose Ra = 
D2 glucose from the continuous infusion (mg/min) + D2 glucose from the various glucose 
infusion (mg/min) - (readily equilibrating glucose pool fraction * average glucose between 
time points (in mg/l)* change in TTR over time 
Average TTR 
 
Glucose Rd = 
 
Total Glucose Ra (mg/min) - (readily equilibrating glucose pool fraction * change in glucose 
over change in time) + variable glucose infusion (mg/min) 
 
 
The values are averaged to give the Ra and Rd during the final 30 minutes of the 
basal, low and high dose insulin infusion. During the basal state, the non-steady state 
modified equations provide the same result as the one-compartment model (section 2.6.2) 
because there is no exogenous glucose infusion and the TTR and glucose are modelled to 
be equal during the final 30 minutes of the basal infusion therefore, the change over time 
is 0. 
The model provides measurements for the glucose Ra and Rd at baseline and 
during the clamp. This represents endogenous glucose production and peripheral glucose 
utilisation, respectively. A number of indices and measures which use these 




• Peripheral insulin sensitivity was determined as the percentage increase in the rate 
of glucose disappearance (glucose Rd) from basal to the final 30 minutes of the 
high dose clamp (224, 239, 343).  
• The peripheral insulin sensitivity index (PISI) was also calculated as the rate of 
glucose disappearance (glucose Rd) divided by the mean plasma insulin 
concentration during the final 30 minutes of the high dose clamp (153).  
• Endogenous glucose production (glucose Ra) was calculated by subtracting the 
exogenous glucose infusion rate from total glucose Ra. Hepatic insulin sensitivity 
was measured as the percentage suppression of endogenous glucose production 
(glucose Ra) from basal to the final 30 minutes of the low dose insulin infusion of 
the clamp (163, 344)  
• The hepatic insulin sensitivity index was also assessed during the basal and low 
dose insulin infusion of the clamp. This was calculated as the reciprocal of the 
product of endogenous glucose production (glucose Ra) and mean plasma insulin 
(153, 203, 204, 344).  
 
2.6.2.2 Adipose tissue insulin sensitivity 
A similar modelling methodology was employed to quantify the insulin-mediated 
suppression of total lipolysis during the clamp. Lipolysis involves the hydrolysis of 
triglycerides into glycerol and fatty acids, the former of which can be measured accurately 
(144). Whole-body/total lipolysis is primarily contributed by adipose tissue lipolysis, 
particularly during the basal state; therefore, changes in total lipolysis during a clamp 
reflect adipose tissue insulin sensitivity (143, 160).  
Similar to basal glucose Ra, basal glycerol Ra was quantified using a single-




and basal TTR. The basal assessment of glycerol Ra also assumed the TTR and glycerol 
concentration was equal during the final 30 minutes of the basal infusion period.  
During the non-steady state, unlike the glucose Ra equation, the equation to assess 
glycerol Ra was not modified to incorporate a readily mixable pool. The equation, 
therefore, assumed a single compartment model for glycerol flux. Also, for the non-steady 
state equation used to assess glycerol Ra, there was no exogenous glycerol applied during 
the clamp (outside of the isotope tracer) therefore, no additional modifications required. 
However, in line the equation used to assess glucose Ra during the clamp, the glycerol 
Ra equation was adjusted to incorporate the change in glycerol TTR equilibrium and 
changes in plasma glycerol concentration. The glycerol TTRs and glycerol concentrations 
were also smoothed with optimal segments analysis (341) to fit with the mathematical 
equations.  
Modelling the glycerol data provides a direct measurement for the glycerol Ra at 
baseline and during the steady-state of the low dose insulin infusion of the clamp. This 
reflects whole-body/total lipolysis (primarily from adipose tissue) and has been used to 
express different measures of adipose tissue insulin sensitivity in this thesis: 
• Adipose tissue insulin sensitivity was measured as the percentage suppression of 
whole-body/total lipolysis (glycerol Ra) from basal to the final 30 minutes of the 
low dose clamp (163).  
• Adipose tissue insulin sensitivity was also estimated using the adipose tissue 
insulin sensitivity index (ATIS) at baseline and during the steady state of the low 
dose insulin infusion. ATIS is the reciprocal of the product of basal whole-body 
lipolysis (glycerol Ra) and mean basal plasma insulin (153). 
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2.7 Statistical analyses 
Variables were assessed for normality using the Shapiro-Wilks test and 
histograms. Where data produced a normal distribution, summary statistics are presented 
as mean (SD). Data which required transformation (log 10) for normality, are presented 
as geometric mean (95% CI). Data which remained nonparametric, are presented as 
median (lower-upper IQR). Where appropriate, either two-way analysis of variance 
(ANOVA), a Student's T-test or Mann-Whitney U test was conducted to assess ethnic 
differences. In cases where the homogeneity of variance was not equal (assessed using 
the Levene's test) and therefore one of the assumptions behind the parametric ANOVA 
test had been violated, a more stringent statistical significance cut-off has been employed 
at p<0.01 (345, 346) otherwise, statistical significance was defined as p <0.05. Linear 
regression analyses were employed to adjust the mean difference in insulin sensitivity 
measures between BAM and WEM for fat, these data are presented as the unadjusted and 
adjusted mean difference (95% CI) calculated as the mean for the WEM minus the mean 
for the BAM. Pearson’s correlation analyses were used to assess the associations between 
insulin sensitivity measures and fat. To determine whether these associations were 
ethnically distinct, an interaction term (ethnicity* fat depot) was applied using the linear 
multiple regression analysis. In addition to assessing the ethnicity interaction, the Y-
intercept of the associations were compared using a t-test based on the intercepts 
themselves and their standard errors (SE). The test statistic was: t= (difference in 
intercepts)/(SE(difference). Data analyses were performed using SPSS software, version 
25 (IBM Analytics, Armonk, NY, USA). 
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2.7.1 Power calculation 
The Soul-DeEP study was powered on the primary outcome which was to assess 
insulin secretory function between black west African and white European men. Power 
calculations are traditionally based on randomised control trials and previously published 
data (347) which were far less extensive when the Soul-DeEP study was initially 
designed. Data reported at the time comparing multiple glucose tolerant groups using an 
intravenous glucose tolerance test with minimal modelling analysis found that differences 
in insulin secretory function were large (>1 standard deviation) (348-350) . Therefore, a 
two-group comparison of 20 vs 20 participants was deemed sufficient to detect a 1 
standard deviation difference with 90% power at a 2 sided significant of 5%. Studies 
which also assessed lipolysis and insulin sensitivity using isotopic tracers and the 
intravenous glucose tolerance test (292, 351, 352), were also factored into the power 
calculation and it was concluded that a two group comparison of 20 vs 20 participants 
would be sufficient to detect and differences.  
A retrospective power calculation was conducted based on an observation study 
by DeLany et al. who assessed tissue specific insulin sensitivity in lean normal glucose 
tolerant African-American and Caucasian women using the hyperinsulinaemic-
euglycaemic clamp (322). This data suggested that to detect a 1 standard deviation 
difference with 90% power and a 2-sided significant of 5%, 56 participants per group are 
required.   
 
 




- Black and white men were recruited to be similar in BMI however, 
this occurred in the presence lower waist circumference, visceral and 
hepatic fat in black men. 
- Plasma triglycerides were lower and glycated hemoglobin was 
slightly higher in black men which are typical characteristics when 
comparing black and white populations.  
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3.1 Chapter introduction 
There are multiple factors that influence insulin sensitivity which can be 
explained, in part, by evaluating the characteristics of the participants assessed. Insulin 
resistance associates significantly with obesity and adiposity thus, understanding 




This chapter aims to describe the characteristics of the Soul-DeEP study 
participants who underwent a two-step hyperinsulinaemic-euglycaemic clamp.  
 
3.3 Methods  
3.3.1 Participants and study design 
As detailed in chapter 2 (section 2.1 and 2.2), participants were recruited from the 
general population using various advertisements and through primary care by members 
of the research team. To confirm normal glucose tolerance (NGT) or impaired glucose 
tolerance (IGT), participants with no history of type 2 diabetes (T2D) underwent a 75g 
oral glucose tolerance test. Patients with T2D had been diagnosed by their physician 
within 5 years. Ethnicity was self-declared, and participants were categorised as either 
black west African or white European men (BAM or WEM, respectively). In addition to 
ethnicity and glucose tolerance, weight, height, waist circumference, blood pressure, 
glycated haemoglobin (HbA1c), plasma glucose, cholesterol and triglycerides were 
assessed at a screening visit. Finally, kidney and liver function tests were evaluated for 




3.3.2 Statistical analyses 
Each characteristic was assessed for normality using the Shapiro-Wilks test and 
histograms. Parametric data are presented as mean (SD); however, data which required 
transformation (log 10) for normality are presented as geometric mean (95% CI). Data 
which were nonparametric, and remained so after log 10 transformation, are presented as 
median (IQR). The main effect of ethnicity and glucose tolerance on each characteristic 
was assessed using a two-way analysis of variance (ANOVA), which assumes data are 
parametric. In cases where data were non-parametric, the ethnicity outcome of the two-
way ANOVA was confirmed by the non-parametric Mann-Whitney U test in each glucose 
tolerance group. To assess the outcome of the ANOVA, the interaction statistic was 
interpreted before interpreting the main effect of ethnicity and glucose tolerance. To 
comply with statistical test assumptions of an ANOVA, in cases where the variance of 
the characteristic was unequal among groups (assessed using the Levene’s statistic), a 
more stringent statistical significance cut-off has been employed at p<0.01. Otherwise, 
statistical significance was defined as p <0.05. Data analyses were performed using SPSS 






3.4.1 Participant recruitment 
A consort diagram detailing non-diabetic participant recruitment for Soul-DeEP 
II, adapted to include the participants from Soul-DeEP I, is shown in figure 9. Within 
Soul-DeEP II, from April 2016 to January 2019, 148 individuals volunteered to take part 
in the study and were screened for eligibility. Of these, 31% were defined as NGT, 14% 
were defined as IGT and 55% were excluded for either not meeting the inclusion criteria, 
declining to participate or were found to be NGT after completion of recruitment into that 
category. Of the BAM assessed for eligibility in Soul-DeEP II, 32% (n=23) were 
allocated as NGT and 14% (n=10) were allocated as IGT. In comparison, 30% (n=23) of 






3.4.2 Characteristics of black west African and white European participants 
The characteristics of the Soul-DeEP participants are shown in table 2. Forty-nine 
BAM (21 NGT, 10 IGT,18 T2D) and 47 WEM (23 NGT, 9 IGT, 15 T2D) underwent a 
two-step hyperinsulinaemic-euglycaemic clamp to assess insulin sensitivity. The men 
were aged between 18-65 with an overall average age of 44. Eighty% (n=77) of 
participants were overweight/obese, as defined by a BMI of ≥25 kg/m2, and this included 
almost all IGT and T2D participants. The remaining 20% (n=19) of lean participants were 
NGT, although 1 lean participant had IGT. 
Concerning ethnicity, there was a non-significant trend towards BAM being 
younger than WEM, and this finding was based on a more stringent statistical significance 
cut-off to account for unequal variances between groups (see section 3.3.2). The lower 
age found in BAM compared to WEM was only statistically significant in men with IGT 
(p=0.02), the ethnic difference in age in men with NGT or T2D was not significant 
(p=0.18 and 0.51, respectively). The ethnic groups were similar in body weight and height 
and, as intended, the ethnic groups were similar in BMI within each glucose tolerance 
group; all averages fell within the overweight/obese BMI category. There were also no 
ethnic differences in body fat percentage or fat free mass, where the data were available 
for men with NGT or IGT. A trend towards lower waist circumference in BAM compared 
to WEM did not reach statistical significance but was consistent in each glucose tolerance 
group, there was an overall mean difference of 4.07cm when pooling all participants. 
Visceral adipose tissue (VAT) and intrahepatic lipid (IHL) content were also significantly 
lower in BAM compared to WEM. This finding was based on a more stringent statistical 
significance cut-off to account for unequal variances between groups (see section 
3.3.2).The significant ethnic difference in VAT was significant within each glucose 




was statistically significant in participants with IGT (p=0.02) tended towards statistical 
significance in participants with T2D (p=0.07) and was not significant between 
participants with NGT (p=0.33). There were no ethnic differences in fasting plasma 
glucose or 2-hour glucose during the oral glucose tolerance test in participants without 
T2D, although there was a trend towards higher glycated haemoglobin (HbA1c) in BAM 
compared to WEM. In participants with T2D, there were no ethnic differences in diabetes 
duration or the proportion of those on metformin. There was a trend towards lower total 
cholesterol and significantly lower triglycerides in BAM compared to WEM which was 
particularly present between men with NGT (p<0.01) but not between men with IGT 
(0.29) or T2D (0.09). There were no ethnic differences in low-density lipoproteins 
cholesterol (LDL) or high-density lipoprotein cholesterol (HDL).  
For each characteristic, there was no statistically significant interaction between 
ethnicity and glucose tolerance and the interaction statistic has been omitted from table 
2. The main effect of glucose tolerance was statistically significant for all characteristics 
(p<0.05) excluding height, fat free mass, total cholesterol and HDL cholesterol. The post 
hoc test for the characteristics which did show a significant effect of glucose tolerance 
are as follows. Age, BMI, waist circumference, VAT, triglycerides and blood pressure 
were significantly different between participants with NGT and IGT or T2D however 
there was no significant difference between participants with IGT and T2D. Body weight 
and IHL was significantly different between participants with NGT and IGT (p<0.01) 
however, there were no significant differences between any of the other glucose tolerance 
groups. SAT was significantly different between participants with NGT and T2D 
(p=0.03) however there were no significant differences between any other groups. Fasting 




groups. Finally, LDL was not significantly different between participants with NGT or 




Table 2: Characteristics of black west African and white European men who underwent a hyperinsulinaemic-euglycaemic clamp 
Continued  
 


















Age (years) a 25.0  
(22.0 – 40.0) 
29.0  
(25.0 – 53.0) 
45.5  
(41.0 – 49.8) 
57.0  
(47.0 – 63.5) 
54.0  
(48.0 – 60.3) 
59.0 
(53.0 – 60.0) 
0.02 <0.01 













Body weight (kg) 84.9 (14.9) 86.6 (16.5) 97.7 (14.7) 97.2 (14.6) 90.9 (9.3) 94.2 (11.7) 0.62 <0.01 
Height (cm) 177.5 (7.8) 180.3 (5.8) 177.0 (6.0) 177.4 (5.0) 175.6 (7.6) 176.8 (5.8) 0.31 0.20 
Body fat (%) 20.67 (6.21) 20.85 (6.81) 25.73 (4.98) 25.30 (6.09) - - 0.94 <0.01 
Fat free mass (FFM) 
(kg) a 
66.8  
(62.0 – 69.3) 
68.8  
(61.3 – 71.9) 
69.5 
(64.8 – 78.9) 
69.7  
(65.9 – 76.1) 
























Data summarised in this chapter describes the characteristics of the participants 
who underwent a hyperinsulinaemic-euglycaemic clamp in the Soul-DeEP study. The 
analyses suggested that there was a trend towards lower age in black men compared to 
white men, particularly those with impaired glucose tolerance. Although there was an 
ethnic difference in age, the ethnic difference in age may not be a confounding factor 
which requires statistical adjustment when interpreting insulin sensitivity findings. In 
support of this, there is evidence to suggest that black communities are at greater risk of 
developing type 2 diabetes (T2D) at a younger age compared to white communities. Data 
from the UK has shown black African Caribbeans being diagnosed with T2D up to 10 
years earlier compared to white Europeans (63, 67). Thus, the age difference in this 
analysis suggests that the participant sample is reflective of this high-risk population with 
early-onset dysglycaemia. In further support of the age difference not being a 
confounding factor in the assessment of insulin sensitivity, several studies have suggested 
that insulin sensitivity is not associated with age, including a study in black men and 
women authored by Goedecke et al. (353). Goedecke and colleagues assessed insulin 
sensitivity in 439 participants between the ages of 25 and 74 with normal glucose 
tolerance. Insulin sensitivity was estimated based on an oral glucose tolerance test derived 
index and fasting indices of insulin sensitivity. The results showed no significant 
association between insulin sensitivity and age in both men and women however, insulin 
sensitivity was associated with BMI (353). The data from Goedecke et al. and other 
research articles suggest that insulin sensitivity is not independently associated with age, 
rather insulin sensitivity is associated with age-related changes in body composition (259, 
260, 354). To account for this, participants were recruited to be similar in BMI between 




consistent link between obesity and T2D (23, 24). The data here show that despite having 
similar BMIs, black men presented with lower waist circumference, ectopic fat, visceral 
fat, circulating lipids but slightly higher HbA1c compared to white European men. These 
ethnic differences have been reported elsewhere (247, 256, 279, 355-358) and support the 
suggestion that this sample of participants was representative of the general population. 
Data from this study shows no evidence of an ethnic difference in SAT which agrees with 
studies in adolescents and adults (359, 360). However, the literature on whether there is 
an ethnic difference in SAT is highly contradictory with other reports showing an ethnic 
difference (361). These inconsistences may be due to differences in the tools used to 
measure SAT. 
All characteristics measured were affected by glucose tolerance, and this occurred 
independently of ethnicity. This finding was to be expected due to the progressive and 
multifactorial nature of type 2 diabetes (71) as well as the fact that the study design was 
centred around ethnicity and matching for this within glucose tolerance groups. 
In addition to the participant characteristics, this chapter also describes the 
recruitment data from the Soul-DeEP study. The study aimed to recruit men with normal 
glucose tolerance (NGT), impaired glucose tolerance (IGT) and T2D. In particular, the 
recruitment of IGT is thought to be more difficult than recruiting individuals with NGT 
or T2D because there are limited clinical diagnostic features and they are not routinely 
sought in clinical practice.  
To conclude, the participants assessed in this thesis were recruited as part of the 
Soul-DeEP study which was able to recruit black men and men with impaired glucose 
tolerance, both of which have traditionally been identified as a difficult to reach groups. 
The characteristic data suggests the cohort can be considered representative of the 
population from which the sample was drawn. 
 
Chapter 4: A comparison of whole-body 




- Whole-body insulin sensitivity was similar in both ethnic groups 
o Normalising whole-body insulin sensitivity for different 
expressions of metabolic size did not alter the ethnicity 
findings, BSA will be used in all other chapters going forward.  
o Normalising whole-body insulin sensitivity for insulin did not 
alter the ethnicity findings  
- Similar whole-body insulin sensitivity occurred in the presence of 
lower VAT in BAM compared to WEM 
- Adjusting whole-body insulin sensitivity for VAT resulted in lower 
whole-body insulin sensitivity in BAM. Lower VAT may protect 
BAM from being more insulin resistant. 
Data presented in this chapter have been published: 
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Insulin sensitivity is a measure of responsiveness to insulin, a decline in such is 
termed insulin resistance and is an early defect in the pathophysiology of type 2 diabetes 
(T2D) (95, 157). Insulin is an integral driver of glucose homeostasis. It has been shown 
to 1) increase glucose disposal in peripheral tissues by promoting glucose uptake, storage 
and oxidation and 2) suppress endogenous glucose production in the liver (71, 362). The 
result of these actions is a reduction in circulating glucose. The term “whole-body insulin 
sensitivity” generally refers to the combined effects of insulin-mediated total glucose 
disposal and the suppression of endogenous glucose production. The hyperinsulinaemic-
euglycaemic clamp has been termed the “gold standard” in vivo method to assess whole-
body insulin sensitivity directly (156, 157). The procedure involves a peripheral insulin 
infusion which is thought to suppress endogenous glucose production. The glucose 
infusion required to maintain euglycemia during the hyperinsulinaemic procedure, M 
value, is a measure of whole-body insulin sensitivity to glucose metabolism. The M value 
is normalised by expressing the data per unit of metabolic body size, e.g. per kg body 
weight, to allow for comparison amongst different individuals (84, 104). Studies which 
have assessed whole-body insulin sensitivity in adults with T2D show insulin action to 
be at least 38% lower in comparison to those without T2D (75, 97).  
Efforts to understand what influences insulin sensitivity to fall or insulin 
resistance to increase have implicated excess adiposity as a culprit. Various indirect and 
direct methods have consistently linked insulin resistance to adiposity, particularly central 
fat (182, 363). An increase in visceral adipose tissue (VAT), a highly lipolytic fat store, 
has been linked with whole-body insulin resistance (182, 186). Animal studies have 




The potential mechanisms which link VAT and insulin sensitivity have been discussed in 
chapter 1 (section 1.7.1). 
Assessments of insulin sensitivity using surrogate indices or the intravenous 
glucose tolerance test with minimal model analysis have almost consistently shown 
increased insulin resistance in black compared to white participants, particularly in 
participants without T2D as reviewed by Kodama and colleagues (265). Their systematic 
review of 71 cohorts included 801 Africans-Americans and 2454 Caucasian participants 
who had either normal glucose tolerance (NGT), impaired glucose tolerance (IGT) or 
T2D. Their analysis excluded studies who had mainly recruited obese participants and 
although the black and white participants were similar in BMI, insulin resistance was 
greater in African-Americans compared to Caucasian participants. In comparison, studies 
which have directly assessed and compared whole-body insulin sensitivity in black and 
white adults using the hyperinsulinaemic-euglycaemic clamp have produced inconsistent 
findings. The majority of studies have focused on obese non-diabetic women with the 
average BMI ranging from 32 - 26 kg/m2. The sample sizes also ranged from 9 to 10 black 
women and 10 to 26 which women. These studies have reported up to 60% lower insulin 
sensitivity in black compared to white women (245, 251, 311). More recent data from the 
POP-ABC study which includes men and women across a range of BMIs have also 
assessed insulin sensitivity derived from the clamp however , participants were not 
matched for BMI such that the black participants were more obese which may confound 
the insulin sensitivity findings. Their data has also shown lower (or a trend towards lower) 
insulin sensitivity in black compared to white participants (319-321). A single study 
which matched participants for BMI (the average BMI of 29.0 kg/m2) has provided 
evidence for 25% greater insulin sensitivity in non-diabetic black compared to white men 




sensitivity, there are also multiple reports of no ethnic difference in whole-body insulin 
sensitivity between black and white participants (307, 312-318). These studies contain 
participants with a range of BMIs and glucose tolerances. However, the black and white 
participants were not consistently matched for BMI such that black participants were 
heavier which may confound results considering the influence of adiposity, particularly 
central adiposity, on insulin sensitivity. 
Overall, the inconsistencies in the ethnic findings from clamp studies assessing 
whole-body insulin sensitivity may reflect differences in participant populations such as 
sex, glucose tolerance, family history, and whether BMI was matched. The majority of 
studies have assessed obese women and participants without T2D. Some studies have not 
matched for BMI. The impact of not matching for BMI and whether findings from obese 





This chapter aims to determine whether there are ethnic differences in whole-body 
insulin sensitivity to glucose metabolism in black west African (BAM) and white 
European men (WEM) with normal glucose tolerance (NGT), impaired glucose tolerance 
(IGT) or early type 2 diabetes (T2D). 
It could be hypothesised that BAM without T2D will have lower whole-body 
insulin sensitivity than WEM. In T2D, there will be no ethnic difference in whole-body 






Details for the study methods including the participant inclusion criteria and 
metabolic assessments can be found in chapter 2. In brief, black west African (BAM) and 
white European men (WEM) were categorised as normal glucose tolerant (NGT) or 
impaired glucose tolerant (IGT), based on their oral glucose tolerance test, or as having 
type 2 diabetes (T2D) if diagnosed within 5 years by their primary care practitioner.  
Participants were invited to attend a two-step hyperinsulinaemic-euglycaemic 
clamp with a continuous insulin infusion at 10mU/m2BSA/min and 40mU/m2BSA/min 
for 2 hours each. During the insulin infusion, a steady-state equilibrium is achieved 
whereby the glucose infused to maintain euglycemia (5 mmol/l) equilibrates to the total 
glucose disposal from the circulation. The steady-state equilibrium is defined as the final 
30 minutes of each insulin infusion; blood samples were drawn during steady states as 
well as the basal period for assessment of plasma glucose and insulin. 
On a separate day, participants also attended a magnetic resonance imaging scan 
to assess visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) area at 
anatomical position L4/5. Intrahepatic lipid (IHL) was also assessed as the average 
hepatic fat fraction from 8 circular regions of interests from the superior and inferior 
surface of the liver. 
 
4.3.1 Calculations 
Whole-body insulin sensitivity was assessed using the M value, which computes 
the mean total glucose disposal during the final 30 minutes of the high dose insulin 
infusion. The M value was normalised per person by expressing glucose disposal per kg 
body weight (mg/kg min-1), m2 body surface area (BSA; mg/m2 BSA min-1) and per kg 




have been suggested to be a more accurate assessment of insulin sensitivity which are less 
likely to underestimate insulin sensitivity in obese participants, which has been found 
with a kg body weight normalisation (84, 104, 339). To account for background insulin 
exposure, M value was divided by mean plasma insulin during the final 30 minutes of the 
clamp to generate M/I; (mg/m2 BSA min-1)/(pmol/l) and (mg/kg FFM min-1)/(pmol/l) 
(104, 156). 
 
4.3.2 Statistical analyses  
Data for each dependent variable were assessed for normality using the Shapiro-
Wilks test and histograms. Parametric data are presented as mean (SD), data which 
required transformation (log 10) are presented as geometric mean (95% CI) and data 
which remained non-parametric are presented as median (interquartile range). Mean 
glucose and insulin concentrations during the basal and steady-state periods were 
compared by an independent samples t-test or Mann-Whitney U test where data were 
parametric and non-parametric, respectively. The relationship between basal glucose and 
insulin concentrations were assessed in participants with and without T2D using a 
Persons’ correlation co-efficient.  
To assess the main effect of ethnicity and glucose tolerance, a two-way analysis 
of variance (ANOVA) was conducted. To assess the outcome of the ANOVA, the 
interaction statistic was interpreted before interpreting the main effect of ethnicity and 
glucose tolerance. Where the interaction statistic was non-significant, the main effect of 
ethnicity and glucose tolerance were independent of one another, thus interpreted in 
isolation. Glucose tolerance had more than 2 groups (NGT, IGT, T2D); therefore, where 
a significant main effect was found, the Tukey’s post hoc tests were employed to 




shown in chapter 3 (section 3.4.2), linear regression was employed to assess the effect of 
ethnicity on whole-body insulin sensitivity whilst adjusting for glucose tolerance, VAT 
and IHL. These data are reported as the unadjusted and adjusted mean difference and 95% 
CI (WEM minus BAM). Statistical significance was defined as p<0.05 and data analyses 





The characteristics of the participants have been described in chapter 3. Briefly, 
men were between the ages of 18 to 65 years, with an average BMI within the overweight 
and obese category. There were no ethnic differences in BMI status in each glucose 
tolerance group (p=0.93); however, BAM were younger compared to WEM, particularly 
those with impaired glucose tolerance (p=0.02). Despite no ethnic difference in BMI 
status, there was a non-significant trend towards lower waist circumference in BAM 
(p=0.05) and significantly lower visceral and hepatic fat in BAM compared to WEM 
(p<0.01 and p<0.01, respectively). Plasma triglycerides were significantly lower in BAM 
compared to WEM (P<0.01) and total cholesterol tended to be lower in BAM compared 
to WEM (p=0.08).  
 
 4.4.1 Glucose and insulin during the clamp procedure 
Glucose and insulin concentrations during the clamp time course are shown in 
figure 10A for participants with NGT, figure 10B for participants with IGT and figure 
10C for participants with T2D. Table 3 summarises of the average glucose and insulin 
concentrations during the basal and steady-state periods of the clamp. During each steady-
state, there were no ethnic differences in mean glucose in any glucose tolerance group. 
The mean insulin concentration during the basal and low dose insulin infusion was no 
different between BAM or WEM in any glucose tolerance. During the high dose insulin 
infusion, there were no ethnic differences in insulin in participants with IGT or T2D. 
However, in participants with NGT, a trend towards higher mean insulin concentration in 
BAM compared to WEM was present, mean difference and 95% CI 53.1 (-1.5, 107.6) 
pmol/l, but did not reach statistical significance. When compared to the basal state, on 




WEM which was not statistically different (p=0.96). Overall, there were no ethnic 
differences in the average increase in insulin during the low or high dose insulin infusion 






Figure 10: Glucose and insulin concentrations during the clamp in black west African (BAM) 
and white European men (WEM) with A) normal glucose tolerance B) impaired glucose 






4.4.3 Whole-body insulin sensitivity 
Whole-body insulin sensitivity, computed as the M value, expressed as kg body 
weight, BSA, kg FFM and as M/I, are presented in table 4 and BSA expressions are also 
shown in figure 12A. In each glucose tolerance group, there were no ethnic differences 
in whole-body insulin sensitivity in all expressions of the M value. When expressing M 
as a function of insulin (M/I), the main effect of ethnicity on whole-body insulin 
sensitivity remained non-significant (table 4, figure 12B). 
There was a statistically significant main effect of glucose tolerance on all 
expressions of the M value (p<0.01). The post hoc analysis indicated that for all 
expressions of whole-body insulin sensitivity, participants with NGT had statistically 
higher insulin sensitivity than those with IGT or T2D (p<0.01). However, there was no 






Table 4: Whole-body insulin sensitivity during the hyperinsulinaemic-euglycaemic clamp 
 
Data are expressed as mean (SD) 
P1 :Main effect of ethnicity, P2 :Main effect of glucose tolerance, P3 : Ethnicity and glucose tolerance interaction 
Measures of whole-body insulin sensitivity in men with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes (T2D) of black west African 
(BAM) or white European (WEM) ethnicity.  
 
 






















M; mg/kg min-1 7.72 (2.32) 7.71 (3.43) 4.50 (1.40) 4.36 (1.35) 4.52 (2.07) 4.00 (1.71) 0.66 <0.01 0.98 
M; mg/m2 BSA min-1 315.4 (76.1) 309.6 (127.5) 197.0 (59.9) 188.2 (51.1) 191.0 (85.3) 172.6 (69.7) 0.57 <0.01 0.92 
M/I; (mg/m2 BSA 
min-1)/(pmol/l) 
0.56 (0.20) 0.62 (0.31) 0.32 (0.11) 0.32 (0.11) 0.34 (0.19) 0.30 (0.11) 0.97 <0.01 0.56 
M; mg/kg FFM min-1 9.65 (2.32) 9.51 (3.86) 6.02 (1.77) 5.79 (1.59) - - 0.82 <0.01 0.95 
M/I; (mg/kg FFM 
min-1)/(pmol/l) 
17.1 x10-3  
(5.9 x10-3) 
18.9 x10-3  
(9.4 x10-3) 
9.84 x10-3  
(3.29 x10-3) 
9.69 x10-3  
(3.46 x10-3) 






Figure 12: Whole-body insulin sensitivity in black west African (BAM) and white European 
men (WEM) by glucose tolerance. 
Data are presented as mean (SD). 




4.4.4 Whole-body insulin sensitivity adjustments for VAT and IHL 
The ethnic and glucose tolerance comparison of VAT and IHL in chapter 3 
(section 3.4.2) showed a statistically significant main effect of ethnicity and glucose 
tolerance. VAT and IHL was lower in BAM compared to WEM (p<0.01). VAT was also 
lower in NGT compared to IGT or T2D (p<0.01); however, there was no difference 
between IGT to T2D (p=0.47). IHL was lower in NGT compared to IGT (p=0.04); 
however, there was no difference between participants with NGT and T2D or participants 
with IGT and T2D (p>0.14) 
The overall unadjusted mean difference and 95% CI of whole-body insulin 
sensitivity (M; mg/m2 BSA min-1) between BAM and WEM was non-significantly higher 
in BAM at -1.45 (-46.6, 43.7) mg/m2 BSA min-1. Adjusting whole-body insulin sensitivity 
(M; mg/m2 BSA min-1) for VAT resulted in significantly lower insulin sensitivity in BAM 
with an overall adjusted mean difference and 95% CI of 34.1 (3.09, 65.05) mg/m2 BSA 
min-1, p=0.03. Adjusting whole-body insulin sensitivity for IHL resulted in a trend 
towards lower insulin sensitivity in BAM with an overall adjusted mean difference and 
95% CI of 29.1 (-3.44, 61.6) mg/m2 BSA min-1, p=0.08. Adjusting for IHL and VAT in 
the same model resulted in significantly lower insulin sensitivity in BAM with an overall 
adjusted mean difference and 95% CI of 42.8 (13.2, 72.4). 
Similarly, adjusting whole-body insulin sensitivity expressed as a function of 
insulin (M/I; (mg/m2 BSA min-1)/(pmol/l)) for VAT, resulted in lower whole-body insulin 
sensitivity in BAM. The unadjusted overall mean difference and 95% CI between BAM 
and WEM was not significant at 0.029 (-0.074, 0.131) (mg/kg FFM min-1)/(pmol/l), 
however the overall VAT adjusted mean difference and 95% CI was 0.11 (0.003, 0.18) 
(mg/kg FFM min-1)/(pmol/l), p<0.01. Adjusting whole body insulin sensitivity expressed 




sensitivity in BAM compared to WEM with an adjusted mean difference and 95% CI of 







The analyses presented in this chapter assessed the effect of ethnicity on whole-
body insulin sensitivity, as measured from a hyperinsulinaemic-euglycaemic clamp. 
Black west African and white European men showed no evidence of an ethnic difference 
in whole-body insulin sensitivity in any glucose tolerance group. This disproves the 
hypothesis of pronounced insulin resistance in black men without T2D compared to their 
white counterparts but agrees with the hypothesis of similar insulin sensitivity in men 
with T2D. When adjusting for ethnic differences in visceral adipose tissue, whole-body 
insulin sensitivity was lower in black men. This may suggest that the lower visceral fat is 
protecting black men from displaying greater whole-body insulin resistance compared to 
white men assuming that high volumes of VAT has a causal role in insulin resistance.  
The finding of similar whole-body insulin sensitivity in black and white men 
conflicts with the consensus that black communities are more insulin resistant than their 
white counterparts (265). Population-based studies assessing a large number of 
participants, using less sensitive surrogate insulin sensitivity assessments, show 
pronounced insulin resistance in black participants (256, 282-284). However, participants 
are not consistently matched for BMI with black participants having a greater BMI, 
particularly in females, with a BMI difference of between 4 and 5.56kg/m2 and an average 
body weight difference of 12kg and 24% more participants defined as obese by BMI (256, 
282, 284). A high BMI is a surrogate indicator of greater fat mass which has been 
associated with insulin resistance (364). Given the association between adiposity and 
insulin resistance (26, 182), greater BMI in black participants may have confounded the 
insulin sensitivity findings. In addition to surrogate insulin sensitivity assessments, the 
intravenous glucose tolerance test (IVGTT) with minimal modelling analysis has been 




estimate of insulin sensitivity. One of the earliest and most compelling reports of ethnic 
differences in insulin resistance was based on the Insulin Resistance Atherosclerosis 
Study which assessed 288 African-Americans and 229 non-Hispanic white Americans 
using the frequently sampled IVGTT with minimal modelling analysis (289, 291). Again, 
participants were not matched for BMI by ethnicity such that black participants were 
heavier than white participants with an average BMI difference 1.7kg/m2. Recent data 
from clamp studies have also shown lower or a trend towards lower insulin sensitivity in 
black compared to white participants (319-321). However, yet again, participants were 
not matched for BMI such that the black participants were more obese than white 
participants with a mean BMI difference between 2.9 and 4.0kg/m2. Overall ethnic 
differences in BMI may have confounded the insulin sensitivity findings in the literature 
leading to a misinterpretation of insulin resistance in black populations. In order to avoid 
this potential confounding factor, participants in this study were recruited to be similar in 
BMI. These data, therefore, contribute to the literature by suggesting that when matched 
for BMI, ethnic differences in insulin sensitivity between black and white men are absent. 
Despite the importance which has been placed on BMI matching, studies have criticised 
BMI for overestimating adiposity in black communities such that for the same BMI, black 
participants have less fat percent (365). Ethnic-specific BMI cut-offs for obesity have 
been suggested with a lower cut off point for black participants because the data show 
that lower BMI thresholds are required in black participants to produce the same diabetes 
incidence level found in white communities (357). Given that body fat percentage is lower 
per unit of BMI in black communities; the higher BMIs in the black participants presented 
in the literature may have resulted in the white and black participants being matched for 
fat content and therefore the difference in BMI would not confound the insulin sensitivity 




when comparing insulin sensitivity in black and white participants to minimise the 
limitations of matching for BMI which does not accurately reflect body composition or 
predict fat mass. 
Prior studies in the literature have also emphasised that pronounced insulin 
resistance may be an early defect in black populations thought to explain the 
disproportionate risk and prevalence. This is supported by lower insulin sensitivity found 
in black compared to white healthy children and adults (248, 289, 292-302). In 
comparison, this study showed no ethnic difference between participants with normal 
glucose tolerance or impaired glucose tolerance which contradicts the hypothesis of early 
insulin resistance in black men, and also suggests pronounced early insulin resistance 
may not explain the greater prevalence in black communities.  
The discrepancies between the findings from this chapter and the literature may 
result from differences in the methodologies used to measure insulin sensitivity. This 
study utilises the hyperinsulinaemic-euglycaemic clamp (156) whereas the evidence for 
pronounced insulin resistance in black communities has primarily been driven by studies 
which assess insulin sensitivity using surrogate indices and the IVGTT (265, 285, 286). 
Insulin sensitivity measures derived from surrogate indices and the IVGTT are based on 
mathematical models of ambient insulin and glucose concentrations. Pisprasert and 
colleagues conducted a validation study assessing insulin sensitivity using the clamp and 
surrogate indices and their findings criticised the use of surrogate indices in black 
populations (307). They assessed and compared 99 African Americans and 141 European 
Americans and found no ethnic difference in insulin sensitivity from the 
hyperinsulinaemic-euglycaemic clamps; however, surrogate indices indicated that black 
participants had lower insulin sensitivity. The authors discussed that hyperinsulinaemia, 




model in such a way that it underestimates insulin sensitivity in black populations (307). 
The circulating insulin concentration is in part determined by insulin secretion and insulin 
clearance, both of which have not been assessed during the hyperinsulinaemic-
euglycaemic clamp. Interestingly, the black participants in this analysis were not more 
hyperinsulinaemic at baseline or during the low dose insulin infusion and the increment 
increase in insulin concentration was not ethnically different. This may have been the 
result of prolonged fasting as the study protocol involved a 2-hour isotope infusion period 
prior to the clamp. The hyperinsulinemia presented in black compared to white 
communities is particularly present during obesity (323) rather than in lean participants 
(322). However, there was a trend towards a higher insulin concentration during the high 
dose steady-state in NGT which may reflect exaggerated hyperinsulinaemia to a degree. 
This hyperinsulinaemia is thought to be due to reduced insulin clearance (266, 366, 367). 
The hyperinsulinaemic-euglycaemic clamp suppresses endogenous glucose production 
which would usually contribute to the circulating insulin. In comparison, other surrogate 
methods for assessing insulin sensitivity do not halt this natural feedback loop showing 
that what we are measuring depends on the tools that we use to measure it. 
Overall, the validation study suggests interpretations of insulin sensitivity from 
indirect assessments should be made with caution and may explain the contrasting 
findings reported in this analysis. In contrast, it could also be interpreted that the surrogate 
indices assess insulin sensitivity in a more physiological setting. The insulin and glucose 
concentrations are based on basal and post load responses, in comparison to the 
hyperinsulinaemic-euglycaemic clamp which creates a supraphysiological controlled 





Whilst different methods have been proposed to explain the differences in 
findings from this study in comparison to the literature, other hyperinsulinaemic-
euglycaemic clamp studies have shown ethnic differences in insulin sensitivity (245, 251, 
311, 312, 319-321). This implies that methodological differences alone, are not the sole 
explanation for the conflict in findings. Other clamp studies which have analysed men in 
isolation, who were not consistently matched for BMI, have reported no ethnic difference 
in whole-body insulin sensitivity (307, 313). Another study (Stull et al.) has provided 
evidence for greater whole-body insulin sensitivity in non-diabetic black compared to 
white men matched for BMI (312). Participant adiposity assessments could not explain 
the conflicting finding from Stull et al. compared to the finding of no ethnic difference in 
this study. The sample size was uneven and smaller in the report by Stull et al. (African 
American n = 4, Caucasian n = 35), thus statistical power may explain the conflicting 
results. The finding of no ethnic difference in whole-body insulin sensitivity from this 
study also contrasts with the majority of studies in obese women without T2D, where 
lower insulin sensitivity in black women is reported (245, 251, 311). This may imply that 
the lower whole-body insulin sensitivity in black compared to white participants is 
restricted to women and not men. It may also be evidence that the effect of ethnicity 
depends on obesity, such that ethnic differences are present during obesity. Thus, the 
ethnic difference in whole-body insulin sensitivity may be sex-specific, obesity-specific 
or a combination. In support of a sex-specific response, studies have shown sex 
differences in insulin sensitivity in black populations; black women are more insulin 
resistant and hyperinsulinaemic than black men (353, 368). Studies have also reported 
sex differences in body composition such that black women have less visceral adiposity 




insulin resistance, hyperinsulinemia and body composition in black populations suggest 
that when compared to white populations, sex differences may be plausible.  
Despite a potential sex effect which may explain why similar insulin sensitivity 
was found in this study of men and greater resistance has been shown in black women; 
other clamp studies have found no ethnic differences in whole-body insulin sensitivity in 
women (246, 312). Therefore, the sex explanation is not consistent in all publications. 
The similar whole-body insulin sensitivity in black and white men shown in this chapter 
aligns with some of the clamp studies in the literature which assess a range of glucose 
tolerances, BMIs, both men and women (307, 309, 312-319) and men alone (307, 313). 
In some of the previous studies, BMI was not consistently matched such that black 
participants were heavier (307, 317) which may have confounded their results. Therefore, 
this study contributes to the literature by suggesting that the lack of an ethnic difference 
between black and white men is true in each glucose tolerance group when matching for 
BMI. 
As discussed in chapter 1, there are multiple methods for expressing whole-body 
insulin sensitivity from a hyperinsulinaemic-euglycaemic clamp. Total glucose disposal 
during insulin stimulation is used to measure whole-body insulin sensitivity, and this must 
be normalised by expressing the data per unit of metabolic body size for comparison 
between groups (33, 84, 104). Normalising whole-body insulin sensitivity using body 
weight has been shown to underestimate insulin sensitivity in obesity (33). In this chapter, 
the main effect of ethnicity was not statistically different regardless of whether whole-
body insulin sensitivity was expressed by body weight, body surface area (BSA) or fat-





It has also been suggested that total glucose disposal could be expressed as a factor 
of insulin to represent whole-body insulin sensitivity (156). In this study, although the 
same insulin infusion was applied to all participants, BAM with NGT exhibited a trend 
towards greater insulin concentrations during the high dose insulin infusion. This may be 
due to reduced insulin clearance (266, 366) and would suggest that insulin adjustments 
are appropriate to eliminate this confounding factor. Some authors argue that measures 
must be adjusted and expressed per unit of insulin (89) although, the adjustment for 
insulin relies on the assumption that the relationship with glucose is linear (89), other 
investigators criticise insulin adjustments for increasing variability (104). To assess 
whether the relationship between insulin and glucose was linear, a correlation analysis 
was conducted. In both ethnic groups, data showed a significant linear relationship 
between basal glucose and insulin in men without diabetes but no relationship in T2D. 
This finding agrees with the literature which shows a non-linear inverted “U” relationship 
between fasting insulin and glucose during the progression to T2D; defined as starlings 
curve of the pancreas (76). Initially, as insulin resistance rises, the insulin response from 
the beta cell increases to offset the disruption in glucose metabolism which increases 
insulin concentrations. Once the beta-cell fails to augment this accelerated insulin 
secretory capacity, glucose tolerance declines. Further increases in glycemia occur in the 
presence of declining insulin concentrations which explains why individuals with T2D 
can have insulin concentrations similar to those with NGT (72, 76, 370, 371). The lack of 
linearity in T2D suggests that participants may be at different points along the inverted 
“U” insulin curve, thus insulin adjustment may not be appropriate because glucose and 
insulin are not associated. This is further supported by the highly variable insulin 
concentrations found in men with T2D (104, 372). Overall, whilst there is debate as to 




showed no ethnic difference in whole-body insulin sensitivity with or without insulin 
adjustments. Both approaches will be assessed in subsequent chapters. 
The accumulation of central adiposity has consistently been linked with insulin 
resistance (182, 201, 363). Despite the greater risk of developing T2D in black 
populations, they have repeatedly been reported to present with lower visceral adipose 
tissue in the presence of greater insulin resistance, which does not align with the current 
views of T2D pathophysiology (247, 289). Data in this chapter showed that black men 
have similar whole-body insulin sensitivity in the presence of lower VAT (chapter 3). 
When adjusting whole-body insulin sensitivity for VAT, black men had lower insulin 
sensitivity compared to white men. This may suggest that the comparable whole-body 
insulin sensitivity can be explained partially by lower VAT in black men. The lower VAT 
was found regardless of glucose tolerance; thus lower VAT accumulation may protect 
black men from being more insulin resistant. In support of the concept that lower VAT 
may be protecting black men from being more insulin resistant, a study which assessed 
obese black and white women with similarly high levels of VAT, contradictory to the 
ethnicity literature (because black participants usually present with low VAT), showed 
lower insulin sensitivity in black compared to white women (251). Another study which 
assessed black and white women with similar waist to hip ratios, an indication of central 
adiposity, also showed lower insulin sensitivity in black women (311). These conclusions 
and data in this chapter may imply that having lower VAT may protect black men from 
presenting with pronounced insulin resistance compared to white men.   
Individuals with insulin resistance and T2D have often been reported to present 
with fatty liver (222). Lalia and colleagues assessed 116 non-diabetic men and women 
across a range of BMIs using pancreatic hyperinsulinaemic-euglycemic clamps to assess 




intrahepatic lipids (IHL) and magnetic resonance imaging to assess VAT. They found 
using correlations and multiple linear regression that both IHL and VAT associate with 
and are significant predictors of whole-body insulin sensitivity (373). The data in this 
chapter show that adjusting for the ethnic differences in IHL results in trend towards 
insulin sensitivity being lower in black compared to white men. This finding may suggest 
that presenting with lower hepatic fat may also protect black men from displaying 
pronounced insulin resistance.  
Assessing whole-body insulin sensitivity (total glucose disposal) during a 
hyperinsulinaemic-euglycaemic clamp does have its limitations. It assumes that 
endogenous glucose production is completely suppressed during the insulin infusion 
(156). However, in cases of insulin resistance and type 2 diabetes, an insulin infusion of 
40mU/m2BSA/min has been shown to cause incomplete suppression of endogenous 
glucose production (87, 163). Thus, endogenous glucose production, as well as the 
exogenous glucose infusion, contribute to the glucose entry into the circulation and the 
M value underestimates insulin sensitivity in these groups. This measurement limitation 
can be alleviated by using stables isotopes to directly trace glucose entry and removal 
from the circulation (159). Ethnic differences may occur in the suppression of endogenous 
glucose production and have been published (323), which may therefore 
disproportionately influence an ethnic comparison of the M value which is not able to 
capture the endogenous glucose production without stable isotopes.  
To conclude, this chapter aimed to assess ethnic differences in whole-body insulin 
sensitivity in black west African and white European men across a range of glucose 
tolerances. By using the hyperinsulinaemic-euglycaemic clamp to measure total glucose 
disposal, there were no ethnic differences in insulin sensitivity in any glucose tolerance 




in the presence of lower visceral fat, adjusting for which, reduces insulin sensitivity in 
black men, suggesting that lower central fat accumulation contributes to the comparable 
insulin sensitivity. 
 
Chapter 5: A comparison of peripheral 




- There were no ethnic differences in peripheral insulin sensitivity. This 
finding was consistent in all glucose tolerance groups. 
- Similar peripheral insulin sensitivity occured in the presence of lower 
VAT in black men. 
- There was some evidence to suggest that lower VAT in black men 
may protect them from having greater peripheral insulin resistance. 
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Insulin has a direct action on multiple sites which include skeletal muscle and 
adipocytes, collectively termed peripheral tissue (95). Insulin has been well described as 
a stimulator of peripheral glucose disposal where it increases glucose uptake and 
influences both oxidative and non-oxidative glucose metabolism. These actions lead to a 
reduction in circulating glucose (95). During the insulin-stimulated state, the majority of 
glucose is disposed of in peripheral tissues, and almost all peripheral glucose disposal 
occurs in the skeletal muscle (76, 90, 95, 97, 103-105) with relatively little in the adipose 
tissue (95-99). Thus, peripheral insulin sensitivity is primarily an assessment of skeletal 
muscle insulin sensitivity (95). Studies have shown over 45% lower insulin-mediated 
skeletal muscle glucose disposal in participants with obesity (98, 374) or type 2 diabetes 
(T2D) (75, 86, 90, 97) compared to healthy controls. This large difference supports the 
conclusion drawn by multiple investigators that identify skeletal muscle insulin resistance 
as a primary contributor to T2D (95). The hyperinsulinaemic-euglycaemic clamp enables 
quantification of total glucose disposal, the M value, which is derived from an exogenous 
glucose infusion. As discussed in chapter 1 (section 1.6) and chapter 4 (section 4.5), this 
procedure assumes that hyperinsulinaemia causes complete suppression of any 
endogenous glucose production, which is not the case in individuals with more 
pronounced insulin resistance (87, 163). In these cases, the M value can underestimate 
peripheral insulin sensitivity. The use of stable isotope tracers allows for a more direct 
assessment of glucose disposal by measuring the glucose disappearance, which removes 
the limitation of the M value. During insulin stimulation, glucose disposal occurs 
primarily in the peripheral tissues, thus when placed in the context of hyperinsulinaemia, 




Insulin sensitivity has been consistently linked to adiposity (particularly central 
adiposity) such that high levels of adiposity are associated with low insulin sensitivity 
(182). Increases in visceral adipose tissue, in particular, have been associated with an 
increased risk of insulin resistance and type 2 diabetes (186). Where peripheral insulin 
sensitivity has been assessed using isotopic tracers, a significant association with visceral 
adipose tissue has been identified (203-205). Theories which may explain this association 
have been discussed in chapter 1 (section 1.7.1). 
Studies in black and white adults, which assess peripheral insulin sensitivity using 
glucose isotopic tracers, have been restricted to women. The first of which was conducted 
by DeLany et al. in non-diabetic lean women who were matched for age and BMI which 
was on average 23 years and 22.7 kg/m2, respectively. The participants also presented 
with similar levels of free-living physical activity assessed as time in vigorous activity, 
time in moderate activity and steps per day. The data presented by DeLany et al. showed 
peripheral insulin sensitivity to be 26% lower in African-American women compared to 
white women (322). Since then, a single study in obese women has been conducted by 
Goedecke and colleagues. They assessed south African black and white women matched 
for age and BMI which was on average 36 years and 36.6 kg/m2, respectively, and found 
no ethnic differences in peripheral insulin sensitivity (323). This study included 
participants with impaired glucose tolerance and normal glucose tolerance; however, their 
data were not presented by glucose tolerance. The interpretation of these results may 
imply that lower insulin sensitivity in black compared to white women occurs only in a 
lean state. Whether these findings can be extrapolated to men and whether it occurs in all 






This chapter aims to determine whether there are ethnic differences in peripheral 
insulin sensitivity to glucose metabolism between black west African (BAM) and white 
European men (WEM) with normal glucose tolerance (NGT), impaired glucose tolerance 
(IGT) or early type 2 diabetes (T2D).  
It could be hypothesised that BAM will have lower peripheral insulin sensitivity 




5.3 Methods  
A full description of the study methods including the participant inclusion criteria, 
metabolic assessments and insulin sensitivity calculations is provided in chapter 3. In 
summary, black west African (BAM) and white European (WEM) participants were 
categorised as normal glucose tolerant (NGT) or impaired glucose tolerant (IGT) based 
on their oral glucose tolerance test, or as having type 2 diabetes (T2D) if diagnosed by 
their primary care practitioner within 5 years.  
Eligible participants attended a two-step hyperinsulinaemic-euglycaemic clamp 
with a stable [6,6 2H2]-glucose isotope infusion as a direct assessment of peripheral 
glucose disposal (glucose rate of disappearance (Rd)) for peripheral insulin sensitivity 
measures. The primed continuous infusion of [6,6 2H2]-glucose isotope was initiated at 
time -120 minutes and ran until the end of the procedure at time 240 minutes. Basal 
assessments of the peripheral glucose disposal rate were made using samples drawn from 
time -30 to 0 minutes. Subsequently, at time point 0 minutes an insulin infusion was 
initiated at 10mU/m2BSA/min and 40mU/m2BSA/min for 2 hours each, this defined the 
two-steps of the hyperinsulinaemic-euglycaemic clamp. Peripheral glucose disposal 
during the high dose insulin infusion was assessed from samples drawn during the last 30 
minutes of the high dose insulin infusion. At this point, a steady-state equilibrium is 
achieved whereby the glucose infused to maintain euglycemia (5mmol/l) equilibrates to 
the total glucose disposal from the circulation.  
Participants also attended a magnetic resonance imagining scan for assessment of 
visceral adipose tissue (VAT) area at the L4/5 anatomical position. Intrahepatic lipid 
(IHL) was also assessed as the average hepatic fat fraction from 8 circular regions of 






Peripheral glucose disposal (rate of disappearance, Rd) at basal and during the 
high dose insulin infusions were expressed per m2 body surface area (m2 BSA). Peripheral 
insulin sensitivity was assessed as the percentage increase in peripheral glucose disposal 
rate from basal to the steady-state of the high dose insulin infusion (224, 239, 343). The 
relatively small contribution of adipose tissue to glucose uptake suggests that the rise in 
peripheral glucose disposal is a measure of skeletal muscle insulin sensitivity (97). The 
peripheral insulin sensitivity index (PISI) was also calculated during the steady-state of 
the high dose insulin infusion. This was computed as the peripheral glucose disposal 
divided by the peripheral insulin concentration (153). 
 
5.3.2 Statistical analyses 
Data were assessed for normality using the Shapiro-Wilks test and histograms. Parametric 
data are presented as mean (SD), data which required transformation (log 10) are 
presented as geometric mean (95% CI) and data which remained non-parametric are 
presented as median (interquartile range). A two-way analysis of variance (ANOVA) was 
conducted to assess the main effect of ethnicity, glucose tolerance and the interaction. 
This was conducted on parametric data and non-parametric data however, the ethnicity 
findings for the latter were confirmed with Mann-Whitney U tests. To interpret the 
ANOVA, the interaction statistic was first checked before assessing the main effect of 
ethnicity and glucose tolerance. Where the interaction statistic was non-significant, the 
main effect of ethnicity and glucose tolerance were independent of one another, thus 
interpreted in isolation. There were more than 2 glucose tolerance groups (NGT, IGT, 
T2D), therefore when a significant main effect of glucose tolerance was found, Tukey’s 




differences in VAT shown in chapter 3 (section 3.2.2), linear regression was used to 
assess the effect of ethnicity on peripheral insulin sensitivity whilst adjusting for glucose 
tolerance, VAT and IHL. These data are reported as the unadjusted and adjusted mean 
difference and 95% CI (WEM minus BAM). Statistical significance was defined as p 
<0.05. Data analyses were performed using SPSS software, version 25 (IBM Analytics, 






A full description of the characteristics of the participants analysed in this chapter 
has been presented in chapter 3. In summary, participants were between the ages of 18-
65 years with a BMI between 20 – 40 m2/kg. Within each glucose tolerance group, the 
age of BAM was lower compared to WEM, particularly in those with IGT (p=0.02). There 
were no ethnic differences in BMI in any glucose tolerance group (p=0.93), and on 
average, the majority of the men were overweight or obese. Visceral and hepatic fat were 
also significantly lower in BAM compared to WEM (p<0.01 and p<0.01, respectively). 
A full description of the plasma glucose and insulin profiles during the clamp are shown 
in chapter 4 (section 4.4.1). A trend towards an ethnic difference was found in participants 
with NGT, whereby BAM had higher insulin concentrations during the steady-state of 
high dose insulin infusion. 
 
5.4.1 Peripheral glucose disposal 
Peripheral glucose disposal (Glucose Rd) was measured at basal and during the 
high dose insulin infusion (table 5). The results of the two-way ANOVA showed no 
statistically significant main effect of ethnicity on basal or insulin stimulated peripheral 
glucose disposal (table 5). As expected, there was a statistically significant main effect of 
glucose tolerance for all measures of peripheral glucose disposal. During the basal state 
mean peripheral glucose disposal expressed was higher in NGT compared to T2D 
(p<0.01) but not different from IGT (p=0.48) and there was no difference between IGT 
and T2D (p=0.31). During the high dose insulin infusion, peripheral glucose disposal was 
statistically higher in men with NGT compared to those with IGT and T2D (p<0.01) 




5.4.2 Peripheral insulin sensitivity 
Peripheral insulin sensitivity was assessed using the peripheral insulin sensitivity 
index (PISI) during the high dose insulin infusion, which expresses peripheral glucose 
disposal as a function of insulin (table 5, figure 13A). The two-way ANOVA shows no 
statistically significant effect of ethnicity on PISI however, as expected, there was an 
effect of glucose tolerance. PISI was higher in NGT compared to IGT or T2D (p<0.01) 
but there was no difference between participants with IGT or T2D (p=0.96). 
Peripheral insulin sensitivity was also calculated as the percentage increase in 
peripheral glucose disposal from basal to the high dose insulin infusion. This measure 
accounts for differences in basal metabolism and the change in insulin (table 5, figure 
13B). The outcome of the two-way ANOVA showed no ethnic difference in peripheral 
insulin sensitivity (p=0.22). As expected, there was a statistically significant effect of 
glucose tolerance. Participants with NGT had higher peripheral insulin sensitivity than 
those with IGT or T2D (p<0.01) and there was no difference between participants with 






Figure 13: Peripheral insulin sensitivity in black west African (BAM) and white European men 
(WEM) by glucose tolerance.  
Peripheral insulin sensitivity calculated as A) peripheral glucose disposal as a function of 
insulin during the high dose infusion steady-state and B) the percentage increase in peripheral 
glucose disposal from basal to high dose insulin infusion steady-state. 
Data expressed as mean (SD). 





5.4.3 Peripheral insulin sensitivity adjustment for VAT and IHL 
Ethnic differences in VAT and IHL were observed whereby VAT and IHL were 
lower in BAM compared to WEM as shown in chapter 3 (section 3.4.2).  
The overall unadjusted mean difference and 95%CI of the percentage increased 
in peripheral glucose disposal between BAM and WEM was -20.0 (-75.3, 35.3) %, 
p=0.47, peripheral insulin sensitivity was higher in BAM however this was not 
statistically significant. Adjusting the percentage increase in peripheral glucose disposal 
for VAT resulted in lower peripheral insulin sensitivity in BAM in the overall cohort. 
Again, this did not reach statistical significance with an unadjusted mean difference and 
95% CI of 22.9 (-20.0, 65.8)%, p=0.29. Adjusting the percentage increase in peripheral 
glucose disposal for IHL resulted in an adjusted mean difference and 95% CI of 12.6 (-
33.5, 58.6) %, p=0.59. When adjusting for VAT and IHL there was no significant 
difference with an adjusted mean difference and 95% CI of 30.6 (-11.7, 73.0), p=0.15. 
PISI was also used as an assessment of peripheral insulin sensitivity. The overall 
unadjusted mean difference and 95%CI in PISI between BAM and WEM was 0.15 (-
0.43, 0.72) (μmol/m2 BSA min-1)/(pmol/l), p=0.62. Adjusting PISI for VAT resulted in 
significantly lower peripheral insulin sensitivity in BAM compared to WEM with an 
overall adjusted mean difference and 95% CI of 0.58 (0.16, 1.00) (μmol/m2 BSA min-
1)/(pmol/l), p<0.01. Adjusting PISI of IHL also resulted in significantly lower peripheral 
insulin sensitivity in BAM compared to WEM with an overall adjusted mean difference 
and 95% CI of 0.51 (0.07, 0.95) (μmol/m2 BSA min-1)/(pmol/l), p=0.03. Adjusting PISI 
for VAT and IHL, resulted in significantly lower peripheral insulin sensitivity in BAM 
compared to WEM with an overall adjusted mean difference and 95% CI of 0.68 





5.5 Discussion  
In this study, peripheral glucose disposal was assessed in black west African and 
white European men of various glucose tolerances. This was assessed using a two-step 
hyperinsulinaemic-euglycaemic clamp with a glucose isotope tracer for a more direct 
quantification for peripheral glucose disposal and peripheral insulin sensitivity. There 
was no evidence for an ethnic difference in peripheral glucose disposal or peripheral 
insulin sensitivity in men of normal glucose tolerance, impaired glucose tolerance or type 
2 diabetes. This disagrees with the hypothesis of lower peripheral insulin sensitivity in 
black compared to white men. 
There are multiple reports for greater insulin resistance in black compared to white 
populations which are generally described to reflect whole-body or peripheral insulin 
sensitivity (265, 285, 286). A defect in peripheral tissues response to insulin is thought to 
be an early sign of the progression to T2D (95). Whilst assessments of whole-body insulin 
sensitivity are primarily a reflection of peripheral tissue glucose disposal, using isotopic 
tracers are a more accurate method to assess peripheral glucose disposal (159). This is the 
first analysis to directly compare peripheral insulin sensitivity in black and white men 
using isotopic tracers and a hyperinsulinaemic-euglycaemic clamp. It is also the first 
study to assess peripheral insulin sensitivity in black and white participants over a range 
of glucose tolerances. Prior literature which use isotope methods to measure peripheral 
insulin sensitivity in black and white populations are limited to women (322, 323). In 
agreement with the findings in this analysis, a single study in obese non-diabetic women 
matched for BMI and age, on average 36.6 kg/m2 and 36 years respectively, by Goedecke 
et al. also found no ethnic difference in peripheral insulin sensitivity (323). This occurred 
using the same protocol (insulin infusion, insulin duration and glucose isotope) as this 




and impaired glucose tolerance. Goedecke et al. were therefore unable to assess a 
potential ethnic difference in both glucose tolerances. This study showed no ethnic 
difference in peripheral insulin sensitivity men in each glucose tolerance group and 
contributes to the literature by suggesting that black and white men have similar 
peripheral insulin sensitivity across the spectrum of glucose intolerance and potentially 
during the disease progression. These data also suggest that the early peripheral insulin 
resistance is not present in black men and the peripheral insulin response is not likely to 
contribute to the ethnic-specific acceleration of T2D risk. 
However, the finding of similar peripheral insulin sensitivity does not agree with 
Delany et al., who studied lean normal glucose tolerant women who were matched for 
BMI and age which was on average 22.7kg/m2 and 23.6 years, respectively. Using the 
same protocol (insulin infusion, insulin duration and glucose isotope), they found lower 
peripheral insulin sensitivity in black compared to white women (322). The conflicting 
findings are not likely to reflect sex differences as data in this chapter agree with 
Goedecke et al. (323) who studied obese women. The conflict with Delany et al. may, 
therefore, be explained by the BMI status of participants. The participants studied by 
Delany et al. were significantly leaner, the average BMI difference was 13kg/m2, 
compared to this study or Goedecke et al. It’s possible that increased insulin resistance in 
black women may be present in the younger, leaner healthy state which supports the 
notion of early insulin resistance shown in individuals without T2D (289, 297, 299-302). 
However, the presence of obesity may outweigh or attenuate any ethnic differences, 
which has been discussed in another study (375). The relationship between insulin 
sensitivity and measures of adiposity may be ethnically distinct as supported by the 
continuous finding of insulin resistance in the presence of lower ectopic fat. An ethnic 




by a study in black and white South African women which showed a weaker relationship 
in black compared to white women (255). White participants may, therefore, be more 
susceptible to obesity-related insulin resistance such that, during obesity insulin 
resistance becomes comparable to that seen in black participants, hence why similar 
peripheral sensitivity may have been found in obese black and white women in Goedecke 
et al. (323). 
The method used by Delany et al. to assess peripheral insulin sensitivity may also 
explain the contrasting findings with this study. They did not comment on whether 
residual endogenous glucose production was accounted for when measuring peripheral 
insulin sensitivity and their methods describe the M value, which is generally used to 
assess whole-body insulin sensitivity (peripheral glucose uptake and suppression of 
endogenous glucose production). Whilst this may be a potential factor to consider, their 
participants were lean and insulin-sensitive; therefore, it could be assumed that 
endogenous glucose production was completely suppressed, and only peripheral glucose 
uptake was captured.  
One of the strengths of this analysis is the assessment of peripheral insulin 
sensitivity using the percentage change in peripheral glucose disposal (239) and the 
peripheral insulin sensitivity index (PISI) (153). There is no consensus on the most 
appropriate way to express peripheral insulin sensitivity from a hyperinsulinaemic-
euglycaemic clamp with isotopic tracers; both methods are employed throughout the 
literature. When peripheral insulin sensitivity is compared between groups, in cases 
where insulin concentrations between groups are similar, peripheral or total glucose 
disposal in response to insulin is compared without an insulin adjustment. However, 
insulin has a dose-dependent effect on glucose, thus adjustments for insulin are often used 




was a trend towards a higher insulin concentration during the steady-state of the high dose 
infusion in black men with normal glucose tolerance compared to white men shown in 
chapter 4 (section 4.4.1). These data suggested that an insulin adjustment may have been 
warranted and was made directly using the PISI and indirectly using the percentage 
increase in peripheral glucose disposal in response to insulin. Both assessments showed 
no ethnic difference thus did not change the ethnicity finding. Finally, by assessing whole-
body (chapter 4) and peripheral insulin sensitivity in the same cohort of participants, the 
findings suggest that ethnic differences are absent whether the glucose infusion or more 
accurate isotopes are used to quantify peripheral glucose disposal. 
Central adiposity, particularly visceral adipose tissue (VAT), has been associated 
with insulin resistance and T2D. Studies have reported a significant association between 
peripheral insulin sensitivity and VAT, where it has been implied that increasing VAT 
increases peripheral insulin resistance (203-205). Details for the mechanisms which may 
link VAT to peripheral insulin resistance have been discussed in chapter 1 (section 1.7.1). 
Black populations have consistently been reported to present with reduced VAT (245-
252) which was also found when comparing the men in this cohort shown in chapter 3 
(section 3.4.2). This study shows similar peripheral insulin sensitivity in black and white 
men occurs in the presence of lower VAT in black men. When adjusting PISI for the 
ethnic differences in VAT, black men presented with significantly lower peripheral 
insulin sensitivity. This mirrors the finding in chapter 4 (section 4.4.3) whereby adjusting 
whole-body insulin sensitivity for VAT resulted in lower whole-body insulin sensitivity 
in black men. The adjustment suggests that lower VAT may protect black men from 
having greater peripheral insulin resistance. In comparison, using the percentage increase 
in peripheral glucose disposal as a measure of peripheral insulin sensitivity did not result 




not a large contributor to peripheral insulin resistance in black populations, and the 
association may be less significant. It may also imply that the theories which implicate 
VAT as having a causal influence of peripheral insulin resistance, are less relevant in 
black populations who have less VAT, thus would be expected to have lower peripheral 
insulin resistance. The conflict in the ethnicity findings when adjusting PISI and the 
percentage increase in glucose disposal for VAT may be due to differences in sample 
size, thus a power issue. More participants had a measurement of PISI in comparison to 
the percentage increase in peripheral glucose disposal. Larger studies are required to 
confirm whether ethnic differences are present in peripheral insulin sensitivity after 
adjusting for lower VAT in black populations. 
Intrahepatic lipids (IHL) have also been suggested to associate with insulin 
resistance to glucose homeostasis. Fabbrinia and colleagues studied 42 obese men and 
women without T2D or a history of hepatic abnormalities using magnetic resonance 
imaging to assess VAT, proton magnetic resonance spectroscopy to assess hepatic fat and 
Hyperinsulinaemic-euglycaemic clamps to assess insulin sensitivity (224). Using linear 
regression analyses, they found that hepatic fat was the best predictor of hepatic, skeletal 
muscle and adipose tissue insulin sensitivity. The data in this chapter show some evidence 
that adjusting for IHL, which was significantly lower in black men, resulted in lower 
peripheral insulin sensitivity in black compared to white men. Similar to the adjustment 
fpr VAT, this finding occurred when correcting PISI and not the percentage change in 
glucose disposal for IHL. Larger studies are required to confirm whether ethnic 
differences are present in peripheral insulin sensitivity after adjusting for the lower IHL 
found in black communities.  
To summarise, this chapter aimed to assess whether ethnic differences in 




in multiple glucose tolerance groups. By using multiple direct assessments of peripheral 
glucose disposal in response to insulin stimulation, these data show no evidence for an 
ethnic difference in peripheral insulin sensitivity which disproves the original hypothesis. 
This occurred in each glucose tolerance groups and suggests that peripheral insulin 
sensitivity alone is, unlikely to explain the high risk of T2D in black compared to white 
men. Participants were matched for BMI; however, black men presented with lower VAT 
compared to white men. After adjusting peripheral insulin sensitivity for ethnic 
differences in VAT, peripheral insulin sensitivity appeared to be lower in black men 
compared to white men; however, these data were inconsistent. Whether visceral 
adiposity is equally detrimental to peripheral insulin sensitivity in black and white men 
cannot be concluded by these data. 
 
Chapter 6: A comparison of hepatic 






- There were no ethnic differences in hepatic insulin sensitivity. This 
finding was consistent in all glucose tolerance groups. 
- Similar hepatic insulin sensitivity occured in the presence of lower 
visceral and hepatic fat in black men. 
- Lower visceral and hepatic fat in black men may protect them from 
having lower hepatic insulin sensitivity when compared to white men. 
Data presented in this chapter have been published: 
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As discussed in chapter 1 (section 1.5.2), insulin has been described to affect 
hepatic function through multiple mechanisms, which lead to a reduction in hepatic 
glucose production (128). During the fasted state, insulin action at the liver is low; the 
resulting hepatic glucose production provides a fuel source for all organs, particularly 
neural tissues. In comparison, during the fed state, when insulin concentrations increase, 
hepatic glucose production is suppressed to prevent excess hyperglycaemia. A reduction 
in hepatic insulin sensitivity, termed hepatic insulin resistance, has been well documented 
to be greater in type 2 diabetes and has been implicated in the disease progression (128, 
132).  
In order to assess hepatic insulin sensitivity, glucose isotopes have been 
employed, which trace glucose flux (159). The glucose isotopic tracers allow for a direct 
assessment of glucose appearance, a reflection of total endogenous glucose production. 
Hepatic glucose production makes up 95% of total endogenous glucose production (130); 
thus, quantifying endogenous glucose production is used as an assessment of hepatic 
glucose production. When placed in the context of insulin, this is used to derive hepatic 
insulin sensitivity. The majority of studies which directly assess hepatic insulin sensitivity 
do so; by measuring the percentage suppression of endogenous glucose production in 
response an insulin infusion, by calculating the basal hepatic insulin sensitivity index 
(HISI) or by calculating the basal hepatic insulin resistance index (HIRI) (204, 344).  
Hepatic insulin sensitivity has been tightly associated with visceral adipose tissue 
(VAT) and intrahepatic fat (IHL), it may potentially influence or be influenced by VAT 
and IHL (203-205, 226, 227, 373). The potential mechanisms which link VAT and IHL 
to hepatic insulin resistance have been described in chapter 1 (section 1.7.1 and 1.7.2) 




Studies which assess hepatic insulin sensitivity using isotopic tracers in black and 
white adults have primarily been conducted in women, in each case the black and white 
participants were matched for BMI and age. There have been reports of no ethnic 
difference in hepatic insulin sensitivity either during the basal or insulin stimulated state 
in obese and lean participants with an average BMI of 32.5kg/m2 and 22.7 kg/m2, 
respectively (246, 322). There have also been reports that obese black women have 
greater hepatic insulin sensitivity during the stimulated state compared to obese white 
women with a cohort average BMI of 36.6 kg/m2 (323). A study which assessed women 
across a range of BMIs found lower hepatic insulin sensitivity during the basal state in 
black compared to white women (296). Only a single study has included both male and 
female participants which covered a range of BMIs; the authors reported no ethnic 
difference in basal or insulin suppressed endogenous glucose production (315). The 
inconsistent findings may be due to basal versus insulin stimulated assessment of hepatic 
insulin sensitivity, the degree of participant obesity, the sex of the participants or the 
glucose tolerance status of participants. 
 
6.2 Aim 
This chapter aims to determine whether there are ethnic differences in hepatic 
insulin sensitivity between black west African (BAM) and white European men (WEM) 
of normal glucose tolerance (NGT), impaired glucose tolerance (IGT) or early type 2 
diabetes (T2D).  
It could be hypothesised, based on lower visceral and ectopic fat in black 






6.3 Methods  
A full description of the study methods is provided in chapter 2. This includes the 
participant inclusion criteria, metabolic assessments and the calculations used to derive 
insulin sensitivity. To summarise, black west African (BAM) and white European men 
(WEM) were defined as normal glucose tolerant (NGT) or impaired glucose tolerant 
(IGT) based on their oral glucose tolerance test. Participants with type 2 diabetes (T2D) 
had a diagnosis of T2D within 5 years documented in their medical records.  
Eligible participants attended a two-step hyperinsulinaemic-euglycaemic clamp 
with a stable [6,6 2H2]-glucose isotope infusion to assess endogenous glucose production 
(glucose rate of appearance (Ra)) which was used to calculate hepatic insulin sensitivity. 
A primed continuous infusion of [6,6 2H2]-glucose isotope was initiated at time -120 
minutes and ran until the end of the procedure at time 240 minutes. A basal assessment 
of endogenous glucose production was made using samples drawn from time -30 to 0 
minutes by which time the [6,6 2H2]-glucose isotope infusion had achieved an equilibrium 
enrichment with plasma glucose. Subsequently at time point 0 minutes, an insulin 
infusion was initiated at 10mU/m2BSA/min and 40mU/m2BSA/min for 2 hours each, 
which defined the two-steps of the hyperinsulinaemic-euglycaemic clamp. Endogenous 
glucose production during the low and high dose insulin infusion was assessed from 
samples drawn during the last 30 minutes of each step. At this point, a steady-state is 
achieved whereby the glucose infused to maintain euglycaemia (5mmol/l) equilibrates to 
the total glucose disposal from the circulation.  
Participants also attended a magnetic resonance imagining scan for assessment of 
visceral adipose tissue (VAT) area and intrahepatic lipid (IHL). VAT was assessed from 
the L4/5 anatomical position, and IHL was assessed as the average hepatic fat fraction 





Endogenous glucose production was assessed by measuring the glucose rate of 
appearance, expressed per m2 of body surface area (BSA), during the basal period and the 
final 30 minutes of the low and high dose insulin infusion as discussed in chapter 2 
(section 2.6.1). The hepatic insulin sensitivity index (HISI) was calculated as the 
reciprocal of the product of endogenous glucose production (μmol/m2BSA min-1) and 
mean plasma insulin (pmol/l) (203, 344). This was used as an estimate of hepatic insulin 
sensitivity at basal and during insulin stimulation. The primary assessment of hepatic 
insulin sensitivity was calculated as the percentage suppression of endogenous glucose 
production from basal to the low dose insulin infusion steady state which accounts for 
differences in basal activity and represents an assessment of the dynamic change in 
glucose metabolism in response to the clamp (163, 204, 344). Finally, the residual 
endogenous glucose production during the steady-state of the high dose insulin infusion 
was assessed. Any negative or zeros values were defined as 100% suppression of 
endogenous glucose production, although this was minimised by enriching the glucose 
infusion with [6,6-2H2]-glucose to stabilise the tracer-to-tracee ratio. 
 
6.3.2 Statistical analyses 
Data were assessed for normality using the Shapiro-Wilks test and histograms. 
Normally distributed data are presented as mean (SD), data which required transformation 
(log10) are presented as geometric mean (95% CI) and data which remained skewed are 
presented as median (interquartile range). A two-way analysis of variance (ANOVA) was 
conducted to assess the main effect of ethnicity, glucose tolerance and the interaction. 
This was conducted on the normally distributed data and skewed data; however, the 




outcome of the two-way ANOVA, the interaction statistic was interpreted before 
interpreting the main effect of ethnicity or glucose tolerance. Where the interaction 
statistic was non-significant, the main effects of ethnicity and glucose tolerance were 
assessed independently. Glucose tolerance had more than two groups (NGT, IGT, T2D); 
thus, where a significant main effect was found, the Tukey’s post hoc tests were employed 
to determine where the differences lay. To control for ethnic differences in VAT and IHL 
shown in chapter 3 (section 3.4.2); linear regression was used to assess the effect of 
ethnicity on insulin sensitivity whilst adjusting for glucose tolerance, VAT and IHL. 
These data are reported as the adjusted mean difference and 95% CI. Statistical 
significance was defined as p <0.05. Data analyses were performed using SPSS software, 





The clinical characteristics of the participants assessed have been described in 
chapter 3. To summarise, all participants were adults aged between 18 to 65. BMI status 
identified most participants as either overweight or obese. There were no ethnic 
differences in BMI (p=0.98); however, there was a trend towards BAM being younger in 
age compared to WEM. There was a trend towards lower waist circumference in BAM 
compared to WEM (p=0.05), and the MRI analysis showed significantly lower VAT and 
IHL in BAM compared to WEM in each glucose tolerance group (p<0.01). 
 
6.4.1 Endogenous glucose production 
Endogenous glucose production (glucose Ra), which primarily reflects hepatic 
glucose production (129, 130), was assessed during the different clamp phases, as shown 
in table 5. During the basal state, there were no ethnic differences in endogenous glucose 
production in any glucose tolerance group (table 6). Basal endogenous glucose production 
appeared to be higher in WEM compared to BAM in participants with IGT or T2D 
however, this was not statistically significant. Basal endogenous glucose production was 
similar between NGT and IGT (p=0.45) however, participants with NGT or IGT had 
higher basal endogenous glucose production compared to those with T2D (p<0.01). 
Higher basal endogenous glucose production in participants with NGT and IGT was also 
found when expressing basal glucose production as a rate shown by a mean and standard 
deviation of NGT 917.8 (125.4) vs IGT 933.0 (158.6) vs T2D 803.5 (156.3) μmol/ min 
p<0.01. 
During the steady-state of the low dose insulin infusion, there were no ethnic 
differences in endogenous glucose production in each glucose tolerance group (table 6). 




significantly lower in participants with NGT compared to T2D and IGT (p<0.01). There 
was a trend towards lower endogenous glucose production in participants with IGT 
compared to T2D (p=0.06).  
 
6.4.2 Hepatic insulin sensitivity 
The hepatic insulin sensitivity index (HISI) assesses endogenous glucose 
production whilst accounting for insulin. During the basal state, HISI showed no evidence 
for an ethnic difference in each glucose tolerance group (table 6, figure14A). The main 
effect of glucose tolerance on HISI showed a trend towards significance (p=0.08) such 
that participants with IGT had a lower HISI compared to participants with T2D (p=0.05) 
however, there were no other glucose tolerance differences.  
During the low dose steady state, there were no ethnic differences in HISI in each 
glucose tolerance group (table 6). There was a statistically significant effect of glucose 
tolerance such that HISI was higher in NGT compared to IGT and T2D (p<0.01), but 
there was no difference between IGT and T2D (p=0.95). 
The percentage suppression of endogenous glucose production from basal to the 
low dose insulin infusion steady-state was used as the primary assessment of hepatic 
insulin sensitivity (table 6, figure 14B). There was no statistical difference between BAM 
and WEM in any glucose tolerance group with a median ethnic difference of -8.4 vs 10.8 
vs 9.6%, p=0.62 in men with NGT vs IGT vs T2D, respectively. Hepatic insulin 
sensitivity was significantly higher in participants with NGT compared with IGT and T2D 










Figure 14: Hepatic insulin sensitivity in black west African (BAM) and white European men 
(WEM) by glucose tolerance. 
Hepatic insulin sensitivity was calculated as A) endogenous glucose production as a function 
insulin (HISI) during the basal state, B) the percentage suppression of endogenous glucose 
production from the low dose insulin infusion steady-state compared to basal endogenous 
glucose production.  
Data expressed as mean (SD). 





6.4.3 Hepatic insulin sensitivity adjustment for VAT and IHL 
Based on the findings shown in chapter 3 (section 3.4.2) of lower visceral adipose 
tissue (VAT) and intrahepatic lipids (IHL) in BAM compared to WEM, the percentage 
suppression of endogenous glucose production was adjusted for VAT and IHL. The 
unadjusted mean difference and 95% CI in hepatic insulin sensitivity (the percentage 
suppression of endogenous glucose production) between BAM and WEM was 1.32 (-
8.28, 10.92)%, p=0.79. Adjusting hepatic insulin sensitivity for VAT alone resulted in a 
trend towards lower hepatic insulin sensitivity in BAM compared to WEM. The overall 
adjusted mean difference and 95% CI was 6.49 (-0.82, 13.8)%, p=0.08. When adjusting 
hepatic insulin sensitivity for IHL alone, hepatic insulin sensitivity was lower in BAM 
compared to WEM although, this was not statistically significant with an overall mean 
difference and 95% CI of 5.10 (-2.26, 12.46)%, p=0.17. Combining VAT and IHL into 
the same regression model resulted in a trend towards lower hepatic insulin sensitivity in 
BAM compared to WEM with an overall adjusted mean difference and 95% CI of 7.36 






The analysis in this chapter assesses the effect of ethnicity on hepatic insulin 
sensitivity measured from a two-step hyperinsulinaemic-euglycaemic clamp with a 
glucose isotopic tracer. There was no evidence for an ethnic difference in hepatic insulin 
sensitivity between black west African and white European men in any glucose tolerance 
group. This finding occurred when assessing hepatic insulin sensitivity during the basal 
and insulin stimulated state, this disagrees with the hypothesis for greater hepatic insulin 
sensitivity in black compared to white men. 
There has been an abundance of reports which indicate that black communities 
are more insulin resistant in comparison to their white counterparts (256, 282-284). The 
methods utilised by these studies primarily assess peripheral insulin sensitivity. However, 
insulin is a pleiotropic hormone which acts at multiple sites across the body, including 
the liver (89, 90). In order to capture the hepatic response to insulin (the suppression of 
endogenous glucose production), isotopic tracers are required (159); tracers have not been 
utilised by the majority of the ethnicity-specific literature. Studies which have assessed 
hepatic insulin sensitivity in black and white participants have primarily been restricted 
to women and show inconsistent findings. This may be due to participant characteristics 
such as sex, glucose tolerance and obesity, or due to the method used to assess hepatic 
insulin sensitivity, i.e. basal compared to insulin stimulated assessments. This is the first 
analysis which has focused on black and white men over a range of glucose tolerances 
and BMI statuses which assesses both the basal and insulin-stimulated state. The finding 
of no ethnic difference in hepatic insulin sensitivity agrees with studies assessing men 
and women across a range of BMIs (315), lean women (322) and obese women (246). 




during insulin stimulation in participants with normal glucose tolerance or equal 
proportions of impaired glucose tolerance in black and white participants. 
In contrast, the findings in this analysis do not align with Goedecke et al., who 
studied severely obese women with an average BMI of 36.6 kg/m2 and found greater 
hepatic insulin sensitivity in black compared to white women (323). Goedecke et al. 
assessed hepatic sensitivity using the same methodological procedure and hepatic insulin 
sensitivity calculations as this study; thus, the differences in findings are not likely to be 
due to methodology. A comparison of the median percentage suppression of endogenous 
glucose production reported in this study and Goedecke et al., show that the black men 
with normal glucose tolerance in this study had 15% higher hepatic insulin sensitivity 
than black women studied by Goedecke et al. However, the white men studied in this 
analysis had 77% higher hepatic insulin sensitivity than white women studied by 
Goedecke et al. Therefore, the disagreement between ethnic differences in this analysis 
and Goedecke et al. may reflect the observation that the white women studied were 
significantly more resistant than the white men studied in this analysis. Whilst there is no 
cut-point to define hepatic insulin resistance, the median percentage suppression of 
endogenous glucose production for the white women reported by Goedecke et al. was 
also lower than studies in healthy participants, NAFLD and T2D patients using the same 
insulin clamp dose (163, 376). This adds further evidence to the notion that the white 
women studied by Goedecke et al. may have exhibited pronounced insulin resistance. 
Therefore, it could be interpreted that the black women did not have greater hepatic 
insulin sensitivity but rather the control white women were more insulin resistant than 
expected.  
The contrasting results between this study and Goedecke et al. may also reflect a 




in women but absent for men. In support of obesity status potentially influencing ethnic 
differences in hepatic insulin sensitivity, a study which assessed lean women found no 
ethnic difference in basal or stimulated hepatic insulin sensitivity (322). In comparison, 
an assessment of severely obese women using a similar protocol did find an ethnic 
difference (323) which suggests that ethnic differences in hepatic insulin sensitivity are 
more apparent in the presence of obesity. In support of sex altering ethnic differences, an 
assessment of whole-body insulin sensitivity in black South African men and women has 
shown men to be more insulin sensitive (353). The higher insulin sensitivity in black men 
may be close to the insulin sensitivity values displayed by white men which may explain 
why no ethnic differences were identified in the men in this study. Whilst a sex and 
obesity influence may be interpreted from these findings and the literature, data 
comparing black and white women do not fully support this sex and obesity interaction. 
A more recent study in American obese black and white women, with an average BMI of 
32.5kg/m2, has assessed basal hepatic insulin sensitivity and found no ethnic difference 
(246) whereas south African obese black women are shown to have greater hepatic insulin 
sensitivity (323). This undermines the suggestion of ethnic differences being present in 
obese women and suggests assessments of geographical influences are warranted and 
suggests that grouping participants as ‘black’ may be inappropriate. In further support of 
geographical differences influencing ethnicity findings, South African black women 
appear to display a distinct diabetogenic phenotype shown by the higher prevalence of 
obesity and T2D in black South African women compared to black African men residing 
in the UK (259, 377). 
The findings in this chapter also conflict with Ellis et al., who reported lower basal 
and stimulated hepatic insulin sensitivity in normal glucose tolerant black compared to 




on a mathematical model with the intravenous glucose tolerance test and glucose tracer, 
which has yet to be validated (322), thus cannot be directly compared to the findings in 
this analysis. However, their assessment of basal hepatic insulin sensitivity is comparable 
to the method used in this analysis (296). Ellis et al. found lower basal hepatic insulin 
sensitivity in black women (296) which contrasts with the analysis of men in this chapter 
and may provide further evidence for a sex difference in the effect of black ethnicity on 
hepatic insulin sensitivity. In contrast to the findings of studies in women which show 
inconsistent results, the findings in this chapter show a consistent message in men 
regardless of their adiposity status, glucose tolerance or method for assessing hepatic 
insulin sensitivity. In each glucose tolerance group, hepatic insulin sensitivity was similar 
in white and black men which could imply that pronounced hepatic insulin resistance 
does not explain the increased risk of T2D in black communities. It may also imply that 
the progression of hepatic insulin resistance with impaired glucose tolerance is not 
ethnically different. In contrast, the conflicting ethnic-specific results in the literature may 
reflect an interaction between sex, obesity and geographical region which impact whether 
ethnic differences in hepatic insulin sensitivity are present. Ethnic differences appear to 
be present more so in women; whether it is higher or lower in black women depend on 
obesity and geographical region of the black women; however, from this analysis, ethnic 
differences are absent in black and white men.  
The presence of high visceral adipose tissue (VAT) and intrahepatic lipids (IHL) 
has been significantly associated with hepatic insulin resistance (203-205, 226, 373). The 
characteristics presented in chapter 3 (section 3.4.2) showed significantly lower VAT and 
IHL in the black men which agree with the literature (247, 256). Thus, similar hepatic 
insulin sensitivity occurried in the presence of lower visceral and hepatic fat in black men. 




non-significant trend towards lower hepatic insulin sensitivity. This may suggest that 
having lower levels of visceral and hepatic fat is protective in black men and prevents 
them from presenting with greater hepatic insulin resistance. Whilst IHL is consistently 
reported to be lower in black populations, a study which assessed black and white patients 
with fatty liver disease showed no ethnic difference in estimated insulin resistance (326). 
This may indicate that other variables outside of IHL are protecting black populations 
from having pronounced hepatic insulin resistance.  
The analysis in this chapter was derived from data from the two-step 
hyperinsulinaemic-euglycaemic clamp. Hepatic insulin sensitivity was assessed during 
the low dose insulin infusion, which was below the maximum concentration for complete 
suppression of endogenous glucose production in all glucose tolerances. The higher dose 
insulin infusion was used to assess peripheral glucose disposal at which point the method 
assumed complete suppression of hepatic glucose production (156). The residual 
endogenous glucose production during the high dose infusion has also presented in this 
chapter. There were no ethnic differences in residual endogenous glucose production 
which further suggest similar hepatic insulin sensitivity at this high dose. However, 
endogenous glucose production increased with worsening glucose tolerance reflecting the 
increasing hepatic insulin resistance, which was also observed during the low dose insulin 
infusion. Accounting for the residual endogenous glucose production is of importance 
when drawing any conclusions during the high dose infusion and this discussed in more 
detail in chapter 9. 
Whilst this chapter did not aim to assess the effect of glucose tolerance on hepatic 
insulin sensitivity, the finding of significantly lower endogenous glucose production in 
participants with T2D compared to those without T2D was unexpected. Increased hepatic 




production as a rate (μmol/ min) to remove the metabolic body size parameter (BSA) did 
not change the significant impact of glucose tolerance. Impairments in hepatic glucose 
production have been described to be more pronounced in severe T2D when compared to 
the early stages of T2D (380, 381) which may explain why the participants with early 
type 2 diabetes did not have higher basal EGP. This is also supported by studies which 
show no difference in basal endogenous glucose production between Swedish men of 
NGT, IGT and mild T2D (129) or between lean and obese participants (382). Adjusting 
for insulin via the hepatic insulin sensitivity index reduced the glucose tolerance effect. 
However, there was a trend towards greater hepatic insulin sensitivity in participants with 
T2D compared to IGT. The apparent greater hepatic insulin sensitivity in T2D may be 
due to residual effects of the metformin. The majority of the participants were on 
metformin, and this has been shown to reduce hepatic insulin resistance in T2D 
independently of weight change (383). However, participants were instructed to stop 
medication 7 days before their metabolic assessments to reduce this effect; therefore, this 
explanation is less likely. A more likely reason for lower endogenous glucose production 
in participants with T2D is that the participants with NGT were less insulin resistant and 
therefore, needed to make more glucose to maintain plasma glucose following a 
prolonged fast. This is supported by the peripheral glucose disposal data which showed 
lower insulin resistance in NGT. It may also be the result of a lack of statistical power as 
the sample size in T2D was not large. Overall, the hepatic insulin response finding 
(percentage suppression of endogenous glucose production) does agree with the 
consensus that hepatic insulin resistance increases as glucose tolerance gets worse. 
Therefore this data shows, the main effect of glucose tolerance on hepatic insulin 




To conclude, hepatic insulin sensitivity appears to be similar between black west 
African and white European men across a range of glucose tolerances which disagrees 
with the hypothesis of greater hepatic insulin sensitivity in black compared to white men. 
This finding occurs when expressing hepatic insulin sensitivity in multiple ways in 
participants with a range of BMIs. The comparable hepatic insulin sensitivity occurs in 
the presence of lower visceral and hepatic fat in black men. Lower storage of visceral and 
hepatic fat may protect black men from having greater hepatic insulin resistance.  
 
Chapter 7: A comparison of adipose 
tissue insulin sensitivity between black 




- There were no ethnic differences in adipose insulin sensitivity in all 
glucose tolerance groups. 
- Absolute rates of lipolysis were significantly lower in BAM, this was 
not explained by insulin but could partially be explained by lower 
visceral fat in BAM. 
- Lower rates of lipolysis in BAM occurred in the presence of lower 
triglycerides and may contribute towards ethnic differences in plasma 
triglycerides. 
Data presented in this chapter have been published: 
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Lipolysis is the process by which triglyceride molecules are hydrolysed into free 
fatty acids and glycerol. This occurs in multiple tissues; however, adipose tissue is the 
only one which releases the fatty acids and glycerol for use in non-adipose tissue (138). 
Insulin has been well characterised as a potent inhibitor of adipose tissue lipolysis (72, 
100, 107, 139-142). Resistance to insulin-mediated suppression of lipolysis has been 
implicated in the development of type 2 diabetes (T2D) (152-154, 384). Adipose tissue 
insulin resistance has been shown to be up to 4 times higher in T2D compared to normal 
glucose tolerance (153, 154).The insulin resistance to lipolysis results in inappropriately 
high rates of lipolysis causing elevated circulating fatty acids, which promote peripheral 
and hepatic insulin resistance through lipotoxicity and by increasing gluconeogenesis 
(107, 128, 135, 136, 221, 233, 241). Lipolysis occurs in both subcutaneous and visceral 
adipose tissue depots; the latter has been described as a highly lipolytic fat store (211). 
Stable isotopic tracers have been employed in the assessment of lipid kinetics whereby 
the flux of glycerol appearance into the circulation is used as a direct quantification of 
lipolysis. Particularly during the fasted state, fatty acid and glycerol entry into the 
circulation primarily reflects lipolysis in peripheral adipose tissue. Lipolysis also occurs 
in the circulation as triglycerides in lipoproteins are hydrolysed; however, this has a minor 
contribution to total lipolysis as shown by relatively low VLDL clearance rates (143, 144, 
241). There is currently no “gold standard” method to assess adipose tissue insulin 
sensitivity to lipolysis; however, using isotopic tracers in the presence of insulin has been 
highly regarded (166, 384, 385). 
Only a single in vivo study has assessed the effect of insulin on adipose tissue 
lipolysis using tracers in black and white adults (304). Albu et al. showed significantly 




white women who were matched for BMI which was 34.9kg/m2 on average (304). In 
comparison, a recent study of obese black and white women who were also matched for 
BMI (32.5kg/m2 on average) found no ethnic difference in basal adipose tissue insulin 
sensitivity (246). Other studies have used isotopic tracers to assess lipolysis, without 
accounting for insulin, and have shown either no ethnic difference in lipolysis (303, 386) 
or lower lipolysis (252, 304, 325, 387) in black compared to white populations. These 
studies have predominantly been conducted in obese women; however, whether they can 
be extrapolated to men is unknown. Sex differences in adipose tissue function, outside of 
ethnicity, have been reported such that women display higher rates of lipolysis in 
comparison to men (388, 389) suggesting that findings in women may not be extrapolated 




This chapter aims to determine if there are ethnic differences in the effect of 
insulin on adipose tissue lipolysis between black west African (BAM) and white 
European men (WEM) of normal glucose tolerance (NGT), impaired glucose tolerance 
(IGT) or early type 2 diabetes (T2D).  
It could be hypothesised that BAM will display greater adipose tissue insulin 






7.3 Methods  
Chapter 2 provides a full description of the study methods which include the 
participant inclusion criteria, metabolic assessments and the calculations used to derive 
measures of insulin sensitivity. In brief, black west African (BAM) and white European 
men (WEM) were defined as normal glucose tolerant (NGT) or impaired glucose tolerant 
(IGT) based on an oral glucose tolerance test. Participants defined as having type 2 
diabetes (T2D) had been diagnosed by their primary care practitioner within 5 years. 
Eligible participants were invited to attend a two-step hyperinsulinaemic-
euglycaemic clamp with a stable [2H5]-glycerol isotope infusion to assess whole-body / 
total glycerol rate of appearance (Ra). Whole-body / total glycerol Ra primarily reflects 
adipose tissue lipolysis, particularly during the basal state; although the hydrolysis of 
circulating triglyceride-rich lipoprotein contribute a small portion of glycerol Ra which 
increases during insulin stimulation (143, 234). In this study, whole-body/total glycerol 
Ra is referred to as adipose tissue lipolysis. This was assessed during the basal phase and 
low dose insulin infusion to calculate adipose tissue insulin sensitivity. To begin the 
procedure, a primed continuous infusion of [2H5]-glycerol was initiated at time -120 
minutes and ran until time 120 minutes. The assessment of basal adipose tissue lipolysis 
was made from samples drawn from time -30 to 0 minutes; by which time the [2H5]-
glycerol glucose isotope infusion had reached an equilibrium enrichment with plasma 
glycerol. At time 0 minutes, an insulin infusion was initiated at 10mU/m2BSA/min for 
120 minutes, which defined the first step of the hyperinsulinaemic-euglycaemic clamp, 
termed the low dose insulin infusion. Adipose tissue lipolysis during the low dose insulin 
infusion was assessed from samples drawn during the last 30 minutes. At this point, a 
steady-state was achieved whereby the glucose infused to maintain euglycemia (5mmol/l) 




Participants also attended a magnetic resonance imagining scan for assessment of 




The rate of adipose tissue lipolysis was determined by measuring the glycerol rate 
of appearance, expressed per m2 of body surface area (BSA), during the final 30 minutes 
of the basal and low dose insulin stimulation. The primary assessment of adipose tissue 
insulin sensitivity was calculated as the percentage suppression of lipolysis from basal to 
the low dose insulin stimulation which accounts for differences in basal activity and 
reflects the response to the insulin clamp (166, 224, 343). The adipose tissue insulin 
sensitivity index (ATIS) was also calculated as the reciprocal of the product of adipose 
tissue lipolysis (μmol/m2BSA min-1) and mean plasma insulin (pmol/l) (153, 165, 166). 
This was used as an estimate of adipose tissue insulin sensitivity at basal and during 
insulin stimulation. 
 
7.3.2 Statistical analyses 
The Shapiro-Wilks test and histograms were used to assess the distribution of data 
for each dependent variable. Data which were normally distributed are presented as mean 
(SD), and data which required transformation (log10) are presented as geometric mean 
(95% CI). To assess the main effect of ethnicity, glucose tolerance and the interaction, a 
two-way analysis of variance (ANOVA) was conducted on the normally distributed data. 
For the dependent variable which required a transformation (log 10) in two glucose 
tolerance groups but not the other, the transformed (log 10) data were used in the two-




assess the outcome of the two-way ANOVA, the interaction statistic was interpreted 
before interpreting the main effect of ethnicity or glucose tolerance. Where the interaction 
statistic was not significant, the main effect of ethnicity and glucose tolerance could be 
assessed in isolation. Glucose tolerance had more than two groups (NGT, IGT, T2D); 
thus, where a significant main effect was found, the Tukey’s post hoc tests were employed 
to determine where the differences lay. To control for ethnic differences in VAT and IHL 
shown in chapter 3 (section 3.4.2), linear regression was used to assess the effect of 
ethnicity on insulin sensitivity whilst adjusting for glucose tolerance and VAT. These 
data are reported as the unadjusted and the adjusted mean difference and 95% CI for 
normally distributed data and the adjusted and unadjusted ratio of the geometric mean 
and 95% CI for log-transformed data. 
To comply with statistical test assumptions of an ANOVA, in cases where the 
variance of the characteristic was unequal among groups (assessed using the Levene’s 
statistic), a more stringent statistical significance cut-off has been employed at p<0.01. 
Otherwise, statistical significance was defined as p <0.05. Data analyses were performed 






The characteristics of the participants assessed in this analysis have been 
described in detail in chapter 3. To summarise, BAM and WEM were similar in BMI, by 
design, with most participants identified as overweight or obese. Participants with IGT 
and T2D were more overweight or obese than those with NGT. There was a trend towards 
an ethnic difference in age such that, BAM were younger than WEM, specifically those 
with IGT (p=0.02); however, all participants were between the age of 18 and 65. In all 
glucose tolerance groups, BAM displayed significantly lower VAT than WEM (p<0.01).  
 
7.4.1 Adipose tissue lipolysis 
Adipose tissue lipolysis, measured as the rate of glycerol appearance, was 
assessed during the basal and low dose insulin steady-state period of the 
hyperinsulinaemic-euglycaemic clamp, shown in table 6. During the basal state, BAM 
exhibited significantly lower lipolysis compared to WEM in all glucose tolerance groups 
(table 7). The mean ethnic difference was most pronounced in participants with IGT. 
Similar to the basal state, BAM presented with significantly lower adipose tissue lipolysis 
during the low dose insulin steady state of the clamp, compared to WEM. This was 
apparent in all glucose tolerance groups (table 7). During both the basal and low dose 
insulin infusion steady-state, glucose tolerance status had a significant effect on adipose 
tissue lipolysis such that lipolysis was significantly greater in participants with T2D 
compared to NGT or IGT (p<0.01). However, there were no differences between 





7.4.2 Insulin sensitivity to adipose tissue lipolysis 
Adipose tissue lipolysis was adjusted for insulin using the adipose tissue insulin 
sensitivity index (ATIS); basal ATIS was higher in BAM compared to WEM (table 7, 
figure16A). During the low dose insulin infusion steady-state, BAM presented with a 
non-significant trend towards higher ATIS compared to WEM (table 6). This finding was 
based on a more stringent significance cut-off to account for the unequal variances 
between groups (see section 7.3.2).  
The percentage suppression of adipose tissue lipolysis from basal to the low dose 
insulin infusion steady state was used as the primary assessment of adipose tissue insulin 
sensitivity because it accounts for the ethnic differences in basal lipolysis activity and is 
a response to insulin (table 7, figure16B). There was no statistical difference in percentage 
lipolysis suppression between BAM and WEM in all glucose tolerance groups. The mean 
ethnic difference was -8.5 vs 0.2 vs-0.3 % in men with NGT, IGT and T2D, respectively.  
For the various measures of adipose tissue insulin sensitivity which showed a 
statistically significant effect of glucose tolerance, participants with NGT were more 
insulin sensitive compared to those with T2D (p=0.02) whereas there was no statistical 







7.4.3 Adjusting lipolysis for VAT and SAT 
The findings in chapter 3 (section 3.4.2) showed lower VAT in BAM compared to 
WEM but no ethnic difference in SAT. 
The overall unadjusted ratio of the geometric mean and 95% CI for basal ATIS was 
1.35 (1.01, 1.80), p=0.045 which reflects higher basal ATIS in BAM compared to WEM. 
After adjusting basal ATIS for VAT, the ethnic difference was lost (ratio of the geometric 
mean and 95% CI of 1.16 (0.87, 1.54) p=0.31). When adjusting basal ATIS for SAT, the 
ethnic difference in geometric mean and 95%CI remained significant at 1.36 (1.03, 1.80), 
p=0.029. Adjusting basal ATIS for VAT and SAT resulted in no ethnic difference with a 
ratio of the geometric mean and 95% CI of 1.19 (0.89, 1.61), p=0.24. 
 ATIS was also assessed during the low dose insulin infusion steady state with an 
overall unadjusted mean difference and 95% CI of 3.47 x10-5 (-1.8 x10-5, 8.8 x10-5) [(μmol 
/m2 BSA min-1)*(pmol/l)]-1, p=0.20 between BAM and WEM. Adjusting ATIS during the 
low dose insulin infusion for VAT resulted in an adjusted mean difference and 95% CI of 
1.39 x10-5 (-3.4 x10-5, 6.1 x10-5) [(μmol /m2 BSA min-1)*(pmol/l)]-1, p=0.56. Adjusting ATIS 
calculated during the low dose insulin infusion for SAT resulted in a mean difference and 
95% CI of 3.76 x10-5 (-6.0 x10-6, 8.2 x10-5) [(μmol /m2 BSA min-1)*(pmol/l)]-1, p=0.09. 
Adjusting ATIS during the low dose insulin infusion for VAT and SAT resulted in no ethnic 
difference with an adjusted mean difference and 95% CI of 2.93 x10-5 (-1.9 x10-5, 7.7 x10-5) 






The analyses in this chapter assessed the effect of ethnicity on insulin-mediated 
suppression of lipolysis (adipose tissue insulin sensitivity) in black west African and white 
European men. Adipose tissue insulin sensitivity was assessed during a hyperinsulinaemic-
euglycaemic clamp with a stable glycerol isotopic tracer. The findings suggested that there 
were no ethnic differences in the adipose tissue insulin sensitivity to lipolysis, which 
disagrees with the hypothesis of greater adipose tissue insulin sensitivity in black men. This 
finding was consistent in each glucose tolerance group. 
Populations of black ethnicity are at high risk of developing T2D and are repeatedly 
reported to be more insulin resistant as shown by multiple methods (256, 265, 282-286) (256, 
282-284). This view primarily focuses on insulin-mediated effects on glucose homeostasis. 
Insulin has also been shown to have a direct influence on lipid kinetics such that it reduces 
adipose tissue lipolysis; resistance to this action is described as an early defect in the 
progression to T2D (152-154, 384). Studies in black and white populations which assess 
changes in lipolysis or lipid kinetics in response to insulin are scarce. Prior to this analysis, 
no in vivo study had focused on insulin-mediated suppression of lipolysis in black and white 
men. Previous studies have been restricted to obese women who show either greater adipose 
tissue insulin sensitivity in black compared to white women (304) or no ethnic difference in 
adipose tissue insulin sensitivity (246). The conflicting results may reflect differences in the 
method used to assess adipose tissue insulin sensitivity in obese women. In one study, 
changes in lipolysis were assessed in response to an insulin stimulation (304), whereas the 
other study assessed basal adipose tissue insulin sensitivity (246). The different findings in 




VAT is a highly lipolytic fat store, and high VAT is an indicator of metabolic dysfunction 
(211, 324). This analysis provides evidence that the suppression of lipolysis in response to 
insulin is similar in black and white men across all glucose tolerance groups, suggesting that 
there are no ethnic differences in adipose tissue insulin sensitivity between black and white 
men. The primary assessment of the insulin-mediated effect on adipose tissue lipolysis was 
the percentage change in lipolysis from basal to the low dose insulin infusion steady-state. 
This calculation accounts for differences in basal activity, hence, reflects the change in 
lipolysis in response to the insulin infusion applied. However, the black men began with 
lower basal lipolysis and continued to have lower lipolysis during the insulin stimulation. 
The percentage decrease in lipolysis was similar in black and white men, particularly in those 
with IGT or T2D. Therefore, it can be concluded that the insulin-stimulated response was 
similar in black and white men.  
In comparison to the literature, the finding of no ethnic difference in adipose tissue 
insulin sensitivity disagrees with Albu et al., who found greater insulin-mediated suppression 
of lipolysis in black compared to white obese women with an overall average BMI of 34.9 
kg/m2 (304). The different sexs of the participants studied here and by Albu et al. may explain 
why their findings disagree with the analyses in this chapter. It has been reported that 
lipolysis is greater in women compared to men; hence the glycerol and fatty acid flux is 
higher (388-390). It could be postulated that an ethnic difference in insulin-mediated 
suppression of lipolysis may not be present in men because basal lipolysis is at a 
comparatively low rate compared to women, and to see an ethnic difference may require a 
higher baseline value. Differences in the methodology may also contribute an explanation as 




analysis utilised the hyperinsulinaemic-euglycaemic clamp (156) whereas Albu et al. utilised 
a pancreatic clamp. Whilst the hyperinsulinaemic-euglycaemic clamp has been termed the 
“gold standard” assessment of insulin sensitivity, this view focuses on insulin-mediated 
glucose uptake. There is currently no agreement for the “gold standard” procedure or 
calculation to assess the antilipolytic action of insulin (384, 385). It is accepted that isotopic 
tracers work well at tracing lipid metabolism, particularly glycerol as it is less actively re-
esterified back into triglycerides, which would lead to an underestimation of lipolysis (385). 
However, an optimal metabolic procedure in which to apply the tracers has yet to be 
concluded. A number of studies have calculated the percentage suppression of lipid 
appearance in response to insulin (162, 165, 166) however; there is no consensus on the ideal 
equations for adipose tissue insulin sensitivity assessments (151, 166, 385). Currently, a 
multistep pancreatic clamp using somatostatin and low doses of insulin has been proposed as 
the most sensitive procedure to assess insulin’s antilipolytic action in the adipose tissue (385). 
Somatostatin, used in a pancreatic clamp, suppresses endogenous insulin and allows for a 
measurement of lipolysis at an insulin concentration of zero. Insulin doses, chosen by the 
investigator, can then be applied during the multistep clamp to assess the change in lipid flux. 
From this procedure, the IC50 is calculated and defined as the insulin concentration required 
to produce half the maximal response. A comparison of the IC50 from a single step 
hyperinsulinaemic-euglycaemic clamp and multistep pancreatic clamp has shown a 
significant association (151); thus the hyperinsulinaemic-euglycaemic clamp is also a robust 
method to assess insulin’s antilipolytic activity. This may imply that although different 
methodological procedures were used by Albu et al. in comparison to this study, both 




procedure to assess adipose tissue insulin sensitivity are not likely to explain the difference 
in findings. To date, Albu et al. is the only study to utilise a pancreatic clamp to assess and 
compare the lipolysis response to insulin in black and white adults however, lipolysis at zero 
insulin was not measured and the IC50 was not interpreted. They did use lower insulin doses 
compared to this study (2 mU/m2BSA/min and 8 mU/m2BSA/min), which also form part of 
the methodological difference and could be involved in the contrasting findings. Overall, sex 
and obesity differences are likely to explain why ethnic differences were not found in men 
but were apparent in obese women. Interestingly, the sex differences explanation is not 
conclusive based on the literature. Chung et al. recently studied obese black and white 
women, similar to Albu et al., with an average BMI of 32.5kg/m2 and reported no ethnic 
difference in basal adipose tissue insulin sensitivity (246). This suggests that the result of an 
ethnic comparison between adipose tissue insulin sensitivity in women alone also depend on 
whether inulin sensitivity is assessed during the basal or insulin stimulated state. The present 
study shows no impact of ethnicity on adipose tissue insulin sensitivity when assessed during 
a clamp and contributes to the literature by showing no ethnic differences in men in any 
glucose tolerant group. The data imply the pronounced adipose tissue insulin resistance is 
not likely to contribute to the increased risk of T2D in black communities.  
The analysis in this chapter is focused on the insulin-mediated actions on lipolysis. 
The percentage suppression of lipolysis from basal to the low dose insulin infusion was the 
primary assessment of adipose tissue insulin sensitivity, and there was no evidence of an 
ethnic difference. However, the analysis did show that black men have lower absolute rates 
of lipolysis at baseline and during the clamp when assessed in isolation. When accounting 




have greater adipose tissue insulin. Lower rates of lipolysis have been reported almost 
consistently in black populations (252, 304, 325, 387) although a few groups have shown no 
difference (303, 386). This may suggest that black individuals have an intrinsic push towards 
lower circulating free fatty acids or resistance to high circulating free fatty acids. Some 
studies have attributed the lower rates of lipolysis in black individuals to lower levels and 
gene expression of hormones known to regulate adipose tissue lipolysis. Hormone-sensitive 
lipase (391) and adipose triglyceride lipase (392) have been reported to be lower in black 
compared to white women. These enzymes hydrolyse triglycerides and are therefore 
mediators of lipolysis, so lower quantities of these enzymes may explain lower rates of 
lipolysis. 
Triglycerides are hydrophobic molecules; therefore, in the aqueous plasma, the 
primary sources of triglycerides are within lipoprotein complexes, e.g. chylomicrons which 
contain dietary lipids or VLDLs which are produced by the liver (393). The latter is the 
greatest source of triglycerides during the postabsorptive state. The endogenous production 
of VLDLs by the liver involves fatty acids and triglycerides from multiple sources including 
chylomicron remnants which remain after Lipoprotein lipase hydrolysis of chylomicrons; de 
novo lipogenesis in response to hyperglycaemia and hyperinsulinaemia; triglycerides stored 
in the liver (intrahepatic lipids) and free fatty acids in the plasma pool bound to albumin 
which is predominantly from lipolysis of triglycerides in adipose tissue (394). Due to the 
latter, adipose tissue lipolysis has been shown to associate with circulating triglycerides, the 
product of lipolysis (fatty acids) are taken up by the liver as a precursor/substrate molecule 
for triglyceride-rich VLDL synthesis (142, 241, 395-397). The relatively low rate of lipolysis 




this association. The low rates of lipolysis may contribute towards the low plasma 
triglycerides in black compared to white individuals. 
Visceral adipose tissue (VAT) has been shown to be a highly lipolytic fat depot (211). 
The black men analysed in this chapter had lower VAT compared to the white men, which 
agrees with the existing literature (398, 399). Accounting for insulin did not explain the 
ethnic differences in lipolysis at baseline or during insulin stimulation which agrees with a 
study in black and white adolescents (400). However, after adjusting lipolysis for VAT, the 
ethnic differences in lipolysis were lost. This may suggest that lower VAT contributes 
towards the lower lipolysis in black men. In comparison, adjusting lipolysis for SAT, which 
was not ethnically different, did not change whether a statistical difference was observed 
between black and white men. This may suggest that the volume of SAT is not contributing 
to the lower rates of lipolysis in black men. This analysis is limited in that the contribution 
of lipolysis from visceral and subcutaneous fat stores cannot be determined, whole-body/total 
lipolysis was assessed rather than tissue-specific lipolysis. In addition, it is not clear whether 
the lower VAT is causing lower overall systemic lipolysis or if the lower rates of lipolysis 
are leading to less VAT accumulation in black communities. Studies show that visceral 
adipose tissue contributes less than 6% and 15% of whole-body venous fatty acid flux in lean 
and obese subjects, respectively (401-403). The relatively small percentage contribution to 
fatty acid flux may suggest the latter is occurring (lower rates of total lipolysis protect black 
men from high VAT accumulation). Another study has also concluded that there may be a 
resistance to storing VAT in black populations (256). It could be postulated that the lower 
lipolysis may be an intrinsic protective mechanism in black communities as it has been 




having lower rates of lipolysis reduces the circulating fatty acid pool which may prevent the 
low fatty acid oxidation rate from becoming pathogenic.  
The data from this study shows lower rates of lipolysis, plasma triglycerides and 
visceral adiposity in black men compared to white men. Adjusting for differences in visceral 
adipose tissue removed ethnic differences in lipolysis. This finding could suggest that the 
rate of lipolysis and therefore triglycerides, may be lower in black men as a result of less 
lipolytic VAT storage. 
In conclusion, the antilipolytic action of insulin appears to be equal in black and white 
men in response to a hyperinsulinaemic-euglycaemic clamp across all glucose tolerance 
groups. Resistance to insulin-mediated lipolysis is therefore not likely to explain the 
increased risk of T2D in black compared to men. Black men had lower levels of absolute 
lipolysis; however, when accounting for differences in basal activity using the percentage 
change assessment, insulin appears to suppress lipolysis at a similar rate in both ethnic 
groups. The absolute lipolysis rates, when assessed in isolation, are lower in black men and 
could partially be explained by lower visceral adipose tissue. 
 
Chapter 8: An ethnic comparison of the 
relationship between peripheral and hepatic 
insulin sensitivity with visceral fat, hepatic 
fat and adipose tissue insulin sensitivity  
Chapter highlights: 
- In both ethnic groups there is a relationship between peripheral and 
hepatic insulin sensitivity with: 
1. VAT 
2. IHL 
3. Adipose tissue insulin sensitivity 
- For point 1 and 2, the association occurs at a lower VAT and IHL 
quantity which imply that for every unit of fat, insulin sensitivity is 
lower in BAM. 
- The link between adipose tissue insulin sensitivity and 
peripheral/hepatic insulin sensitivity (point 3) may be independent of 
VAT or IHL accumulation in BAM as there was no association 
between adipose tissue insulin sensitivity with VAT or IHL. 
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Ectopic fat, defined as the storage of triglycerides in non-adipose tissue, promotes 
insulin resistance and has been implicated in the development of type 2 diabetes (T2D) (137, 
195). The liver is one of the organs prone to ectopic fat storage. Intrahepatic lipids (IHL) are 
stored exclusively within hepatocytes and have been linked to hepatic insulin resistance (137, 
215, 407). Whilst visceral adipose tissue (VAT), by definition, is not an ectopic depot, 
increased accumulation of VAT occurs alongside ectopic fat accumulation and has also been 
linked to insulin resistance and the development of T2D (203, 215, 221, 373, 408). The 
potential mechanisms which link VAT and IHL to whole-body and tissue-specific insulin 
resistance have been described in detail in chapter 1. In brief, the portal theory has been 
proposed as a mechanism which links VAT to insulin resistance. It dictates that highly 
lipolytic VAT releases fatty acids, adipokines and inflammatory cytokines into the portal 
vein, which drains into the liver, where they increase hepatic insulin resistance, worsen other 
aspects of hepatic metabolism and encourage hepatic steatosis. The cytokines and fatty acids 
may also enter the systemic circulation causing peripheral insulin resistance (182, 409). The 
portal theory has been supported by molecular (213), animal (212) and human clinical studies 
(215). 
In addition to insulin’s action on peripheral and hepatic tissues, it also acts on white 
adipose tissue to suppress lipolysis. Lipolysis is defined as the hydrolysis of triglyceride 
molecules into free fatty acids and glycerol (138). Resistance to the antilipolytic effect of 
insulin has been implicated early on in the progression towards T2D, prior to the development 
of hyperglycaemia (151-154). Adipose tissue insulin resistance increases systemic lipolysis, 




peripheral and hepatic insulin resistance (107, 153, 154). This mechanism has been supported 
by a wealth of in vivo studies using various methods which show increasing or decreasing 
fatty acids reduces and increases peripheral and hepatic insulin sensitivity, respectively (72, 
135, 152, 197, 238). Whilst this mechanism appears promising, it has been suggested that the 
link between adipose tissue insulin resistance and peripheral insulin sensitivity is not a 
response of increased fatty acids, but rather the result of all tissues becoming resistant at the 
same time (239); hence the mechanism of lipolysis related insulin resistance have yet to be 
concluded. Adipose tissue insulin resistance, along with excess caloric intake (high in fats 
and carbohydrates) and other metabolic dysfunctions, has also been suggested to contribute 
towards the deposition of ectopic fat and VAT; as described in the spillover theory discussed 
in chapter 1 (134, 135, 137, 188, 220, 240). The deposition of visceral and ectopic fat may 
also be a mechanistic link between adipose tissue insulin resistance with peripheral and 
hepatic insulin resistance. 
Black populations have consistently been reported to have less ectopic fat compared 
to white populations: however, they are thought to be more insulin resistant (324). Until now, 
in vivo studies comparing the relationship between ectopic fat and tissue-specific insulin 
resistance in black and white adults have been restricted to obese women. Peripheral insulin 
sensitivity has been shown to associate with VAT in white but not black women (323). 
Hepatic insulin sensitivity has consistently shown a relationship with VAT and IHL in black 
women (246, 323), although the relationship in white women was absent in one study (323). 
It is therefore implied that VAT may not have a role in peripheral insulin resistance in black 
women but that IHL and VAT appear to play a role in hepatic insulin resistance in black 




women can be extrapolated to men. No in vivo study, using precise assessments of substrate 
fluxes, has compared adipose tissue insulin resistance to peripheral or hepatic insulin 
sensitivity in black and white populations. Using an estimate of adipose tissue insulin 
resistance (Adipo IR, calculated as the product of basal NEFA and insulin), a significant 
positive relationship has been shown with IHL in black and white participants (326). Whether 
this finding is present when using more refined measures of adipose tissue insulin resistance 
to lipolysis has yet to be determined.  
 
8.2 Aim 
This investigation aims to assess the effect of ethnicity on the relationship between 
peripheral and hepatic insulin sensitivity with 1) ectopic/visceral fat and 2) the antilipolytic 
effect of insulin (adipose tissue insulin sensitivity). It also aims to explore the potential 
mechanisms which lead to insulin resistance by ethnicity. This investigation is to be 
conducted in black west African (BAM) and white European men (WEM) with normal 
glucose tolerance (NGT), impaired glucose tolerance (IGT) or early type 2 diabetes (T2D). 
It could be hypothesised that the association between peripheral or hepatic insulin 







A full description of the study methods is detailed in chapter 2, which includes the 
participant inclusion criteria, metabolic assessments and the calculations to derive measures 
of insulin sensitivity. To summarise, black west African (BAM) and white European men 
(WEM) were recruited and categorised as normal glucose tolerant (NGT) or impaired glucose 
tolerant (IGT) based on an oral glucose tolerance test. Participants defined as having type 2 
diabetes (T2D) had been diagnosed by their primary care practitioner within five years 
preceding the screening visit. 
Participants attended a two-step hyperinsulinaemic-euglycaemic clamp with a stable 
[6,6 2H2]-glucose and [
2H5]-glycerol isotope infusion to assess whole-body and tissue-
specific insulin sensitivity. The procedure began with a primed continuous [6,6 2H2]-glucose 
and [2H5]-glycerol isotope infusion from -120 minutes and ran until 240 and 120 minutes, 
respectively. The basal phase was defined from -30 to 0 minutes by which time the isotope 
infusion reaches an equilibrium enrichment with plasma glucose and glycerol. At time 0 
minutes, an insulin infusion was initiated at 10mU/m2BSA/min for 120 minutes, defining the 
first step (low dose insulin infusion) of the clamp. This was followed by a 40mU/m2BSA/min 
insulin infusion for 120 minutes which defined the second step (high dose insulin infusion) 
of the clamp. A variable glucose infusion was used to maintain euglycemia at 5mmol/l from 
0 to 240 minutes. The final 30 minutes of each step was defined as the steady-state whereby 
the glucose infused to maintain euglycemia (5mmol/l) equilibrates to the total glucose 
disposal from the circulation. The glycerol rate of appearance (Ra) and glucose Ra were 




insulin infusion. The glucose rate of disappearance (Rd) was assessed from samples drawn 
during the basal phase and the last 30 minutes of the high dose insulin infusion.  
Participants also attended a magnetic resonance imaging scan to quantify visceral 
adipose tissue (VAT) area from the L4/5 anatomical position. Intrahepatic lipid (IHL) 
percentage was quantified from 8 circular regions of interest covering the superior and 
inferior surface of the liver.  
 
8.3.1 Calculations 
Basal and stimulated whole-body / total lipolysis (predominantly adipose tissue 
lipolysis) was quantified using the glycerol Ra expressed per m2 of body surface area (BSA) 
during the final 30 minutes of basal and low dose insulin infusion. The percentage 
suppression of adipose tissue lipolysis from basal to the low dose insulin stimulated state was 
calculated as the primary assessment of adipose tissue insulin sensitivity to lipolysis, termed 
‘adipose tissue insulin sensitivity’ or also defined as ‘insulin’s antilipolytic action’ 
throughout this chapter (343). 
The basal and stimulated endogenous glucose production was quantified using the 
glucose Ra expressed per m2 of body surface area (BSA) during the final 30 minutes of basal 
and low dose insulin infusion. The percentage suppression of endogenous glucose production 
from basal to the low dose insulin stimulated state was calculated as the primary assessment 
of hepatic insulin sensitivity (163, 204, 344). 
Peripheral glucose disposal was assessed using the glucose Rd expressed per m2 of 
body surface area (BSA) during the basal and high dose insulin infusion. The primary 




from basal to the high dose insulin infusion (343). The peripheral insulin sensitivity index 
(PISI) was also calculated during the steady-state of the high dose insulin infusion. This was 
computed as the peripheral glucose disposal divided by the peripheral insulin concentration 
(153). 
 
8.3.2 Statistical analyses 
Each variable was assessed for normality by ethnic group using the Shapiro-Wilks 
test and histograms. Pearson’s correlations coefficients were determined between pairs of 
variables with at least one variable having a parametric distribution. In cases where both 
variables were non-parametric, correlations were assessed using a Spearman's rank 
correlation coefficient. When combining all glucose tolerance groups to give the largest 
sample size, linear multiple regression analyses were conducted to determine ethnicity 
interactions using ‘ethnicity* fat depot’ and ‘ethnicity*adipose tissue insulin sensitivity’ as 
interaction terms where appropriate. In addition to assessing the ethnicity interaction, the Y-
intercept of the associations were compared using a t-test based on the intercepts themselves 
and their standard errors (SE). The test statistic was: t= (difference in 
intercepts)/(SE(difference). Statistical significance was defined as p <0.05. Data analyses 






Clinical characteristics for the participants studied in this investigation are found in 
chapter 3. In brief, BAM and WEM were similar in BMI (p=0.93) which ranged from a 
normal to obese BMI status, body fat percentage (p=0.94) and fasting glucose (p=0.50). 
BAM and WEM with NGT and IGT showed no ethnic difference in their 2-hour oral glucose 
tolerance test plasma glucose (p=0.67), and there were no ethnic differences in the duration 
of diabetes in those who had been diagnosed with T2D (p=0.74). VAT and IHL were lower 
in BAM compared to WEM, and this was consistent in all glucose tolerance groups (p<0.01 
and p<0.01, respectively).  
 
8.4.1 Relationships between peripheral insulin sensitivity and visceral fat 
Peripheral insulin sensitivity was inversely associated with VAT in BAM and WEM 
when expressed as peripheral glucose disposal adjusted for insulin (PISI) or the percentage 
increase in peripheral glucose disposal in participants from all glucose tolerance groups 
(Figure 17). There was no significant interaction between ethnicity and VAT when modelled 
in a linear regression with PISI (p=0.22, figure 17A) or peripheral insulin sensitivity assessed 
as the percentage increase in glucose disposal (p=0.21, figure 17B). An ethnic comparison 
of the y-intercept of the linear regression between VAT and PISI showed no significant 
difference with a z score and p value of 1.68 and 0.09 respectively (figure 17A). An ethnic 
comparison of the y-intercept of the linear regression between VAT and peripheral insulin 
sensitivity (percentage change in glucose disposal) showed no significant difference with a z 





8.4.2 Relationships between peripheral insulin sensitivity and hepatic fat 
Peripheral insulin sensitivity was inversely associated with IHL in BAM and WEM 
when expressed as peripheral glucose disposal adjusted for insulin (PISI) or the percentage 
increase in peripheral glucose disposal in participants from all glucose tolerance groups 
(Figure 18). However, the association between IHL and the percentage increase in glucose 
disposal showed a trend towards significance in BAM (p=0.06, figure 18B) but was 
significant in WEM (p<0.06, figure 18B). There was no significant interaction between 
ethnicity and IHL when modelled in a linear regression with PISI (p=0.11, figure 18A) or 
peripheral insulin sensitivity assessed as the percentage increase in glucose disposal (p=0.99, 
figure 18B). An ethnic comparison of the y-intercept of the linear regression between IHL 
and PISI showed a significant difference with a z score and p value of 2.09 and 0.04 
respectively (figure 18A). An ethnic comparison of the y-intercept of the linear regression 
between IHL and peripheral insulin sensitivity (percentage change in glucose disposal) 
showed no significant difference with a z score and p value of 1.29 and 0.20 respectively 







8.4.3 Relationships between hepatic insulin sensitivity and fat 
The percentage suppression of endogenous glucose production in response to the 
insulin infusion was the primary assessment of hepatic insulin sensitivity. When correlated 
with VAT and IHL, there was a significant inverse association to hepatic insulin sensitivity 
for both ethnicities in participants from all glucose tolerance groups (figure 19A&B). When 
modelled in a linear regression with hepatic insulin sensitivity, there was no significant 
interaction between ethnicity and VAT (p=0.60) or IHL (p=0.60). An ethnic comparison of 
the y-intercept of the linear regression between VAT and hepatic insulin sensitivity showed 
no significant difference with a z score and p value of 0.36 and 0.72 respectively (figure 
19A). An ethnic comparison of the y-intercept of the linear regression between IHL and 
hepatic insulin sensitivity showed no significant difference with a z score and p value of 0.09 







Figure 19: The relationship between hepatic insulin sensitivity with visceral adipose tissue (VAT) 
and intrahepatic lipids (IHL). 
Data presented as Pearson's correlation coefficients (r) and spearman’s rank coefficient (rho) with 
log-transformed VAT and IHL. Hepatic insulin sensitivity was assessed as the suppression of 





8.4.4 Relationships adipose tissue insulin sensitivity with peripheral or hepatic 
insulin sensitivity 
The percentage suppression of lipolysis was used as the primary assessment of 
adipose tissue insulin sensitivity (insulin’s antilipolytic action). This showed a significant 
positive correlation with peripheral insulin sensitivity (percentage increase in peripheral 
glucose disposal) in both ethnic groups (figure 20A). There was also a positive relationship 
between adipose tissue insulin sensitivity and hepatic insulin sensitivity (percentage 
suppression of endogenous glucose production) in BAM and WEM, although this did not 
achieve statistical significance in the BAM (figure 20B). There was a significant interaction 
between ethnicity and adipose tissue insulin sensitivity when modelled with peripheral 
insulin sensitivity (p=0.01) but no significant interaction when modelled with hepatic insulin 
sensitivity (p=0.15). An ethnic comparison of the y-intercept of the linear regression between 
adipose and peripheral insulin sensitivity showed a significant difference with a z score and 
p value of 3.03 and <0.01 respectively (figure 20A). An ethnic comparison of the y-intercept 
of the linear regression between adipose and hepatic insulin sensitivity showed no significant 







Figure 20: The relationship between adipose tissue insulin sensitivity with peripheral and hepatic 
insulin sensitivity. 
Data presented using the Pearson correlation coefficients (r). Peripheral insulin sensitivity was 
measured as the percentage increase in glucose disposal from basal to the high dose insulin 
infusion. The suppression of endogenous glucose production and lipolysis were measured from 






8.4.5 Relationships between adipose tissue insulin sensitivity and ectopic fat  
Adipose tissue insulin sensitivity (insulin’s antilipolytic action) showed a significant 
inverse relationship between VAT and IHL in WEM, but there was no significant association 
in BAM (figure 21A&B). When modelled with adipose tissue insulin sensitivity, there was 
a significant interaction between ethnicity and VAT (p=0.03); however, there was no 
significant ethnicity and IHL interaction (p=0.28). An ethnic comparison of the y-intercept 
of the linear regression between adipose insulin sensitivity and VAT showed a significant 
difference with a z score and p value of 4.61 and <0.01 respectively (figure 21A). An ethnic 
comparison of the y-intercept of the linear regression between adipose insulin sensitivity and 
IHL showed a significant difference with a z score and p value of 3.65 and <0.01 respectively 








Figure 21: The relationship between adipose tissue insulin sensitivity with visceral adipose tissue 
(VAT) and intrahepatic lipid (IHL). 
Data presented as Pearson’s correlation coefficients assessed with log-transformed intrahepatic 





The analyses in this chapter explore some of the potential mechanisms behind 
peripheral and hepatic insulin resistance observed in the progression to type 2 diabetes (T2D). 
Visceral adipose tissue (VAT), hepatic fat (IHL) and adipose tissue insulin resistance have 
been identified as factors which affect peripheral and hepatic insulin sensitivity and 
contribute to the development of T2D. Whether these have a causal effect on peripheral and 
hepatic insulin resistance and evidence for the mechanisms by which this may occur are not 
conclusive. The present analysis compared the effect of ethnicity on the associations between 
these variables in black west African and white European men. Prior to this analysis, no such 
assessment had been conducted in men of black ethnicity using rigorous assessments of 
insulin sensitivity and fat deposition. 
Central adiposity has been linked with insulin resistance and the development of T2D 
for many years. The accumulation of visceral adiposity has been marked as a key perpetrator 
in this association (200). Whilst black populations have a higher risk of T2D; they are 
consistently reported to present with lower VAT (256), as was found in this cohort of 
participants. The analysis in this chapter showed a significant relationship between peripheral 
insulin sensitivity and VAT in both ethnic groups. Participants with high VAT had lower 
peripheral insulin sensitivity, and those with low VAT had higher peripheral insulin 
sensitivity. This association supports the current thought which implicates high VAT to play 
a role in the pathophysiology of T2D (203). The lack of an interaction effect suggested that 
the significant relationship was not ethnically distinct. Therefore, the association between 
peripheral insulin sensitivity and VAT in black and white men were similar. In contrast, 




women (323). The difference in findings for black women compared to men may reflect sex 
differences. In support of sex affecting the associations, a study assessing participants from 
multiple ethnic groups has shown significant associations between insulin sensitivity and 
multiple measures of total and regional adiposity in men which are absent in women (410). 
Another larger study in white adults found that for each incremental increase in a body fat 
measure, the decline in insulin sensitivity was less in women compared to men (411) which 
may also imply weaker associations in women. No study has assessed regional adiposity and 
peripheral insulin sensitivity in black men and women; however, the findings from the 
reported studies and this analysis imply that sex differences are present in the relationship 
between regional body fat and insulin sensitivity. This could explain why a significant 
relationship was found in this analysis but not in the obese black women studied by Goedecke 
et al. (323). The different findings may also be explained by the degree of obesity of the 
participants. This analysis studied men across a range of BMIs whereas Goedecke et al. 
studied obese women. It could be interpreted that in black women, the association between 
peripheral insulin sensitivity and VAT is lost in severe obesity. In comparison, when 
assessing a range of BMIs, a relationship is present. Finally, the inclusion of participants with 
T2D in these analyses may also explain the difference in findings between this study and 
Goedecke et al (323). Participants with T2D had greater quantities of VAT which may have 
increased the spread of the VAT data in comparison to Goedecke et al (323). Overall, the 
association and interaction findings from this analysis indicate that there is no ethnic 
difference in the negative association between VAT and peripheral insulin sensitivity in black 
and white men. This therefore suggests that the potential detrimental impact of VAT on 




other study has compared the relationship between VAT and peripheral insulin sensitivity in 
black and white men.  
In addition to VAT, it has been shown that higher levels of hepatic fat are associated 
with lower peripheral insulin sensitivity in a small group of normal glucose tolerant 
participants (412) and a study of over 1400 European participants assessed using 
hyperinsulinaemic-euglycaemic clamps and a fatty liver index (223). In the present study, 
peripheral insulin sensitivity showed a significant relationship and a trend towards 
significance; depending on the measure of peripheral insulin sensitivity; with intrahepatic 
lipids (IHL) which was not ethnically distinct as evidenced by the interaction analysis. The 
finding of a significant relationship in this study does not agree with Goedecke et al. who 
reported no relationship between liver fat and peripheral insulin sensitivity in obese black 
and white women (323). The difference in findings may reflect and effect of sex and obesity. 
Sex and obesity may determine whether an association is present thus the data here contribute 
to the literature by suggesting a relationship is present in men. 
Similar to peripheral insulin sensitivity, hepatic insulin sensitivity has also been 
reported to associate with VAT, such that individuals with high VAT have lower hepatic 
insulin sensitivity or individuals with low VAT have higher hepatic insulin sensitivity (203, 
215). In the present analysis, the relationship between hepatic insulin sensitivity and VAT 
was significant in both ethnic groups. Therefore, both ethnic groups showed an association 
between hepatic insulin sensitivity and VAT with no ethnic difference in this relationship. 
Black women are consistently reported to display a significant inverse association between 
hepatic insulin sensitivity and VAT (246, 323). The analyses in this chapter agree with and 




association with VAT, hepatic insulin sensitivity has also been associated with the storage of 
triglycerides in the liver, termed intrahepatic lipids (IHL) (128). Whilst populations of black 
ethnicity are at high risk of developing T2D; they are almost consistently shown to present 
with lower hepatic fat which is a paradox due to the link between hepatic fat and insulin 
resistance (256). The analysis in this chapter shows a significant inverse relationship between 
hepatic insulin sensitivity and IHL in black and white men. The relationship between IHL 
and hepatic insulin sensitivity was not ethnically distinct, as shown by the interaction 
analysis. The significant relationship agrees with studies in obese black women which also 
show a relationship between hepatic insulin sensitivity and hepatic fat (246, 323) therefore, 
this study extends the conclusion to black men in various glucose tolerance groups and 
suggest it is not ethnically different. Overall the significant association between hepatic 
insulin sensitivity with VAT and IHL in both ethnic groups could suggest that high VAT and 
IHL are equally determinantal to hepatic insulin sensitivity in white and black men. It could 
be interpreted that the pathophysiology of hepatic insulin resistance via VAT or IHL is 
similar in black and white men. 
In line with the literature, the black men assessed in this study were found to have 
lower VAT and IHL compared to white men. The significant associations with peripheral 
and hepatic insulin sensitivity occurred within a lower and smaller range of VAT and IHL 
content in black men. To reflect this, the intercept of the regression slope appeared to be 
slightly different by ethnicity. A formal analysis comparing the intercepts by ethnicity 
showed some evidence for a trend towards significance and a significant ethnic difference 
between VAT and IHL when modelled with peripheral insulin sensitivity. However, there 




with hepatic insulin sensitivity. Although the statistical tests were not consistently 
significant, the graphs provide some suggestion that for a given value of VAT or IHL, hepatic 
insulin sensitivity; and to some extent peripheral insulin sensitivity, was lower in black 
compared to white men. It could be interpreted that while there were no ethnic differences in 
the relationship between VAT or IHL with peripheral and hepatic insulin sensitivity, the 
relationships occur at lower VAT and IHL level in black compared to white men. This may 
imply that even though VAT and IHL are lower in black men, increasing fat deposition 
remains detrimental to peripheral and hepatic insulin resistance as higher levels of fat are 
associated with greater insulin resistance. 
In this chapter, the association analysis was limited in that it was not able to assess 
the direction of the association between VAT or IHL with peripheral or hepatic insulin 
sensitivity. The ‘portal theory’ has been proposed to explain the association between VAT 
and peripheral or hepatic insulin resistance. It postulates that fatty acids, adipokines and 
cytokines released from VAT drain into the portal vein and cause hepatic and peripheral 
insulin resistance (182, 199, 212-214). This implies a causal relationship between VAT 
accumulation and insulin resistance. However, not all data support a causal effect of VAT on 
insulin resistance. The association may be a result of decreasing insulin sensitivity causing 
an increase in visceral fat. The ‘portal theory’ combined with the ‘twin cycle hypothesis’ 
both postulate a causal role of IHL accumulation on hepatic insulin resistance (222, 409). 
Alternatively, the relationship between IHL and hepatic insulin resistance could be due to 
hepatic insulin resistance increasing IHL accumulation. Regardless of the interpretation of 
the association direction, the analyses in this chapter show no evidence for ethnic differences 




In addition to liver and visceral fat, a resistance to insulin’s antilipolytic action 
(adipose tissue insulin resistance) has also been associated with peripheral and hepatic insulin 
resistance to glucose homeostasis with a causal role implied (107, 135, 152-154, 197, 238). 
Data in this chapter contribute to the literature by confirming that this relationship is also 
present in black men. The interaction analysis suggested that the relationship was 
significantly weaker in black compared to white men; the ethnic comparison of the y-
intercepts also shows evidence for an ethnic difference. The finding of a significant 
association in black and white men is in keeping with Bril et al., who used less sensitive in 
vivo methods to estimate adipose tissue insulin resistance (326). Whether the antilipolytic 
action of insulin plays a causal role in insulin resistance to glucose homeostasis in black and 
white men cannot be assessed here because associations do not assess the direction of 
relationships. However, the idea that peripheral or hepatic insulin sensitivity cause adipose 
tissue insulin resistance is not supported by any existing reports. In addition, resistance to the 
antilipolytic effect of insulin has been shown to occur prior to hyperglycaemia and insulin 
resistance to glucose metabolism (154). As a result, a resistance to the antilipolytic action of 
insulin is more likely to drive peripheral and hepatic insulin resistance than the reverse. The 
association analysis in this thesis suggests that this drive is significantly weaker in black 
compared to white men. Therefore, the potential effect of increased adipose tissue resistance 
affecting skeletal muscle glucose uptake and hepatic glucose suppression is less in black 
compared to white men. This may suggest that adipose tissue insulin resistance plays less of 





Adipose tissue insulin resistance has been described to encourage insulin resistance 
to glucose homeostasis by increasing FFA availability (220, 237) and increasing ectopic fat 
accumulation (135, 137, 240). To assess whether the associations between adipose tissue 
insulin sensitivity with peripheral or hepatic insulin sensitivity are dependent on fat 
accumulation, the associations between adipose tissue insulin sensitivity and fat were 
investigated. In this study, the white men showed a significant association between adipose 
tissue insulin sensitivity with VAT and IHL, in agreement with the literature (153). 
Therefore, the association between adipose tissue insulin sensitivity with peripheral or 
hepatic insulin sensitivity may, in part, depend on the accumulation of VAT or IHL. In 
comparison, the black men showed no significant association between adipose tissue insulin 
sensitivity and VAT or IHL; even though adipose tissue insulin sensitivity was associated 
with peripheral and hepatic insulin sensitivity. In black men, this lack of an association 
between insulin’s antilipolytic action and fat, particularly VAT, was statistically different 
from white men and is in keeping with data in obese women by Albu et al. (304). In addition, 
the ethnic comparison of the y-intercept between adipose tissue insulin sensitivity, VAT and 
IHL also shows an ethnic difference. The analyses from this study, therefore, suggest that the 
relationship between insulin’s antilipolytic action and peripheral or hepatic insulin sensitivity 
occurs independent of VAT and IHL in black men. If adipose tissue insulin resistance is a 
causal mechanism promoting peripheral and hepatic insulin resistance, this may not occur 
through VAT or IHL accumulation in black men. Other mechanisms may link insulin’s 
antilipolytic action to peripheral or hepatic insulin resistance in black populations which have 




The disassociation between adipose tissue insulin sensitivity and IHL or VAT in 
black men may also suggest that the “spillover” theory may not play a role in the 
accumulation of VAT or IHL. The “spillover” theory has been used to describe the 
accumulation of VAT and ectopic fat (including IHL). The theory postulates that 
dysfunctions in the subcutaneous adipose tissue, which include but are not limited to insulin 
resistance, prevent fatty acids from being stored safely. The inability to store fatty acids and 
the increased lipolysis in response to insulin resistance, increase the release of fatty acids into 
the circulation. The spill over of fatty acids into the circulation increases the deposition of 
VAT and IHL (137, 189, 192, 195). In black men, the lack of association between adipose 
tissue insulin sensitivity and VAT or IHL suggests that excessive lipolysis in the presence of 
insulin may not increase fat deposition. Black men appear to have protection or resistance to 
storing VAT or IHL available from excess lipolysis. Whilst data in this chapter support this 
concept, the presence of VAT and IHL, albeit at a lower level, still showed an association 
with peripheral and hepatic insulin sensitivity which was not ethnically different. The 
conclusions drawn from the lipolysis data are limited in that it was not localised visceral or 
subcutaneous fat depot lipolysis. Tracer studies reveal that between 86 to 94% of newly 
hydrolysed fatty acids into the venous circulation are primarily derived from subcutaneous 
adipose tissue (401, 403, 413). The high percentage contribution from subcutaneous adipose 
tissue increases the likelihood that dysfunctional subcutaneous fat was being measured and 
the potential ethnic difference in the accumulation of visceral and hepatic fat is present. 
In conclusion, black men may be protected from accumulating visceral or hepatic fat 
in response to adipose tissue insulin resistance, as described in the “spillover” theory. Despite 




with peripheral and hepatic insulin sensitivity are similar in black and white men. This 
disagrees with the hypothesis of ethnic differences in the associations and suggests that if 
visceral and hepatic fat have a causal role in insulin resistance, both ethnic groups are equally 
susceptible to greater fat deposition causing insulin resistance to glucose homeostasis. In both 
ethnic groups, adipose tissue insulin sensitivity is also associated with peripheral and hepatic 
sensitivity; however, in black men, this relationship is weaker and appears to be independent 
of visceral or hepatic fat. Thus, the potential influence of excessive lipolysis on peripheral or 
hepatic insulin sensitivity may not be dependent on visceral or hepatic fat accumulation in 
black men. Diabetes prevention and remission strategies to reduce visceral or hepatic fat may 
produce ethnically distinct findings in terms of insulin sensitivity to glucose homeostasis.  
 





In countries across the globe, black communities are consistently reported to have an 
increased risk of developing type 2 diabetes (T2D) in comparison to their white counterparts 
(29, 30, 40, 61, 66). The pathological changes which lead to the development of T2D are 
complex and have been summarised as the ‘ominous octet’ (71). An increase in insulin 
resistance has been shown to occur as part of this process, and this develops at multiple sites. 
The sites include the peripheral tissues (skeletal muscle and adipose tissue) and the liver, all 
of which have been the focus of this thesis (71, 76). Populations of black ethnicity have been 
widely described to display pronounced insulin resistance in comparison to white populations 
(265), and this is thought to partially explain the increased prevalence of T2D. Studies 
reporting pronounced insulin resistance in black compared to white participants have been 
discussed in chapter 1 (section 1.8). The narrative of black communities being more insulin 
resistant is driven from large studies which assessed insulin sensitivity using surrogate 
indices such as the homeostatic model assessment (HOMA) which assess insulin sensitivity 
at the basal state (256, 282-284). It is also based on findings from large studies which have 
utilised the intravenous glucose tolerance test (IVGTT) with minimal modelling (248, 255, 
265, 285, 286, 289, 291-298). These studies include men, women and children as well as 
individuals across the spectrum of glucose tolerance, a range of BMIs, with a focus on insulin 
sensitivity of glucose homeostasis. These studies almost consistently report greater insulin 
resistance to glucose homeostasis in black populations, particularly those which assess 
healthy participants without T2D. This data has suggested that insulin resistance is an early 
defect in the progression to T2D, which explain the greater T2D risk (265). The volume of 




narrative of pronounced insulin resistance in black populations. These data are a key indicator 
for an ethnic difference in the physiology of T2D. 
In contrast to the narrative of the literature, the findings from this study showed no 
evidence for an ethnic difference in whole-body or tissue-specific insulin resistance. This 
data disputes the hypotheses that ethnic differences in insulin resistance are present and may 
underlie the increased risk of T2D in black communities. Insulin-mediated effects on glucose 
homeostasis were similar between black and white men in this study. The similar insulin 
sensitivity was found in each glucose tolerance group, including those without T2D, 
suggesting that early pronounced insulin resistance is not present in black compared to white 
men. Therefore, this study does not support the suggestion that early impairments of insulin 
sensitivity alone explain the greater prevalence of T2D in black compared to white men. The 
findings from this study are derived from a hyperinsulinaemic-euglycaemic clamp with 
stable isotopic tracers, described as the optimal procedure for assessing whole-body and 
tissue-specific insulin sensitivity to glucose homeostasis (87, 172). There are multiple 
expressions of insulin sensitivity which can be calculated based on metabolic size (84, 104, 
339) and insulin concentration adjustments (89, 362) and making these adjustments did not 
alter the findings for no ethnic difference. 
The contrast in findings between this study and the literature may reflect the 
characteristics of the participants studied. One particular observation, also discussed in 
chapter 4 (section 4.5), is the inconsistency of BMI matching between black and white 
participants, particularly in the larger studies (256, 282, 284). The average BMI of 
participants assessed is frequently higher in black compared to white participants. Higher 




adiposity and insulin resistance (26, 182), the BMI difference may confound insulin 
sensitivity findings. The participants assessed in this study were recruited to be similar in 
BMI by ethnicity, to remove the potential confounding effect. Therefore, these data show 
that in a BMI matched population, black and white men present with similar insulin 
sensitivity.  
Whilst a lack of BMI matching may partially explain the contrast in findings between 
the narrative of the literature with this study; there have been several studies which have 
successfully matched for BMI and still reported greater insulin resistance in their black 
populations (248, 255, 265, 285, 286, 289, 291-298). The contrast in findings between this 
study and those who report greater insulin resistance in BMI matched black populations may 
reflect differences in the methodology used to assess insulin sensitivity. Most of the studies 
which report greater insulin resistance in black compared to white groups have used indirect 
methods to assess insulin sensitivity. The indirect methods consist of the surrogate indices 
and the intravenous glucose tolerance test with minimal model analysis, both of which are 
based on mathematical modelling of glucose metabolism (87, 168, 172, 173, 414). Pisprasert 
and colleagues (307) provide comprehensive and convincing evidence which concludes that 
caution should be taken when using surrogate estimates to assess insulin sensitivity in black 
populations. In a large cohort of African American and European American participants, they 
show no ethnic differences in total glucose disposal (whole-body insulin sensitivity) from the 
hyperinsulinaemic-euglycaemic clamp. However, when assessing insulin sensitivity in the 
same participants using surrogate indices of insulin sensitivity, the black participants were 
significantly more insulin resistant. This suggests that surrogate methods overestimate 




commonly reported in black populations in response to reduced insulin clearance (266, 366), 
may alter the mathematical models by which the minimal model and surrogate indices are 
based on. The pronounced hyperinsulinaemia is observed in the presence of similar glucose 
in black men which may indicate more insulin is required to produce the same glucose result. 
It may also indicate a more exponential curve linear relationship between glucose and insulin 
in comparison to white populations. This suggestion has yet to be assessed in black compared 
to white communities and is not incorporated into the basis of the minimal model or the 
surrogate indices. Overall, these data suggest that being of black ethnicity may alter the 
assumptions used to model insulin sensitivity in indirect assessments. In comparison, the use 
of the hyperinsulinaemic-euglycaemic clamp in this study and others involves fewer 
assumptions. 
In addition to these ethnic-specific findings which question the use of indirect 
assessments of insulin sensitivity, the minimal model analysis has been suggested to 
oversimplify glucose metabolism (172). It assumes a single compartment model for glucose 
metabolism and is also unable to differentiate between peripheral and hepatic insulin 
sensitivity (172). Using isotopic tracers with the intravenous tolerance test can create a two-
compartment model, and has been suggested to assess peripheral and hepatic insulin 
sensitivity (172, 415). However, this has been shown to yield unreliable results, potentially 
due to inadequate suppression of hepatic glucose production and is yet to be validated against 
the clamp (416, 417). The minimal model outcome from an intravenous glucose tolerance 
test without isotopic tracers has been validated against the “gold standard” clamp (418); 
however, the association is significantly weaker in participants with T2D (418) which may 




this minimal model has also been shown to underestimate insulin sensitivity when compared 
to the clamp. As a result, it is described as an index or an estimate rather than a direct 
measurement of insulin sensitivity (87, 172, 418, 419). In conclusion, the impact of black 
ethnicity on the intravenous glucose tolerance test with minimal model analysis and the 
limitations of the intravenous glucose tolerance test compared to the clamp, imply that 
caution should be taken when interpreting findings from an intravenous glucose tolerance 
test in black participants. 
Whilst differences in methodology has been discussed to be a contributing factor to 
the disagreement between findings from this study and the narrative of the literature, other 
clamp studies have shown lower whole-body, peripheral and hepatic insulin sensitivity in 
black compared to white populations (245, 251, 296, 311, 319-322). Therefore, methods 
alone are not the only reason for the contrasting finings. When comparing the ethnic 
comparison of insulin sensitivity to the clamp evidence base, there are numerous recurring 
themes across the results chapters, which appear to affect whether an ethnic difference is 
present. Sex, BMI status, basal vs stimulated assessments of insulin sensitivity, the different 
procedures to assess insulin sensitivity and geographical differences, have all been discussed 
in previous chapters. Whilst the message is not consistent, these factors all appear to play a 
role in whether ethnic differences in insulin sensitivity and its associations are present. The 
most consistent recurring theme when comparing the analyses in this thesis to the literature 
is a potential sex effect. Most of the evidence comparing site-specific insulin sensitivity in 
black and white populations have been from women. It has almost consistently been reported 
that ethnic differences in insulin sensitivity are present in women, particularly those who are 




sensitivity (246, 307, 312, 313, 322, 323), lower whole-body, peripheral and hepatic insulin 
sensitivity (245, 251, 296, 311, 322) or higher hepatic insulin sensitivity (323) in black 
compared to white women. In comparison, this study consistently shows no ethnic difference 
in whole-body or tissue-specific insulin sensitivity in black and white men. This implies that 
there may be a potential sex and ethnicity interaction affecting whether ethnic differences are 
present. Ethnic differences in insulin sensitivity, when compared to white participants, may 
only be present in women. This concept has yet to be captured in a single study comparing 
tissue-specific insulin sensitivity in individuals of black and white ethnicity; this study is 
limited to men only, thus the sex ethnicity interaction hypothesis is not conclusive. 
In further support of a potential sex ethnicity interaction which determines whether 
ethnic differences are present; total body adiposity is consistently reported to be higher in 
women than men (66, 134, 420). However, women are reported to be more insulin sensitive 
than men. To explain this, detailed studies on body composition show reduced visceral fat 
and hepatic fat but higher subcutaneous and peripheral adipose tissue in women (195, 420). 
This is generally regarded as a protective body fat distribution associated with greater insulin 
sensitivity. Although higher insulin sensitivity is thought to be present in women compared 
to men; this is not consistent in studies comparing black men and women. A few studies 
provide data for a tendency towards higher sensitivity in black women compared to men 
(307, 312, 313) however, studies which directly compare black men and women and found 
lower insulin sensitivity in women compared to men (353, 421). Overall the sex differences 
in insulin sensitivity and the contrasting evidence by sex in black communities may imply 
that participant sex may determine whether ethnic differences are present in black and white 




may be confounded by the other recurring themes listed earlier, such as obesity status and 
geographical differences. Evidence against a sex*ethnicity interaction is shown in studies 
which have recruited and analysed whole-body insulin sensitivity in black men and women, 
of which no ethnic difference in women or men were found (307, 313).  
Nevertheless, sex differences may explain differences in the findings between the 
men in this study and the clamp based literature. Whilst the sex difference is not consistent 
for each insulin action site, these analyses are the first to produce a consistent message in 
men such that ethnic differences in whole-body and tissue-specific insulin sensitivity are 
absent across a range of BMI statuses and glucose tolerances. This is corroborated by 
numerous studies which show no ethnic difference in whole-body or tissue-specific insulin 
using clamp methods as discussed in the results chapters. It could, therefore, be concluded 
that pronounced whole-body or tissue-specific insulin resistance is not likely to contribute 
towards the greater prevalence of T2D in black men. 
 
Efforts to understand what drives insulin sensitivity to fall as part of the progression 
to T2D, have implicated visceral fat (VAT) and ectopic fat (particularly hepatic fat (IHL)) 
(182). Both of these potentially impact on insulin-mediated peripheral glucose disposal and 
the suppression of endogenous (hepatic) glucose production (186, 197, 203-205). The 
accumulation of these fat depots has been described to trigger and exacerbate tissue-specific 
insulin resistance through lipotoxicity and has, therefore, been implicated in T2D 
pathophysiology and progression (195). Black communities are at high risk of developing 
T2D; however, they have consistently shown lower VAT and IHL (245-254, 256-258). 




communities is, therefore, a paradox. This may imply that the relationship with insulin 
sensitivity and VAT or IHL, and potentially the mechanisms which lead to insulin resistance 
are ethnically distinct. In support of an ethnic distinction relating to adiposity, clinical data 
show a higher prevalence of T2D in lean black populations and black communities diagnosed 
as a lower BMI. These data also conflict with views on the development of T2D by 
suggesting that the quantity of adiposity may not be the sole contributor to T2D development 
in black communities. Based on mechanistic and clinical findings, it could be hypothesised 
that the pathophysiology of T2D is less associated with adiposity in black populations and 
therefore the association between insulin sensitivity and fat deposits would be ethnically 
distinct (422). To explore this hypothesis, the relationship between insulin sensitivity with 
VAT and IHL were assessed in black and white men. Despite presenting with lower VAT 
and IHL in the presence of similar insulin sensitivity, these data showed no ethnic differences 
in the relationship between peripheral and hepatic insulin sensitivity to glucose homeostasis 
with VAT and IHL. The potential effect of greater VAT and IHL accumulation on reducing 
insulin sensitivity did not appear to be ethnically distinct. This may imply that black men 
may be equally susceptible to insulin resistance and T2D associated with increasing VAT 
and IHL. This susceptibility may occur at lower levels of VAT and IHL in black men 
however; greater fat deposition remains associated with lower insulin sensitivity. With an 
increasing emphasis on treating, and even reversing T2D, by reducing visceral and intra-
organ fat (423), the potential for there to be ethnic-specific differences in the magnitude of 
the response to such interventions needs urgent attention. Although this analysis did not 
assess the direction of the association between insulin sensitivity and VAT or IHL, the 




These analyses were also unable to assess the potential mechanisms which may link 
VAT and IHL to peripheral and hepatic insulin sensitivity. Adipokines and inflammatory 
markers have been found to be released from VAT (194, 211). Studies comparing black and 
white participants have shown either no difference or lower adipokines (insulin sensitisers) 
in black compared to white participants (392, 424-426). Therefore, although the associations 
with VAT and IHL to insulin sensitivity are similar by ethnicity, the mechanisms may be 
ethnically distinct.  
In this cohort of men, similar whole-body, peripheral and hepatic insulin sensitivity 
occurred in the presence of lower VAT and IHL in black men. Adjusting for ethnic 
differences in VAT and IHL resulted in lower insulin sensitivity in black men. This finding 
was also supported by the association analysis which showed that at any given level of VAT 
or IHL, insulin sensitivity was lower in black men. These findings and analyses suggest that 
depositing less VAT and IHL may protect black men from presenting with pronounced 
whole-body and tissue-specific insulin resistance to glucose homeostasis compared to white 
men. Further analysis of this potential protective mechanism warrants further investigation 
and could be used as a target in other high-risk populations. 
This is the first report to assess adipose tissue insulin sensitivity to lipolysis in the 
same cohort of black and white participants in which peripheral and hepatic insulin sensitivity 
were also assessed. This study, therefore, acknowledges insulin’s other, non-glycaemic, 
metabolic actions which may contribute to T2D development (154). The analysis shows no 
ethnic difference in adipose tissue insulin sensitivity in any glucose tolerance group between 
black and white men. Similar to peripheral and hepatic insulin sensitivity, when compared to 




assessments are made during the basal or insulin stimulated state seemed to determine 
whether an ethnic difference was present. 
In addition to peripheral and hepatic insulin resistance, a resistance to the antilipolytic 
effect of insulin has been implicated in the development of T2D, shown to occur before 
hyperglycaemia (154). This adipose tissue insulin resistance is thought to reduce peripheral 
glucose uptake and the suppression of endogenous glucose production, therefore, peripheral 
and hepatic insulin resistance, respectively (107, 141, 142, 153, 154, 233). This analysis 
showed associations between insulin’s antilipolytic action and peripheral and hepatic insulin 
sensitivity in both ethnic groups; however, the association was weaker in black men. This 
analysis does not assess the direction of the relationship; however, if resistance to insulin’s 
antilipolytic action does promote insulin resistance to glucose homeostasis, then this 
mechanism may occur to a lesser degree in black men. Resistance to insulin’s antilipolytic 
action may be less involved in the pathogenesis of insulin resistance and therefore, T2D in 
black men. No study or data suggest that insulin resistance to glucose metabolism causes 
adipose tissue insulin resistance and adipose tissue insulin resistance has been shown to occur 
before hyperglycaemia (154). Therefore, it is more likely that excess lipolysis contributes to 
insulin resistance to glucose metabolism than the reverse. Mechanistic studies suggest 
adipose tissue insulin resistance is thought to promote peripheral and hepatic insulin 
resistance by either increasing fatty acid supply or by increasing ectopic fat deposition (135, 
137, 240). To assess whether resistance to insulin’s antilipolytic action may influence 
peripheral and hepatic insulin sensitivity through ectopic fat accumulation, an association 
between adipose tissue insulin sensitivity and fat depots was explored. Significant 




potential peripheral and hepatic insulin resistance mediated by excess adipose tissue lipolysis 
occurs independently of VAT or IHL accumulation in black men. Further studies are required 
to understand the mechanisms which may link adipose tissue insulin resistance to peripheral 
and hepatic insulin resistance in black men.  
A resistance to insulin’s antilipolytic effect in the adipose tissue has been described 
as part of the dysfunctions in the spillover theory (192). This theory describes the formation 
of ectopic fat through dysfunctional subcutaneous adipose tissue and highly lipolytic VAT 
(194, 211). In line with this theory, data from white men showed a significant association 
between adipose tissue insulin sensitivity with VAT and IHL. In comparison, no association 
was observed in black men suggesting that the deposition of VAT and IHL may be 
independent of insulin’s antilipolytic action; therefore, the spillover theory may not hold for 
black men. This analysis also suggests that excess lipolysis in the presence of insulin is not 
likely to lead to VAT and IHL deposition in black men. Black men may accumulate fat 
through other mechanisms which require further study. The lack of association combined 
with the finding of black men having lower VAT and IHL (245-252, 256-258) may suggest 
that black men have protection from storing fat. And, as discussed earlier, this may further 
protect black men from having greater insulin resistance to glucose homeostasis. It should be 
noted that the association analysis could also be interpreted in such a way that high VAT or 
IHL has a causal effect on adipose tissue insulin resistance in white men. Whilst data on a 
causal role of IHL is absent; VAT has been described as a highly lipolytic fat depot, thus it 
could contribute to excess lipolysis in the presence of insulin. However, per unit of mass, 
VAT contributes a small portion to overall lipolysis; therefore, the direction of the association 




opposite. Overall regardless of the direction, the relationship is absent in black men and 
further assessment into the mechanisms for visceral and intra-organ fat deposition are 
warranted. 
Whilst this study showed no ethnic difference in adipose tissue lipolysis response to 
insulin from the clamp, absolute rates of lipolysis were lower in black men across all glucose 
tolerance groups. The lower lipolysis rate could not be explained by insulin; correction for 
insulin maintained an ethnic difference. VAT has been shown to be more lipolytic than 
subcutaneous fat; therefore, releasing more fatty acids per unit of mass (211). In line with the 
literature (245-252, 256-258), the black men assessed in this analysis presented with less 
VAT. The statistical adjustment of this data for visceral fat removed the ethnic difference, 
suggesting that the lower absolute rates of lipolysis in black men may be the result of lower 
VAT. However, as discussed earlier, VATs contribution to total lipolysis is low; thus other 
mediators of lipolysis such as catecholamines (142) may explain the lower lipolysis in black 
men.  
 
9.1.1 Strengths and limitations  
The finding of no ethnic difference in insulin sensitivity in any glucose tolerance 
group suggests there are no ethnic differences in the fall of insulin sensitivity during the 
progression to T2D. However, this study was cross-sectional which limits the interpretation 
of disease progression that longitudinal data would provide. Even though early insulin 
resistance in black compared to white men is not supported by the findings in this study due 
to the similar insulin sensitivity in participants without T2D, the cross-sectional nature of this 




T2D and were therefore in the ‘early’ stages of T2D development. The participants with NGT 
were not all obese; assessing obese participants could have been used as a marker to suggest 
that the participants were in the ‘early’ stages of T2D development. Although participants 
were allocated as normal glucose tolerant or impaired glucose tolerant, fasting glucose was 
not accounted for. Therefore, some of the participants with normal glucose tolerance may 
have also had impaired fasting glucose which is a form of impaired glucose regulation. This 
may not have been equal across both ethnic groups and constitutes a study limitation. 
Another potential limitation of this study could be the lower age in black compared 
to white men. The contribution of differences in age to the comparison of insulin sensitivity 
cannot be ruled out completely. As discussed in chapter 3, the trend towards a lower age in 
black men may be an unavoidable reflection of the epidemiological fact that black 
populations develop dysglycaemia at a younger age. The ethnic difference in age was found 
in participants with IGT; however, it is unlikely that age alone removed or created differences 
between black and white men. Indeed studies have shown that age does not associate with 
estimates of insulin sensitivity in black or white populations (353). Rather, age-related 
changes in adiposity are associated with insulin sensitivity (259, 260) which is why 
participants were recruited to be similar in BMI, and detailed fat depot analyses were 
conducted.  
Outside of VAT and IHL, there are other ectopic fat stores which are associated with 
insulin resistance and increase as dysfunctional SAT increases, namely intramyocellular lipid 
(IMCL) (134, 137). This has not been assessed in this thesis and is, therefore, a potential 
limitation. IMCL was initially thought to increase peripheral insulin resistance (427). Black 




does not associate with insulin sensitivity in black cohorts but does in white (317, 428). The 
role of IMCL in insulin resistance has been questioned due to the finding that the skeletal 
muscle of athletes, who are insulin sensitive, have high levels of IMCL. Understanding the 
role, and potentially intracellular mechanisms through biopsy of IMCL may help to 
understand the associations in black and white ethnicity.  
Despite the detailed analysis of region-specific (visceral and hepatic) fat that was 
assessed in this study and matching participants for BMI, this study lacked a quantification 
of total lean or fat mass in each participant; matching for BMI does not account for lean mass. 
As mentioned in chapter 2 and 4, insulin sensitivity is expressed per unit of metabolic mass 
with a preference towards fat-free mass (FFM). This is because lean mass is a highly sensitive 
depot in terms of glucose uptake. FFM was not available for all participants and may have 
limited the interpretations because the insulin sensitivity data could not be adjusted for the 
insulin sensitive tissues. FFM data was available for participants with NGT and IGT however 
adjusting for this was not shown to influence ethnic differences in whole-body insulin 
sensitivity.  
The ideal in vivo assessment of different adipose tissue depots requires whole body 
magnetic resonance imaging scanning (429-431). In this study both VAT and SAT were 
assessed using a single abdominal slice. Although single slice assessments have been 
validated against whole body measures of regional fat, single slice assessments do increase 
measurement uncertainty and introduce inaccuracies (430). This is more so apparent for SAT, 
which unlike VAT, is located in the legs and arms as well as the trunk and constitutes the 
majority of total fat mass thus, a single slice assessment compromises the ability to detect 




important with regards to ethnic comparisons. There is evidence to suggest that black 
adolescents groups present with greater lower-body SAT in comparison to white counterparts 
(432) which has also been shown in older adults (433). Therefore, the single slice assessment 
of SAT is a limitation of this study. 
These analyses were also limited by having no assessment for the potential ethnic 
differences in physical activity. Increasing physical activity is part of the lifestyle changes 
prescribed for impaired glucose tolerance. Physical activity has independently been shown 
to improve peripheral insulin sensitivity to glucose homeostasis (236). Whether this plays a 
role in the effect of ethnicity and insulin sensitivity cannot be assessed in this study. However, 
a single study has assessed black and white participants following a single bout of physical 
activity where it was reported that there were no ethnic differences in insulin sensitivity. This 
may imply that physical activity does not interact with ethnicity to determine insulin 
sensitivity (318). Another aspect of the participants lifestyle which may have influenced 
insulin sensitivity but was not assessed was their dietary intake. This study lacked a 
standardised or rigorous measure of dietary intake before or between the metabolic 
assessments. A high carbohydrate diet has been shown to increased insulin resistance 
compared to high fat diets (434). Ethnic differences in dietary intake make have influenced 
insulin sensitivity and could have been accounted for. A UK based study has shown that 
proportion of total energy intake derived from carbohydrates and starch was significantly 
higher in African Caribbean’s  compared to white Europeans (58). It is therefore plausible 
that ethnic differences in dietary intake may have influenced the insulin sensitivity findings. 




and that may explain why they have similar insulin resistance despite lower visceral and 
ectopic fat.  
The intracellular aspects of insulin-mediated glucose metabolism by ethnicity were 
not in the scope of the present study and limit the discussions. Insulin stimulates glucose to 
undergo both oxidative and non-oxidative disposal (glycogen storage), with the latter shown 
to fall in T2D. Studies which have assessed non-oxidative glucose disposal during a clamp 
in black and white participants show no ethnic difference in non-oxidative glucose 
metabolism (313, 318, 435) particularly when there were no ethnic differences in total 
glucose disposal. However, in cases where insulin sensitivity was lower in black compared 
to white participants, non-oxidative glucose disposal was lower in the black participants with 
no ethnic difference in glucose oxidation (251, 322, 436). Based on this, the present data 
showing no ethnic difference in insulin sensitivity would be likely to show no ethnic 
difference in non-oxidative glucose disposal in the black and white men. 
One of the strengths of this study and analyses is the use of “gold standard” 
procedures, namely the two-step hyperinsulinaemic-euglycaemic clamp with stable isotopic 
tracers. Whilst the procedure has been termed the “gold standard” to assess insulin sensitivity 
and is highly reproducible, it has been criticised for creating a supraphysiological 
environment due to the duration and intensity of the hyperinsulinaemia. This disrupts and 
turns off physiological feedback loops which would be present following a meal. Further 
studies could confirm the findings from this study by using the triple tracer method during a 
meal to get an understanding of the ethnicity response to physiological stimuli (437). The 
findings here indicate that future studies in black and white men are not likely to show an 




using the procedure to assess hepatic insulin sensitivity has also been criticised. The liver is 
primarily exposed to insulin from the portal vein, which contains newly secreted insulin from 
the pancreas, which has yet to undergo first past insulin clearance by the liver. The peripheral 
insulin infusion during the clamp does not go through the portal vein. It increases the 
peripheral insulin concentration, which reduces the insulin gradient between the portal vein 
and peripheral circulation. The insulin detected by the liver does not change much and cannot 
be accurately quantified without portal vein cannulation. For this reason, caution should be 
applied when hepatic insulin sensitivity findings are interpreted (128). 
Whilst these limitations are apparent, the hyperinsulinaemic-euglycaemic clamp is 
still regarded as the “gold standard” procedure for the assessment of insulin sensitivity to 
glucose homeostasis, and its use is therefore a strength of this study (89, 156, 157). By 
combining the procedure with a glucose and glycerol isotopic tracers, more direct 
assessments of the changes in glucose or lipid fluxes in response to insulin are determined 
and used to assess peripheral, hepatic and adipose tissue insulin sensitivity (143, 159). Both 
the adipose tissue and the liver are sensitive to insulin at much lower concentrations than 
muscle (94). The insulin concentrations which almost maximally stimulate the muscle (the 
main component of peripheral tissues responsible for glucose disposal) causes a near 
maximal suppression of endogenous glucose production and lipolysis, used for hepatic and 
adipose tissue insulin sensitivity, respectively. Maximal suppression of these actions would 
not allow for ethnic comparisons to be made; thus, a relatively low and high dose insulin 
infusion was used in this study. Submaximal or partial suppression of endogenous glucose 
production and lipolysis could, therefore, be measured and compared between groups as well 




peripheral hepatic and adipose tissue insulin sensitivity in a single population of black and 
white men.  
The choice of isotopic tracers used to reflect tissue-specific insulin sensitivity is also 
a strength in this study. Glucose appearance and disappearance was historically assessed with 
tritiated glucose; however, there have been reports of inaccuracies from these findings due 
to the contamination (up to 10%) of non-tritiated glucose. These contaminations 
underestimate glucose appearance; whereas, [6,6-2H2]-glucose is a stable isotopic tracer with 
less imprecision and is a preferred choice (342, 438). In order to assess lipolysis, either 
glycerol or fatty acids can be tracers with stable isotopes (143, 144). Glycerol has been 
identified as a superior tracer for the assessment of lipolysis (rate of appearance). Unlike fatty 
acids, when glycerol is released from the lipolytic process, it is not readily re-esterified back 
into triglycerides in adipose tissue as glycerol kinase enzyme is low; therefore, glycerol 
primarily leaves the cell. In comparison, fatty acids are readily re-esterified back to 
triglycerides and are likely to underestimate lipolysis if measured (112, 144, 344). Measuring 
glycerol concentrations alone is also likely to underestimate lipolysis because the plasma 
glycerol is a reflection of glycerol released from lipolysis and the uptake of glycerol in the 
liver where it is used as a precursor for gluconeogenesis (161), using the isotope dilution 
technique prevents this limitation. 
The hyperinsulinaemic-euglycaemic clamp assumes that the peripheral insulin 
infusion is sufficient to suppress any endogenous glucose production. Therefore, the 
exogenous variable glucose infusion is the only glucose source to the circulation and the 
variable glucose infusion rate reflects glucose disposal during steady-state conditions. In 




hyperinsulinaemia (87, 163, 222) and the glucose infusion rate may underestimate total 
glucose disposal (M value) as discussed in chapter 4. The use of isotopic tracers allows for 
the measurement of the residual endogenous glucose production during the high dose insulin 
infusion. This study found incomplete suppression of endogenous glucose production in 
some participants; therefore, whole-body insulin sensitivity (the M value) is likely to 
underestimate insulin sensitivity in these cases which highlight the importance of direct 
measures of glucose flux. In this analysis, the residual glucose production during the high 
dose insulin infusion was not ethnically distinct. However, without accounting for it, the true 
effect of residual glucose production when assessing different ethnicities would have been 
unknown. 
In addition to using a “gold standard” method to measure insulin sensitivity, the 
assessment of VAT and IHL is also a strength of this study. Magnetic resonance imaging is 
the optimal non-invasive method for assessing adipose tissue quantity. This method can 
assess specific sites and differentiate between bone and other tissue types although it does 
have a higher participant burden in comparison to other imaging methods (e.g. DEXA or CT 
scans). 
Finally, the participant characteristics and the main effect of glucose tolerance on 
insulin sensitivity provide evidence that the participants assessed in this study were 
representative of the population. Lower plasma triglycerides and a cardioprotective lipid 
profile are consistently reported when comparing populations of black ethnicity, as discussed 
in chapter 3 and 7 (274-277, 293, 358). In this study, the main effects of glucose tolerance 
on whole-body and tissue-specific insulin sensitivity were consistently significant. 




IGT were either more sensitive or equally resistant than those with T2D which agrees with 
the literature (72, 439). For both ethnic groups, the spread of insulin sensitivity data was 
greatest in NGT which also agrees with the literature (440, 441). Overall, these data suggest 
that the sample was representative of the population which strengthens the credibility of the 
finding for no ethnic difference in whole-body or tissue-specific insulin sensitivity.  
 
9.1.2 Conclusions 
The vast majority of the literature suggests that pronounced insulin resistance is 
present in black populations in comparison to their white counterparts; in contrast, this study 
provides evidence against such. This study found no ethnic difference in multiple measures 
of whole-body or tissue-specific insulin sensitivity between black west African or white 
European men. This occurred in normal glucose tolerance, impaired glucose tolerance and 
type 2 diabetes suggesting that pronounced early insulin resistance in black men is not present 
and may not contribute significantly to the increased prevalence of T2D in this ethnic group.  
Insulin sensitivity is thought to decrease with increasing visceral and hepatic fat 
deposition. The finding of similar insulin sensitivity in black and white men occurred in the 
presence of lower visceral and hepatic fat which is characteristic of black communities. 
Adjusting insulin sensitivity findings for the ethnic differences in visceral and hepatic fat 
generally resulted in lower insulin sensitivity in black west African men. This may imply that 
lower fat deposition protects black men from presenting with pronounced insulin resistance. 
The protection theory is supported by the lipolysis data, which shows no relationship between 
resistance to insulin’s antilipolytic action, a potential cause of visceral and ectopic fat 
deposition, and fat deposition in black men. Ectopic and visceral fat may be stored through 




the presence of visceral and hepatic fat is similarly associated to peripheral and hepatic 
insulin sensitivity, albeit at a lower level in black men, suggesting both ethnic groups have 
the same potential risk of increasing insulin resistance as visceral and hepatic fat increase 
and therefore similar pathogenesis of T2D. 
In addition to visceral and hepatic fat, a resistance to insulin’s antilipolytic action has 
been associated with insulin resistance to glucose homeostasis. These data show that the 
association between the antilipolytic action of insulin and insulin sensitivity to glucose 
homeostasis does appear to be weaker in black men and may imply that this is less of a factor 
in disease pathogenesis. The mechanisms for this relationship appear to be independent of 
visceral or hepatic fat accumulation in black but not white men. Further investigation into 
other mechanisms which may be associated with insulin resistance and a potential target in 
black men are required. 
Overall the data in this thesis suggest fat deposition and lipid metabolism may have 
a causal role in insulin resistance in black men; however, this does not appear to explain the 
pronounced prevalence of T2D in black men. Further studies which assess other aspects of 
the T2D pathophysiology, such as beta-cell function, are warranted to provide targets which 
reduce the healthcare burden of T2D. 
 
9.1.2.1 Future studies 
Although insulin sensitivity to glucose homeostasis was no different between the 
black and white men studied here, the black men did present with lower quantities of 
ectopic and visceral fat. Future studies which aim to assess the paradox between lower 




on assessing the function of adipose tissue per unit of fat, as opposed to the quantity. In line 
with this suggestion, this thesis does show lower adipose tissue lipolysis in black compared 
to white men however, this study was unable to identify if this was a result of differences in 
adipose tissue function or mass. In addition to lipolysis, adipose tissue has been shown to 
release cytokines which promote insulin sensitivity including adipokines and leptin. Few 
studies have assessed this function in black and white participants; those which have 
provide data for lower circulating adipokines and leptin in African Americans compared to 
their white counterparts (442, 443). No single study has assessed multiple aspects of 
adipose tissue biology (including lipolysis, inflammation, adipogenesis and oxidation 
(324)) and their impact on insulin sensitivity in black and white groups. Understanding this 
may help to explain the paradox between lower ectopic fat but similar insulin sensitivity. 
 
Future studies which aim to understand why type 2 diabetes (T2D) is more 
prevalent in black groups could re-visit the beta-cell centric model. This model describes 
that failure of the beta-cell to secrete sufficient insulin is the final common denominator 
before hyperglycaemia. Multi-site insulin resistance increases the demand on the beta-cell 
to produce more insulin and contributes towards failure. The data from this thesis shows no 
evidence for an ethnic difference in insulin sensitivity to glucose homeostasis. The data are 
limited in that insulin secretion and sensitivity were not evaluated together however; it 
could be interpreted that there is no ethnic difference in the demand placed on the beta-cell 
by insulin resistance. The beta-cell centric model identifies other factors which increase 
beta-cell demand and encourage beta-cell failure which have not addressed in this thesis. 




disease prevalence. The other factors include: 1) the incretin response, 2) gastric emptying, 
3) inflammation, 4) the gut microbiome and 5) the alpha-cell defect. There is some 
evidence for an ethnic difference in the incretin response (444) although this is not 
consistent with some reports of no difference (445). There is some evidence for similar 
gastric emptying in black and white participants, however this has been assessed in patients 
with diabetes suffering from Gastroparesis (446). There is also some evidence for 
differences in inflammatory markers (447) and very little evidence assessing the gut 
microbiome and the alpha-cells in black and white groups. Overall, further research on 
these factors thought to influence beta-cell upregulation and failure are required and future 
research should address the magnitude of their effect on the beta-cell.  
Whilst the factors listed encourage the beta-cell to upregulate secretion, once this 
does occur, dysfunctional kidney metabolism can exacerbate the rate of beta-cell failure by 
retaining excess glucose. Further studies could assess whether dysfunctional kidney 
handling is more prevalent in black compared to white populations. This assessment may 
explain why the progression to T2D occurs significantly faster in black populations as 
evidenced by the early diagnosis. It is well documented the populations of black ethnicity 
suffer disproportionately for kidney failure (448), whether that characteristic contributes 
towards the acceleration in T2D progression requires further study.  
 The literature which has directly assessed beta-cell function in black and white 
populations show inconsistent results (449) which may reflect the methods used, or that the 
ethnic difference in beta-cell function is less pronounced. None the less, the beta-cell 
failure is a key factor in progression towards T2D and understanding if there are ethnic 





Further studies which aim to assess the pathophysiology of T2D in black and white 
populations may wish to focus on oral or mixed meal-based methods which can 
simultaneously assess insulin sensitivity, insulin secretion, gastric emptying, the incretin 
effect. Using physiological tools, as opposed to supraphysiological intravenous glucose 
assessments, may also help to understand the if hyperinsulinemia is present in black groups 
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Appendix 1: Black African men with early type 2 diabetes have similar muscle, liver 





































Appendix 2: Differences in the link between insulin sensitivity and ectopic fat in men of 
Black African and White European ethnicity 
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